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Elastin, a primary component of elastic arteries, maintains structural stability of 
the cyclically recoiling artery, and critically regulates vascular cell behavior. Accelerated 
degradation of elastic matrix, such as that seen in vascular pathologies like abdominal 
aortic aneurysms (AAA), can therefore severely compromise vessel homeostasis. Tissue 
engineering and in-situ matrix repair strategies evaluated so far are primarily limited in 
inducing adult vascular cells to replicate the complex elastic matrix assembly process, 
and restore lost matrix integrity. Previously, our lab established the elastogenic benefits 
of concurrent delivery of TGF-β1 and HA-oligomers (together termed elastogenic factors, 
EFs), within 2D cultures of rat aortic smooth muscle cells (SMCs). Since SMCs are 
known to switch to a synthetic, highly matrix producing phenotype, in a manner that 
cannot be replicated in vivo, we sought to develop a relevant 3D in vitro model system, 
where the benefits of EFs can be replicated. We chose a 3D collagen-gel model since the 
presence of a collagenous matrix is centric to replicating vascular tissue architecture and 
mechanics. Further, vascular cells, regardless of the choice of scaffolds, robustly 
synthesize collagen. Examining the impact of a pre-existing collagenous 
microenvironment on the ability of the SMCs to synthesize fibrous elastic matrix in 
response to provided EFs, is pertinent to its clinical translation.  
In the first set of studies, we examined a dose range of EFs on inducing rat SMCs-
seeded within 3D collagen gel constructs. Relative to untreated control, all the three 
doses tested showed up to a 2-fold up-regulation in gene expression of the elastin 
crosslinking enzyme, lysyl oxidase, and increased the accumulation of matrix elastin up 
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to 5-fold. The lowest dose combination of 0.1 ng/ml TGF-β1 and 0.2 µg/ml HA-o, was 
evaluated to be most elastogenic, and this was utilized in subsequent studies. Next, we 
evaluated the application of cyclic strains at varying frequencies in improving EF-
induced elastic matrix output, and to obtain matrix and cell orientation in a manner 
similar to that required in vivo. Further, we tested this system on human SMCs seeded 
within tubular collagen-gel constructs, to examine if they respond to EF-treatment similar 
to rat SMCs. A bimodal trend in elastic matrix output was observed with increasing 
frequencies. Relative to static controls, constructs treated with EFs at 2.5% strains and 
1.5 Hz were found to improve contractile SMC phenotype, up-regulate elastin gene 
expression up to 7-fold, and increase elastic matrix content by 5-fold. These parameters 
were therefore chosen for application in subsequent studies. The presence of high 
concentrations of matrix degrading proteases, such as MMPs-2 and -9, inherent to AAA 
wall, as well as within our 3D system, can compromise the accumulation and efficient 
assembly of newly synthesized elastic matrix components. In the next set of studies, we 
demonstrated that addition of Doxycycline (DOX), a non-specific MMP inhibitor, along 
with EFs, suppressed MMP-2 gene expression, within static and dynamic (2.5% strain at 
1.5 Hz) tubular constructs, and markedly improved overall elastic matrix synthesis.  
Since the effects of EFs and DOX are highly dose-dependent, the successful in 
vivo translation of their benefits relies on their controlled and targeted delivery 
specifically to the site of disease. In the final set of studies, we tested the effects of TGF-
β1 and DOX released from PLGA nanoparticles, incorporated within the cyclically 
stretched tubular 3D model optimized in previous studies. We were able to successfully 
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demonstrate that such localized delivery was able to induce elastogenesis in a manner 
similar to exogenous delivery of the same factors.  
Overall, these results will be useful towards addressing a fundamental and widely 
absent aspect in vascular engineering, that of inducing adult vascular cells to replicate 
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Elastin is one of the primary structural proteins found in the ECM of several 
connective tissues. It crucially maintains configurations of tissues and regulates cell 
signaling pathways involved in morphogenesis, injury response, and inflammation
1-2
. 
Specifically, within elastic arteries, it comprises of 50% of the dry tissue weight, playing 
a major role in maintaining overall vascular homeostasis
3-4
. While the elastic matrix is 
responsible for providing vessels the necessary recoil and compliance to accommodate 
blood flow
5
, intact elastic fibers also regulate vascular smooth muscle cell (VSMC) 
behavior through mechano–transduction
1




Innate homeostatic maintenance of elastin within the extracellular matrix (ECM) 
is a lifelong process that involves its early synthesis and maturation, slow degradation/ 
turnover, and limited replacement of structural and signaling proteins involved in 
elastogenesis
6-7
. Once injured, the elastic matrix is not actively repaired, due to (a) poor 
elastin precursor (tropoelastin) synthesis by adult cells, (b) inefficient recruitment, 
crosslinking and organization of tropoelastin into an intact, mature elastic matrix, and (c) 
further degradation due to the generated matrix metalloproteases (MMPs) and elastin-
peptides
7-10
 Accelerated degradation of the matrix, as encountered in several vascular 
diseases such abdominal aortic aneurysms (AAA)
11
, coupled with the inability of adult 
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vascular smooth muscle cells (SMCs) to regenerate lost matrix
8
, can thus severely 
compromise vascular tissue integrity and even result in fatal rupture of vessel wall
12
. 
Therefore, the failure to reinstate a healthy elastic matrix, when damaged by injury or 
disease, or when congenitally malformed or absent, such as that seen within abdominal 
aortic aneurysms, can adversely impact vascular tissue homeostasis 
13-15
. 
AAAs are conditions wherein localized thinning and dilation of the wall of 
abdominal aortae occur, leading to gradual loss of elasticity, resultant local increase in 
diameter, which can ultimately lead to rupture
11
. A vessel that has expanded in diameter 
by at least 50% is generally considered to be aneurismal
16-17
. Initiation and progression of 
AAA has been attributed primarily to chronic matrix proteolysis by MMPs and 
inflammatory cells that infiltrate the vessel wall in response to smoking, chronic 
vasculitis, atherosclerosis, calcified lipid deposits, vascular hypertension, and less 
frequently, inherited conditions
11, 16
. This is coupled with the absence of intrinsic signals 
in adult vascular cells to regenerate lost elastic matrix or to successfully repair the 
disrupted aortic vessel wall matrix
18
. The accelerated loss of elastic matrix and vessel 
wall integrity, and continuous fluctuations in hemodynamic pressures lead to the 
abnormal ballooning of an aneurysm
19
. AAAs typically grow about 1 cm/year to 
catastrophically rupture causing hemorrhage and embolisms. In the United States alone, 
the estimated incidence for AAAs is about 60 in every 100,000 people per year
16, 20
, with 
a fatality rate of more than 15,000 individuals a year, i.e. about 80% of AAA patients
17, 
21
. While advances in high resolution CT and MRI techniques now enable early detection 





Currently the most common approach to treat aortic aneurysms is the surgical 
replacement of the diseased section of the vessel using synthetic grafts, either by an open 
surgical repair, or more recently, by Endovascular Aneurysm Repair (EVAR)
23
. Although 
synthetic grafts help to isolate the aneurysm and prevent vessel rupture by providing an 
alternative pathway for blood flow, they do not accommodate for the loss of functional 
properties of elastic matrix, pose additional complications due to compliance mismatch 
between the synthetic graft material and the native blood vessels, and do not aid in 
regression of the diseased state
24
. Several device-related complications such as lack of 
endothelialization, prevalence of various types of endoleaks, implant migration and 
fatigue affect long-term patency of the implant, necessitating surgical intervention (> 
30% of cases within 6 years)
25-26
. Synthetic grafts continue to have a failure rate of > 
50% within 10 years
26
.  
Restoring an intact elastic matrix is essential not only to sustain the structural 
requirements of the vessel wall, but also to maintain healthy vascular cell functioning, 
both of which are equally critical for vascular homeostasis
14, 18
. Tissue engineering (TE) 
and matrix regenerative strategies have therefore been extensively investigated to develop 
biomechanically functional and self-renewing vessel components with the aim to mimic a 
viable elastic aorta
27
. However, a large body of this work has been unsuccessful in 
inducing substantial synthesis or regeneration of intact, mature, matrix elastin
10, 28-33
.  
Studies observing reasonable induction of elastogenesis have done so only by utilizing 
naturally elastogenic neonatal or juvenile SMCs; success in inducing elastogenesis in 





. The translational ability of these vascular TE approaches is therefore 
limited. Strategies for successful tissue engineering of elastic matrix-rich vascular 
constructs by adult SMCs are critical and currently unmet. 
Previously, our lab established the elastogenic benefits of exogenous hyaluronan 
oligomers (HA-o; ~756 Da) and TGF-β1 in 2-D-cultures of healthy rat aortic SMCs 
(RASMCs) 
37
. TGF-β1 has shown to increase elastin mRNA levels (by ~ 30-fold) and 
enhance production of LOX, critical for crosslinking collagen and elastin, and fiber 
organization in situ
38-39
. It has also shown to decrease proteolysis by reducing MMP 
expression and up-regulating TIMP-1, 2, and 3 mRNA expressions
40-41
. Hyaluronan (HA) 
also appears to stabilize elastin fibers once formed, against elastase degradation. In 
addition to this, HA is known to enhance formation of mature matrix elastin by 1) 
coacervating soluble tropoelastin via their positive lysine residues and 2) facilitating lysyl 
oxidase (LOX)-mediated oxidation and crosslinking of tropoelastin into insoluble elastic 
fibers
42-43
. Studies from our lab have also confirmed such up-regulation
 
and demonstrated 




The two primary criteria to be satisfied in order to obtain a highly organized and 
mature elastic matrix in vitro, or to restore lost matrix via in situ repair, are 1) inducing 
VSMCs to synthesize and organize sufficient elastic matrix, and 2) maintaining a balance 
between increase in matrix production and suppression of degradative proteases. While 
TGF-β1- HA-o dose combinations enhance elastin synthesis several fold, their 
insufficiencies in suppressing MMP activity limits the accumulation of mature-matrix. 
5 
 
Studies in our lab have therefore investigated dose-specific benefits of Doxycycline 
(DOX), a modified tetracycline, in combination with the above factors, to improve elastic 
matrix output. Known to be a global, non-specific MMP inhibitor, systemic delivery of 
DOX has been clinically shown to reduce the rate of AAA growth and progression of 
disease, a likely outcome of reduced elastic matrix proteolytic disruption
45-47
.  
One of the main limitations of previous studies testing the efficacy of various 
elastogenic factors was that they were all performed in 2D cultures of VSMCs. VSMCs 
are known to take up a highly synthetic phenotype, displaying significantly higher 
proliferation ratios and increased ability to synthesize ECM proteins compared to that 
seen in vivo. Moreover, the matrix ultrastructure in such environments is not replicative 
of that needed within intact tissues in vivo. It is therefore important to test the effects of 
the elastogenic factors within micro-environmental conditions that more closely evoke 
the native vascular tissue. 
 
1.2.  3D CULTURE MODEL FOR INDUCED ELASTIN SYNTHESIS 
The presence of collagenous matrix is centric to replicating vascular tissue 
architecture and mechanics
48
. Collagen gels have been extensively investigated as 3-D 
scaffolding models for vascular TE since the pioneering work of Weinberg and Bell in 
1986
49-50
. SMC-seeded collagen gels are actively remodeled in a process called 
fibrillogenesis, emulating a 3-D environment similar to that seen in the arterial media in 
vivo
51
. SMCs seeded within such scaffolds can therefore be expected to behave in a 
manner more representative of a healthy phenotype
52-53
, compared to other synthetic or 
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. Moreover, vascular cells, 
regardless of the choice of scaffolds, robustly synthesize collagen
10, 27
. This is also true in 
case of auto-regenerative phenomena within proteolytically-disrupted vascular tissues in 
vivo, such as AAAs, where a fibrotic collagen-rich matrix first accumulates
16, 55
.  It is 
therefore further imperative to examine the impact of a pre-existing collagenous 
microenvironment on the ability of VSMCs to synthesize fibrous elastic matrix in 
response to provided elastogenic factors
56
. 
 As described in the previous section, one of the limitations of elastic matrix 
engineering approaches is the lack of sufficient conversion of induced elastin synthesis 
into an organized and aligned elastic ECM, similar to that needed in vivo. Numerous 
studies in literature point towards benefits of cyclic dynamic conditioning to significantly 
influence cell phenotype, alignment, matrix deposition, and growth factor release by both 
native and cultured SMCs
57-59
.  
Lastly, it is important to note that the factors that have been tested so far in vitro 
can only be translated in vivo when their delivery is highly localized at the site of disease. 
This is important not only to ensure higher availability for efficient and timely response, 
but more so since the cellular response to these factors are very different depending on 
their location in the vasculature. For example, while the effects of TGF-β1 delivery 
generate a highly desirable response by VSMCs in AAAs, within thoracic aortae, it is 
involved in initiation and progression of aneurysms
60-61
. Moreover, the therapeutic 
concentrations can be more sensitively controlled and sustained via a localized delivery 
from polymeric scaffolds such as nanoparticles.  
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The 3D model system that we have utilized in this thesis is therefore comprised of 
1) collagen gel constructs seeded with adult vascular cells, which are 2) subjected to 
cyclic mechanical distensions, and 3) treated with various dose combinations of TGF-β1, 
HA-o and DOX, with and without their delivery through nanoparticles. 
The results will be useful towards addressing a fundamental and widely absent 
aspect in vascular tissue engineering, that of being able to engineer elastic tissue 
constructs containing biological and structural mimics of native elastic fiber networks.  
 
1.3. STUDY OBJECTIVES AND AIMS 
The specific aims are designed based on the background and results from previous 
studies discussed in the sections above. They are as follows: 
Aim 1: Investigate basal and induced elastogenesis in static, 3-D collagen gel 
constructs. A range of TGF-β1 and HA-o dose-combinations will be exogenously 
delivered to investigate elastin regeneration and matrix orientation by healthy adult 
RASMCs within static, 3-D constructs of collagenous microenvironments.  
Aim 2: (A) Determine benefits of cyclic distension on induced elastogenesis within 
tubular collagen constructs. Healthy human aortic SMCs (HASMCs) will be cultured 
within tubular collagen-gel constructs subjected to cyclic strains over a range of 
frequencies within a pulsatile bioreactor. The most significantly elastogenic dose 
combination of TGF-β1 and HA-o selected from Aim 1 will be concurrently delivered to 
the cultures under dynamic straining. Static cultures with and without TGF-β1 and HA-o 
will serve as the biologic controls. 
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             (B) Demonstrate that inhibition of matrix metalloproteases improves elastic 
matrix output and quality. HASMCs cultured under dynamic conditions that are most 
conducive to elastic matrix deposition in Aim 2A will be further cultured in the presence 
of exogenous DOX, a modified tetracycline that inhibits synthesis and activity of MMPs. 
Cultures without DOX treatment will serve as controls. 
Effects of the above conditions on elastin synthesis, gelatinase synthesis and 
activity, matrix deposition and orientation, matrix yield and overall architecture will be 
evaluated in comparison to the respective biological controls. 
Aim 3: Evaluate benefits of localized, controlled delivery of elastogenic factors and 
Doxycycline within tubular collagen-gel cultures over exogenous delivery:  
Nanoparticle encapsulation and in vitro release study of TGF-β1, HA-o and DOX will be 
performed. These nano-particles will then be incorporated within collagen gels (at 
concentrations optimized in Aims 1 and 2 prior to gel polymerization, for localized and 
sustained delivery of these factors to HASMC cultures within. 
 
1.4. PROJECT INNOVATION AND IMPORTANCE 
Poor elastogenic potential of adult vascular cells combined with lack of strategies 
to efficiently improve mature elastic matrix yield have thus far deterred successful 
regenerative efforts in elastic vasculature. This study therefore aims at addressing these 
issues by 1) utilizing the elastogenic potential of TGF-β1 and HA-o in combination with 
2) dynamic conditioning for enhancing matrix assembly within 3-D collagen gel 
constructs seeded with adult vascular SMCs. Aim 1 of this study would first establish an 
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optimum dose combination of TGF-β1 and HA-o within collagen gels maintained under 
static strains. Following this, Aim 2 will utilize the benefits of the above factors in the 
presence of cyclic strains in order to achieve a well aligned, mature elastic matrix. The 
application of cyclic strains in combination with targeted delivery of optimized factors 
will be studied in Aim 3. Translational potential of the above methods will also be 
reflected in Aims 2 and 3 with the utilization of adult human VSMCs. 
 The results will be most useful towards addressing a fundamental and widely 
absent aspect in vascular tissue engineering, that of reinstating an intact, mature and 
viable elastic matrix by adult vascular cells. 
 
1.5. ORGANIZATION OF DISSERTATION 
Chapter 2 presents an overview of elastin and elastic matrix components of the 
vasculature, their roles in regulating vascular mechanics and cell behavior during 
development, aging and disease, and a review of current strategies for vascular elastic 
matrix regeneration and repair. 
Chapter 3 evaluates outcomes of induced elastogenesis of adult rat SMCs seeded 
within 3D collagen gel constructs maintained under static tension, to a range of TGF-β1 
and HA-o dose combination. The most elastogenic dose combination (termed 
elastogenic factors or EFs) is chosen from the outcomes of this study for application in 
subsequent studies of this project. 
Chapter 4 discusses outcomes of combined effects of EF-treatment and varying 
cyclic strain frequencies within human aortic SMC-seeded tubular collagen gel constructs, 
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towards improving matrix assembly and alignment. The cyclic strain frequency most 
conducive to elastic matrix synthesis and alignment is evaluated and utilized in 
subsequent studies. 
Chapter 5 evaluates how Doxycycline-mediated MMP suppression within 
cyclically strained and EF-treated SMCs seeded in tubular collagen gel constructs further 
improve outcomes of crosslinked, mature matrix elastin.  
Chapter 6 discusses the benefits of localized delivery of TGF-β1 and Doxycycline 
from PLGA nanoparticles, over their exogenous delivery, within cyclically stretched 
SMC-seeded tubular collagen constructs. 
Finally Chapter 7 details overall conclusions derived from this project and 

















2.1. ELASTIN: PRIMARY COMPONENT OF ELASTIC FIBER ECM 
Elastin is distributed throughout the body, however it is primarily found in elastic 
fibers of circulatory, respiratory and integumentary system that require elastic resilience 
to maintain important tissue functions
3, 62
. Ultrastructure analysis of elastic fibers reveal 
two morphologically distinct parts: a 10-12 nm microfibrillar component, primarily 
fibrillin-1, surrounding the more abundant, amorphous core of elastin
8
.  During early 
stages of fetal development, the elastin precursor, tropoelastin, is deposited within these 
fibrillin-rich microfibril templates within the extracellular space
6-7
. This helps the 
monomer units to coalesce, allowing the Copper-dependent Lysyl oxidase (LOX) enzyme 




2.1.1. Distribution of Elastin 
The elastic property of various connective tissues such as arteries, lungs, elastic 
cartilage and skin is provided by a complex three dimensional network of elastic fibers 
within their ECM
63
. These fibers are primarily made up of structural proteins such as 




Elastin, the main contributor to the elastic recoil in these tissues, is the 
predominant protein of mature elastic fibers
65
. The distribution, structural organization 
and the elastin : microfibril ratio vary between tissues of different organs depending on 
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physiological role, their mechanical functions and age of tissue
8, 66
. Elastic fibers are 
associated with other essential ECM proteins like collagen, surrounded by GAGs and 
proteoglycans, which support the mechanical properties specific to the tissue and help 
maintain their native cell physiology 
8
. In the medial layer of elastic arteries, elastic fibers 
form concentric fenestrated lamellae separated by collagen and smooth muscle cell (SMC) 
layers, which impart resilience to the vessel wall during systolic pressures, and recoil 
during diastole, maintaining blood flow and volume
5
. Within mammalian skin, elastin is 
found primarily in the reticular dermis as large, flat, undulated and perforated sheets, 
running parallel to the skin surface, which are replaced by a more microfibril-rich elaunin 
fibers in the middle dermis, and oxytalan fibers in the papillary dermis consisting only of 
microfibrillar glycoproteins
7
. The alveolar expansion and recoil during breathing is 
supported by thin, highly branched elastic fibers present along the blood vessel walls 
throughout the respiratory tree
62
. While thick elastic fibers ~ 100µm are found in elastic 
ligaments of the vertebral column, a thin network of elastic fibers, ~57µm, interspersed 




2.1.2. Chemical Composition of Elastin 
Purified elastin is found to be rich in hydrophobic amino acids such as glycine 
(33%), alanine (24%), valine (15%) and proline (11%), has very low acidic and basic 
amino acids, and contains no hydroxylisine residues
3, 68-69
. The hydrophobic segments of 
the elastin polypeptide, present as β-sheets, alternate with the crosslinking α-helical 
domains rich in lysine and alanine residues
3
. The highly stable elastic characteristics are 
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maintained by the presence of disulfide bonds and tetrafunctional, heterocyclic 




2.1.3. Elastin Synthesis and Assembly into Elastic Fibers  
In humans, elastin is synthesized as tropoelastin, a 72kDa alkali-soluble protein, 
by the elastin gene present as a single copy on chromosome 7
70-71
. Tropoelastin consists 
of about 750-800 residues, typically grouped into ‘hydrophobic’ domains that alternate 
with lysine-rich ‘crosslinking’ domains.  The hydrophobic sequences are highly repetitive 
and usually consist of overlapping di-, tri-, tetra-, penta-, hexa-and nano-peptides of 
aliphatic amino acids like proline (P), alanine (A), valine (V), leucine (L), isoleucine 
(I)and glycine (G), of which G and V are more commonly found. The crosslinking 
domains consist of lysyl residues within P-and A-rich regions. These domains are coded 
for by the 36 exons of the gene, which have more than 70% homology among various 
species of vertebrates
72
. The variations are primarily seen in the hydrophobic regions, 
while domains that contribute to important structural features remain conserved. The 
most conserved region of the translated protein is the positively charged, hydrophilic C-
terminus, which consists of the only two cysteine residues found in the protein. This aids 
in the formation of disulfide bonds
3, 8, 69
.  
Intracellularly, like most other proteins, tropoelastin is secreted post-
transcriptionally by the endoplasmic reticulum, hydroxylated on a number of proline 
residues and packaged by Golgi apparatus, following which, it is transported to the 
extracellular space by transcytosis, where it coascervates on microfibrillar pre-scaffolds. 
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Tropoelastin transport is mediated by the elastin binding complex, a group of three cell 
membrane proteins. Two of its subuints, 55 and 61kDa, form a transmembrane link 
between the cytoskeleton and intracellular compartment. The third
 
subunit, a 67kDa 
protein called elastin-binding protein (EBP), binds the hydrophobic VGVAPG sequence 
on tropoelastin, the cell membrane and galactosugars on microfibrils
73
. This binding of 
galactosugars to the lectin site on EBP lowers its affinity for both tropoelastin and the 
cell-binding site. The bound tropoelastin is therefore released, coascervated on fibrillin 










Though galactosugar-containing microfibrillar proteins aid in coordinated release of 
tropoelastin, an excess of galactose-containing components such as glycoproteins, 
glycosaminoglycans, or galactolipids in the ECM may adversely affect elastin assembly 
Figure 2.1: Schematic of tropoelastin transport into the extracellular space mediated by 






by inducing premature release of tropoelastin and elastin-binding protein from the cell 
surface
8, 74
. Secreted tropoelastin molecules aggregate in the extracellular space on loose, 
pre-existing bundles of microfibrils that behave as scaffolds for elastic matrix assembly. 
Microfibrils (fibrillin 1, 2, fibulin 4, 5), appear as 12nm long, electron dense tubes, 
grouped in small bundles near the plasma membrane. Within each bundle, tropoelastin 
molecules gradually coalesce, generating a central core of elastin. As the fibers mature, 
these bundles slowly move towards the periphery
8, 66
.   
According to conventional electron microscopy, it was long believed that electron 
dense microfibrils surround an amorphous matrix core. However, recently it was shown 
that the amorphous appearance of elastin core was in fact an artifact, and that elastin 
Figure 2.2: Overview of steps involved in tropoelastin transport and assembly on 






molecules are organized as 5-nm thick filaments forming a three-dimensional network 
along the fiber. Further studies have shown that, besides elastin, a number of matrix 
constituents such as vitronectin, LOX, decorin, osteopontin and biglycan epitopes are 
also present within normal elastic fibers, which are perhaps equally important in 
maintaining elastic fiber integrity. 
Crosslinking of elastin is initiated by a family of copper dependent enzymes 
called lysyl oxidase (LOX), which catalyze oxidative deamination of lysine residues into 
allysine. Specifically, lysyl ε-amino groups present on the α-chain domains of adjacent 
tropoelastin molecules are oxidized into a δ-aldehyde, an allysine. Approximately 40 
lysine residues in 16 crosslinking domains of tropoelastin have been estimated to 
eventually participate in forming the bi-, tri-, and tetra functional crosslinks of the 
polymer that equips it with high resilience. LOX mediated crosslinking occurs early in 
the assembly phase and is critical for matrix elastin formation
43, 75-76
. Subsequent 
formation of the elastin crosslinks by isodesmosine and desmosine occur as a series of 
spontaneous condensation reaction
77
. Inhibition of LOX activity through copper 
deficiency or through the administration of enzymatic inhibitors results in weakened 




2.1.4. Elastic Fiber Maturation, Breakdown and Turnover 
Studies have shown that most of the elastic matrix deposited as a neonate, and 
elastic fibers mature into completely formed matrix by around 16 years of age, following 



















As minimal turnover occurs in healthy tissues, half life of vascular elastin is very 
long (approximately 70 years).  The degradation of elastin is the result of a proteolytic 
cascade that involves the cooperation of several degradative enzyme types such as serine 
proteases, matrix metalloproteinases, and cysteine proteases. These may be present in 
latent forms under healthy physiologic conditions, and can become activated following 
vessel wall injury
79-80
.   
Figure 2.3: Scanning electron micrographs showing elastic fiber formation and 
breakdown with age. (1), (2) Elastin is assembled on microfibrillar scaffolds at the 
fetal stage. (3 A, B and C) Mature elastic fiber bundles are formed until 16 years of 
age. After this elastic fibers start to slowly and progressively degrade with age (3D, 






Matrix-metalloproteases (MMPs), a family of Zinc-dependent enzymes, are 
typically involved in elastin turnover in healthy vessels
81
. Vascular SMCs release 
numerous MMPs that are capable of digesting individual components of the ECM and are 
normally regulated by tissue inhibitors of metalloproteases (TIMPs)
82
. A balance between 
MMPs and TIMPs is maintained at all times within healthy tissues to ensure healthy 
matrix reorganization for cell migration and structural homeostasis of the vessel
80, 83-84
. 
Integrins are the primary ECM receptors for mechano-transduction, responsible for 




2.2. ELASTIN AND THE VASCULATURE 
The largest arteries branching out from the heart, the aorta of systemic circulation, 
and pulmonary artery of the pulmonary circulation, along with their main branches, the 
branchiocephalic, common carotid, subclavian, thoracic, abdominal and common iliac 
arteries are classified as elastic arteries. Elastin constitutes 50% of dry tissue weight of 
the these arteries and plays a crucial role in maintaining unidirectional flow of blood. 
They typically have an internal diameter >10 mm. These arteries further branch out into 
the muscular arteries that have a lower elastic matrix content, higher number of smooth 
muscles cells and a thinner intima. They have an internal diameter of 0.1-10 mm. These 
further branch out to the arterioles (< 0.1 mm diameter) and the capillaries (~5 µm 







2.2.1. Elastic Arteries: Structure and Function 
The elastic arteries have three main structural and functional layers: (1) the 
innermost tunica intima, (2) the tunica media or the middle layer and (3) tunica 
adventitia or the outermost layer (Figure 2.4). Each layer has a specific cell type and a 
distinct ECM composition, which together play a role in maintaining circulation and 




























Tunica intima consists of a layer of endothelial cells resting on a basement 
membrane, surrounded by a sub-endothelial space and a less conspicuous internal elastic 
Figure 2.4: Anatomy elastic artery showing the three layers of the blood vessel, 





lamina, which separates intima from the medial layer. The endothelial cells have flat, 
elongated squamous epithelial cell morphology, with their long axis parallel to the 
direction of blood flow. They are 10-20 µm in diameter and 1-2 µm thick
67
. These cells 
are highly resistant to shear stress imparted by continuous flow of blood. Along with the 
adjoining basement membrane, this layer regulates important functions to maintain 
vascular homeostasis including 1) maintaining selective transport of cells and molecules 
across the vessel wall, 2) preserving a non-thrombogenic barrier between blood and the 
sub-endothelial layers by secreting various anti-thrombogenic substances and 
anticoagulants like prostacyclin and thrombomodulin respectively, 3) modulating blood 
flow and vascular resistance by secreting vascodilators like NO and constrictors like 
endothelin, 4) regulating cell growth, immune response and lipoprotein oxidation, and 5) 
maintaining extracellular matrix of the basal lamina. Any injury or abnormality in the 
endothelial layer would therefore disrupt the vessel wall integrity and homeostasis as 
seen in inflammatory diseases of the vasculature such as aortic aneurysms
86
.  
Tunica Media is usually the thickest layer of the elastic vessel wall. It is defined 
by the internal elastic lamina (IEL) following the intima and external elastic lamina (EEL) 
adjoining the adventitia. Elastin is distributed as fenestrated sheets or lamellae, the 
number and thickness of which vary linearly with the blood pressure and cyclic tension 
experienced by the wall
5, 87
. Concentric layers of SMCs, collagen fibers and thin layers of 
proteoglycan-rich ECM are present between the elastic lamellae. This layer helps 
accommodate the pulsatile flow of blood and provide mechanical resilience to the vessel. 
While elastin acts a reservoir of tensile load, distributing stresses evenly throughout the 
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vessel wall, collagen bears the tensile load and restricts the extent of distension
5
. The 
SMCs are spindle shaped with an elongated nucleus, arranged in a low-pitch spiral with 
respect to the long axis of the vessel
67
. Though it was found that their elimination from 
the wall of a mature aorta does not significantly alter its static mechanical properties, the 
cells actively respond to changes in cyclic stretch, endothelial growth factors and 
inflammatory processes, in remodeling the medial ECM
9
. The secretion of collagen and 
elastin by these cells is dependent on the frequency, magnitude and duration of cyclic 
strain transmitted to the SMCs
5
. Under normal homeostatic conditions, they remain in a 
contractile, non-proliferating phenotype, expressing surface markers such as SM-α-actin, 
calponin, SM22, SM-myosin heavy chain etc
88
. However under pathologic conditions 
such as hypertension, injury to endothelium, inflammatory reactions, response to various 
growth factors such as transforming growth factor-β1 (TGF−β1), tumor necrosis factor-α 
(TNF-α), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), 
insulin-like growth factor-1 (IGF-1), interleukin-1 (IL-1) etc, SMCs can switch to a 
proliferating, synthetic phenotype, which in turn also alter the vascular matrix 
composition and mechanics
89-90
. This has been discussed in detail in subsequent sections.  
Tunica adventitia is the outermost layer of the vessel wall, defined as the region 
outside the EEL in elastic arteries. It consists of fibroblasts that maintain a matrix rich in 
collagen type-I, which helps prevent rupture of the vessel at high pressures. Vasa-
vasorum, the small blood vessels providing nourishment to large elastic and muscular 
arteries and vessel innervations are usually present in this layer. Recent studies have 
shown that this layer may possess injury-sensing capabilities and home progenitor cells 
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capable of differentiating into SMCs
67
. Recent studies have shown that the adventitia 
may be sensitive to injury and may also house progenitor cells capable of repopulating 
the media and intima
91
.  
Functionally, the elastic arteries facilitate in maintaining the uniform flow of 
blood through the vasculature, while at the same time maintaining blood volume and 
pressure. During the systolic phase, the ventricles contract and pump blood into the 
elastic arteries, and simultaneously, the arterial wall distends. The extent of distension is 
limited by the presence of collagen fibers in the medial and adventitial layers. Following 
this, during diastole, when the heart does not generate additional pressure, these vessels 
recoil due to the presence of elastic fibers, therefore maintaining blood flow, restoring 
baseline pressure and triggering the closure of the semilunar valves to prevent back-flow 
of blood into the heart, while the cycle continues. In effect, these arteries store a portion 
of the stroke volume with each systole and release the same during diastole. This helps 
decrease the load on the heart, minimizes systolic flow and maximizes diastolic flow 




2.2.2. Matrix and Cellular Components of elastic arteries and their roles 
While on the one hand, the vascular ECM is responsible for supporting the 
structural and mechanical properties of the vessel wall, they also provide instructions to 
regulate cellular phenotype by binding to specific cell receptors to activate gene 
expressions, control growth factor activity and maintain cell functions. The ECM 
comprises of three main components: (a) structural proteins like elastin and collagen, (b) 
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fibrous proteins like fibrillin, laminin etc, and (c) proteoglycans. These interact with each 
other, the cellular components and the surrounding environment to maintain homeostasis.  
Collagen is present within the ECM of all three layers of the vessel wall and is 
primarily responsible for its load bearing properties. It consists of three α-helical 
polypeptide chains, composed of Gly-Pro and 4-Hydroxyproline, of which the side chains 
of Gly alone occupy the interior of the helix, while that of Pro and Hydroxy-pro face 
outward, helping in coalescing and crosslinking pro-collagen molecules
92
.  17 different 
collagen types have been identified in a mouse aorta depending on the helical size, of 
which collagen types I, III, IV, V and VI were found to have highest expression levels, 
whose distribution varies depending on the region in the vasculature. Types I, III and IV 
are fibrillar collagen, of which I and III are mainly load bearing. While type I is 
predominant in the media and type III is primarily found in the adventitia
4
. Mutations in 
genes encoding either of the two types result in fragile blood vessels prone to rupture. 
Type V collagen is found within the media and basement membranes, and plays a role in 
collagen fibril nucleation and assembly. This has been demonstrated in mice deficient in 
this gene that die during early stages of embryogenesis due to lack of fiber formation. 
Type VI is also a fibrillar collagen that associates with fibrillin-1 of oxytalan fibers, 
connecting the elastic lamellae with the basement membrane and the SMCs with other 
ECM components
92
. Lysyl oxidase helps crosslink fibrillar collagen, by converting the 
lysine and hydrozylysine residues in the non-helical telopeptides into aldehydes, forming 
bi-functional crosslinks. 1-4 crosslinks are found per collagen unit. This helps aggregate 
the 10–30 nm diameter collagen fibrils into densely packed 500-3000 nm thick fiber 
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The amorphous ground substance surrounding cells of the vasculature consist of 
glycosaminoglycans (GAGs) and proteoglycans (PGs). GAGs (e.g., hyaluronan, 
chondroitin sulfate, dermatan sulfate, heparin sulfate, and keratin sulfate) are long un-
branched polysaccharides consisting of a repeating disaccharide unit of an N-acetyl-
hexosamine and hexuronic acid, either or both of which may be sulfated
95-96
. PGs are 
complex macromolecules that contain a core protein, covalently bound to at least one 
GAG chain
97
. They are closely associated with collagen and elastic fibers in the ECM . 
These molecules are characterized by high anionic charge densities, due to the presence 
of sulfate and carboxylate groups on their uronic acid residue
95
. These polysaccharides 
can therefore become highly hydrated and resist compressive forces, while at the same 
time permit diffusion of nutrients, hormones and metabolites between blood and tissue. 




As discussed in the previous section, in elastic arteries, and most muscular arteries, 
Figure 2.5: Schematic of collagen fiber assembly showing aggregation of collagen 






elastin contributes up to 50% of the tissue’s dry weight. Within these vessels, elastin is 
organized as concentric fibers and lamellae around the vessel lumen, that alternate with 
layers of SMCs and collagen within the tunica media. The roles of elastin in elastic 




2.2.3. Role of Elastin in Physiochemical Regulation of Vascular Cells  
ECM-cell interactions in all tissues is synergistic that tightly regulate 
developmental transitions, response to injury and overall homeostasis. Elastin, being an 
important ECM component of elastic tissues, therefore contributes to both structural and 
biochemical state of a tissue and the cells within. This section elaborates the various 
functions of elastin as an ECM protein.  
SMCs interact with their ECM components through anchoring junctions like 
adherins and hemidesmosomes
98
. This in turn regulates their proliferation, migration, and 
in general, cell viability
99
. Mature, intact elastin also affects actin stress fiber orientation 
within SMCs. The integrity of the ECM is therefore important for regulating cell 
phenotype. For example, in healthy, mature vascular tissues, SMCs exist in a quiescent 
state, whose migration is inhibited by the intact, elastin-rich ECM. The matrix 
remodeling maintained by a tight balance between MMPs and TIMPS, is also achieved 
through SMC interaction with intact elastin. However, during an injury to the media, that 
causes degradation of the elastic matrix, the healthy SMC phenotype is found to switch to 
a synthetic, non-contractile, proliferative phenotype, characterized by increased migration, 
proliferation and secretion of disorganized, fibrous ECM
18
. In several in vitro studies, this 
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phenomenon was supported by the observation that exogenous elastin added to healthy or 
diseased SMCs cultured within collagen gels, inhibited their proliferation and migration 
in a dose dependent manner
100
.  
Elastin peptides, generated as a result of elastin breakdown, also increase SMC 
motility and proliferation. These peptides are known to induce tyrosine-dependent 
phosphorylation of β-tubulin, various microtubule associated proteins, α-actin and 
troponin-T, which increase SMC cytoskeletal reorganization and motility. Additionally, 




Arterial calcification, a common phenomenon in various inflammatory vascular 
pathologies localized to regions of intima and media, usually occurs following lipid 
deposition, macrophage infiltration and SMC proliferation
102
. Studies have shown that 
genetic or induced aberration of the lamellar elastin, or the associated microfibrils that 
mediate SMC interaction with elastin, can interrupt SMC-elastin signaling and induce 
SMCs to assume an inflamed, synthetic phenotype, characterized 44,45 by increased Ca
2+
 
influx, subsequent calcium deposition and matrix hardening
80, 103
. Elastin peptides 
interact with the elastin-laminin receptor (ELR) present on the surface of various cell 
types like fibroblasts, lymphocytes, SMCs and ECs. When activated, the ELR receptor 
induces a G-protein linked activation of phospholipase C
104-105
. This results in the 
increase in intracellular concentration of calcium, which in turn phosphorylates MAP 






2.2.4. Contribution of Elastin to Vascular Mechanics and Vascular Homeostasis 
The stresses imparted on a vessel wall include (1) shear stress from blood flow 
across the lumen, (2) longitudinal stress from surrounding tissue and (3) circumferential 
stress from surrounding tissue
5
. SMCs of adult elastic arteries contribute little to the 
passive mechanical properties of the vessel, unlike in smaller vessels. The complex ECM 
they synthesize, therefore defines the mechanical properties of a mature vessel. These 
include: (a) high resilience, that restore a large portion of the energy utilized during 
systole, by elastic recoil during diastole, (b) subsequent low hysteresis or energy loss 
during cardiac cycles, and (c) non-linear elasticity, that protect the wall from rupture by 
stiffening with increasing pressure. This non-linearity exists due the deformation of 
elastin at low strains, and collagen at higher strains. For the same reason, single constants 
like Young’s modulus cannot be used to describe vascular wall properties. It is therefore 
represented in terms of physiologic modulus, which corresponds to incremental elastic 
stress values within the physiological strain values. Physiologic modulus for a human 
thoracic aorta is 0.6-1MPa  (Figure 2.6)
5
.  
The medial elastin, woven into an interconnecting lamellar network, transfers 
stress uniformly throughout the vessel wall. Collagen, arranged in bundles between the 
lamellar networks, become circumferentially aligned as pressure increases, but lack a 
definite arrangement at physiological pressures
108
. Physiologic pressure is the region in a 
stress-strain curve, where the stresses are transferred from the elastic to the inextensible 
components of the wall
5
. Elastin has high reversible distensibility and deforms to large 
extensions with small forces. Its properties of recoil are said to be ‘rubber’ like, i.e., when 
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unstretched, it has maximum disorder, therefore maximum entropy. When stretched, 
order is introduced in the direction of stretch, reducing entropy. When the external force 












To establish the importance of elastin in vascular mechanics, a study was 
conducted in a knock out model of mice deficient in elastin gene (ELN). It was observed 
that these mice had tortuous, stenotic and stiff vessels that showed little diameter change 
between systole and diastole. Due to the absence of elastic recoil, the ventricular 
pressures increased in an attempt to maintain cardiac output, and SMCs proliferated on 
the luminal side to lower wall stress by increasing wall thickness and decreasing inner 
diameter. The proliferation continued till the lumen was completely occluded
18
.  
Figure 2.6: Non-linear tensile properties of elastic arteries. Elastin is the primary load-




SMCs continually respond to changes in hemodynamic pressures and remodel the 
ECM to normalize stresses across the wall. During development, while these changes are 
important to layout the required vessel matrix, in adult tissues, these responses often 
result in pathological remodeling of the vessel. Since collagen is the ECM protein most 
expressed by SMCs, remodeling involves deposition of collagen, which increases wall 
stiffness. This can further change hemodynamics of the vessel wall and start a negative 




2.3. VASCULAR ELASTINOPATHIES 
Abnormalities of vascular matrix elastin may be broadly classified into two types: 
(a) genetic and/or congenital, and (b) acquired vascular disease. While most genetic 
diseases lack the required signaling pathway to lay down a mature elastic matrix, 
acquired diseases usually involve an injury induced inflammation, where macrophage-
derived proteases degrade the vascular elastin. In either of these cases, elastin-smooth 
muscle cell (SMC) signaling pathways are disrupted, causing SMCs to switch to an 
activated, synthetic phenotype. This in turn causes downstream effects of SMC hyper-
proliferation and medial thickening, further results in decreased arterial compliance and 




2.3.1. Genetic Disorders  
Genetic abnormalities affecting the elastic matrix can occur due to mutations in 










, Supravalvular Aortic Stenosis (SVAS)
114
, and Autosomal recessive Cutis 
Laxa
115
, directly result in impaired synthesis and deposition of mature elastic fibers, 
mutations in fibulin and fibrillin genes lead to defective microfibrillar scaffolds, which in 
turn impair matrix assembly
15
. These defects primarily affect the cardiovascular system, 

















Abnormal deposition of elastin in arterial walls, 
increased proliferation of SMCs, formation of 
hyperplastic intimal lesions; elastinolytic enzymes 
secreted by arterial smooth muscle cells contribute 









Defective elastic-fiber assembly; increased 
microfibril/elastic fiber degradation; enhanced 
TGF-b signaling, Results in Vascular disease, 
including aortic aneurysms and dissections, and 










Abnormal structure of dermal and vascular elastic 
fibers Results in inelastic skin, severe aortic disease 
and pulmonary emphysema 
 
Table 2.1: List of genetic abnormalities affecting the elastic matrix proteins 
 
2.3.2. Acquired Disorders: Abdominal Aortic Aneurysms 
Vascular pathologies arising from any injury to an intact vessel wall or in the 
presence of calcified or lipid deposits would elicit a cascade of inflammatory response 
starting with the infiltration of various MMPs and lymphocytes
16, 61, 83
. This results in 
phenotypic variations in SMC behavior and response, massive proteolysis and matrix 
reorganization. Under such conditions, the elastic matrix is degraded at an accelerated 
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rate resulting in generation of elastin peptides (EP) 
104
. EP, through their interaction with 
elastin-laminin receptors (ELR) on various inflammatory cells, further elicit a variety of 
pathologic effects such as MMP over-expression, greater Ca
2+
 influx, enhanced 
vasorelaxation and chemotactic activity
19, 107, 116
. Studies have shown that soon after the 
initiation of an inflammatory response, mRNA expressions of both tropoelastin and pro-
collagen increase within vascular SMCs
48
. While sufficient deposition of collagen matrix 
is observed due to regeneration associated with fibrotic cell response, elastic matrix 
regeneration is highly deficient relative to proteolytic elastin degradation. The failure to 
reinstate a healthy matrix, when damaged by injury or disease (as seen in aortic 
aneurysms), or when congenitally malformed or absent (Marfan’s syndrome), can 









AAA is defined as localized thinning and dilation of aortic walls of abdominal 
aortae leading to more than 50% increase in their original diameter (Figure 2.7) 
16-17
. 
Initiation and progression of AAA has been attributed primarily to chronic matrix 
Figure 2.7: Cartoon representing AAA. AAAs are characterized by a localized 
dilatation of abnomial aortic wall to > 50% their diameter 
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proteolysis by MMPs and inflammatory cells that infiltrate the vessel wall in response to 
atherosclerosis, calcified lipid deposits, vascular hypertension or inherited conditions
11, 16
. 
This is coupled with the absence of intrinsic signals in adult vascular cells to regenerate 
lost elastic matrix or to successfully repair diseased vessel wall
18
. The accelerated loss of 
elastic matrix and vessel wall integrity, and continuous fluctuations in hemodynamic 
pressures lead to abnormal ballooning of an aneurysm
19
. As mentioned earlier, AAAs 
typically grow about 1 cm/year to catastrophically rupture causing hemorrhage and 
embolisms, with fatality rates of approximately 80%. In the United States alone, the 




2.4. STRATEGIES TO RESTORE ELASTIC MATRIX 
As discussed so far, elastin plays important roles in maintaining vascular 
homeostasis, which when compromised can lead to various complications, and even be 
fatal. Its restoration is therefore crucial in reinstating homeostasis. Various strategies 
have been developed so far that directly and indirectly target elastin restoration. These 
can be broadly grouped into (a) preservative, (b) replacement and (c) regenerative 
strategies.  
 
2.4.1. Strategies to Replace Diseased Vessel Wall 
When stability of a diseased vascular wall is severely compromised and 
aneurysms dilate beyond a critical diameter, vascular grafts are surgically introduced to 
isolate the aneurysm and reduce the load on the vessel wall to prevent its rupture. 
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Vascular grafts for elastic arteries can be allogenic, xenogenic or artificial polymeric 
grafts. Autologous grafts like saphenous vein and mammary artery are usually used for 
replacing vessels with smaller diameters
117
. Allogenic grafts from deceased fetuses, 
cryopreserved tissues, cadavers umbilical cords have long been investigated as suitable 
tissue replacements for aortic aneurysms, among many other tissues due to similarities in 
size and mechanical properties. However issues like donor-specific immune rejection and 
high demand-supply ratio of these grafts have made them less popular alternatives
118
. 
Despite developments to improve donor-rejection like uptake of immune-suppressors by 
the recipient, decellularization and removal of immunoreactive epitopes and globular 
proteins from the grafts prior to implantation, their long-term stability and compatibility 
continues to be a problem
119
.   
To minimize donor-recipient supply ratio for transplants, xenogenic grafts have 
long been an attractive alternative. However, these grafts experience higher levels of 
immune rejection, primarily through complement activation
119
. Additional issues like 
disease transmission, permanent alternation to genetic code, higher thrombogenecity due 
to lack of endothelialization, compliance mismatch and mechanical stiffening post-
transplantation, physiological and biochemical variations in blood viscosity, liver 
metabolism and incompatibility of coagulation factors further lead to long-term graft 
rejection and implant-based complications
120-121
. New strategies to improve long term 
graft compatibility like transgenic modifications in pigs to express human complement-
regulatory proteins are currently being researched
122
.  
Replacement of an aneurismal vessel using synthetic grafts is currently the most 
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common approach to treat aortic aneurysms. While they are able to overcome the 
immune-rejection issues of allogenic and xenogenic grafts, they are also readily available 
and have lower risk of implant-related disease transmission
123
. The stent-grafts currently 
in the market follow similar designs. They primarily consist of a metal skeleton called 
‘stent’ that provides a frame for a polymeric ‘graft’, which are either sutured or bonded 
together. The graft is usually an elastomer like Dacron™ or poly(tetrafluoroethylene) 
(PTFE), while metal alloys like cobolt-chromium and stainless steel make up the stents
24
. 
Various stent-grafts currently available in the market are FDA approved (Zenith
®
 
Endovascular Graft, Cook Inc.; Gore Excluder
®
, WL Gore & Associates Inc.) while 
several others are under various stages of clinical trials, as depicted in
124
. The grafts are 
implanted either by a highly invasive open surgery, or a minimally invasive, catheter-
delivered endovascular repair (EVAR), as shown in (Figure 2.8). Both these techniques 
have their own benefits and shortcomings, and the choice of stent-graft or the delivery 
mode depends on the morphology of the disease, the patient and the surgeon
26
. Though 
synthetic grafts help isolate the aneurysm and prevent vessel rupture by providing an 
alternative conduit to blood flow, they are faced with several device-related issues like 
lack of endothelialization, various types of endoleaks, implant migration and fatigue, 
which affect long-term patency of the implant, and often require additional surgical 
intervention
25-26
. Moreover the graft materials have higher tensile properties compared to 
native vessel (~170Mpa for a graft vs. 800-1000 kPa for native aorta) which also lead to 
compliance mismatch
24
. While these grafts may replace the structural role of a blood 
vessel, they do not accommodate for the functional properties of elastic vessel ECM, 
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2.4.2. Strategies to Prevent Matrix Degradation 
As discussed earlier, matrix degradation is accelerated at the site of aneurysm, 
primarily due to the presence of inflammation induced MMP activity. Preservative 
strategies therefore target decelerating, or ideally, arresting matrix degradation to prevent 
or prolong the need for surgical intervention. These strategies mainly use 
pharmacological methods to regulate transcription factors, inhibit MMP and other 
protease activity, and introduce crosslinking agents etc. that stabilize matrix degradation. 
While these approaches slow down the rate of aneurysm progression and reduce medical 
expenses, they do not restore matrix integrity, and are also associated with several side 
effects.  
Expression and production of various MMPs by resident SMCs and fibroblasts at 
Figure 2.8: Cartoon representation of EVAR (left) vs. open surgical repair to treat 




the site of aneurysm accelerates matrix degradation. MMPs 2 and 9 in particular have 
been found to accelerate elastin degradation
12, 125
. Blocking MMP production therefore 
has been an obvious strategy to prevent matrix degradation. Various anti-inflammatory 
drugs, antibiotics, exogenous tissue-inhibitors of metalloproteases (TIMPs) and inhibitors 
of MMP transcription factors have been investigated to inhibit MMP synthesis and 
activity at the site of injury
20
.  
Doxycycline (DOX) is a modified tetracycline compound that has been widely 
administered as a broad-spectrum antibiotic
126
. Known to be a global, non-specific MMP 
inhibitor, systemic delivery of DOX has been clinically shown to reduce the rate of AAA 
growth and progression of disease
45-47
. Studies exploring the mechanisms of MMP 
inhibition have found DOX to significantly reduce protease activity both at transcription 
and translation steps of the protein synthesis
127-128
. Several groups have also specifically 
evaluated its effects on gelatinases, i.e., MMPs -2 and -9, proteases that are up-regulated 
most in the aneurysm wall and primarily responsible for elastolytic activity, both in vivo 
and in vitro
129-130
. In addition to reducing mRNA expression and total protein production, 
DOX also alters the conformation of both the zymogen and the active enzyme by binding 
enzyme-associated Ca
++131
. This makes the proteins more susceptible to proteolysis, 
resulting in their fragmentation into smaller molecular weight fractions and an 
irreversible loss of enzyme activity
131-132
. Studies on in vivo rodent models of AAA
133-134
 
and aortic organ cultures
135-136
 have shown a direct correlation between DOX-mediated 
suppression of gelatinase activity and significant reduction in elastin degradation in the 
vessel wall.  
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Anti-inflammatory drugs like Aspirin and stanins are commonly used by patients 
with AAA
20
. Other inhibitors of MMP activity like indomethacin, dexamethasone
 
and 
green tea catechins for MMP 9 and trapidil for MMP 2 have also been studied
20
. Use of 
exogenous TIMPs in the form of either synthetic TIMP or an adenoviral vector with a 
native TIMP1 cDNA have shown to inhibit SMC migration and reduce neointimal 
hyperplasia formation in a vascular injury model in rats
12
. Inhibitors of MMP mRNA 




Under healthy conditions, various protease inhibitors bind to proteolytic enzymes 
like elastases, and prevent uncontrolled matrix degradation. Absence of such inhibitors, 
such as serine-protease inhibitors seen in anti-trypsin deficiency, confirms the importance 
of these inhibitors. Another strategy to prevent elastin degradation therefore involves the 




Stabilization of matrix elastin within an aneurysm and prevention of further 
degradation by the use of chemical crosslinking agents is another approach to preserve 
elastin. Pentagalloyl glucose (PGG), a polyphenol derived from tannic acid, delivered 
periadventitially in a vascular injury model in rats, is shown to preserve elastic matrix 
integrity by specifically binding to arterial elastin, therefore inhibiting elastin 
degeneration attenuating aneurismal progression. PGG however is not shown to interfere 






2.4.3. Strategies for In vitro Tissue Engineering and In situ Repair of Vascular 
Elastic Matrix 
The strategies discussed so far only address replacing mechanical properties of an 
elastic tissue, but are unable to compensate for the physiochemical roles of elastin. Tissue 
engineering techniques offer potential alternatives to address both these essential 
requirements for successful restoration of an elastic vascular wall.  Though a large 
section of tissue engineering research has been devoted to regenerating completely 
functional blood vessels, obtaining a mature elastic matrix continues to be a challenge. So 
far, scientists have not created a viable vascular graft that possesses the necessary 
complex mechanical properties as well as mimics the biological function of a native 
artery, specifically elastin, but much progress has been made.  
Elastic fiber formation involves several steps of coordinated intracellular 
and extracellular activities. Strategies to regenerate elastin have used various 
combinations of cell types, culture environments, scaffold materials, growth factors and 
dynamic conditioning, each of which, independently and in combination, contribute to 
different levels of elastin synthesis and matrix deposition
10
. Each of these parameters 
influencing elastic matrix output are discussed in further detail as follows. 
 
2D vs. 3D Microenvironments: SMCs in native arteries exist within a 3-dimensional 
collagen matrix, interspersed with lamellar elastin. Isolated SMCs within a 2-dimensional 
culture environment would therefore evoke different responses in terms of cell phenotype 
and morphology, expression of various cell markers and growth factors, and type and 
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ultrastructure of matrix produced. Several studies have compared SMC behavior in 2-D 
culture plates to a 3-D scaffold environment. In one such study, RASMCs cultured on 
hyaluronic acid based scaffolds (gels) demonstrated an increased amount of elastin 
production, both soluble and insoluble, on the hyaluronan gels, compared to polystyrene 
culture plates. Microscopic analysis of the elastin structure further showed smooth, 
highly fenestrated sheets composed of fibers, visible along the sheet edges
34
. In another 
study, SMCs cultured within 3-D collagen gels showed lower rates of cell proliferation 
and matrix deposition, both collagen and elastin, compared to that seen in 2D collagen 
matrices. Similar trends were observed in synthetic scaffolds such as polyglygolic acid 
(PGA) and poly-lactic-co-glycolic acid (PLGA) as well. It has been shown that the cells 
acquire a more contractile, non-proliferative phenotype, much like in an in vivo condition, 
as opposed to a synthetic, proliferative phenotype within 2-D cultures
140
.This was 
additionally confirmed with the observation that tyrosine phosphorylation of FAK and 
the number of focal adhesions were far lesser in cells within 3-D collagen matrix, than 




Though SMC behavior within 3-D cultures also depend on the nature of scaffold 
used, apart from several other culture conditions, it is reasonable to believe that to 





Growth Factors─Induced Elastogenesis: Of the many growth factors investigated in the 
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field of regenerative strategies, insulin-like growth factor-1 (IGF-1)
142-144
, TGF-β family 
of growth factors
38, 145
 and human recombinant interleukin (IL-1β)
146
 are found to be 
elastogenic at various levels of elastin synthesis and matrix formation. Several methods 
of delivering these growth factors have also been explored in various tissue engineering 
applications, for example, surface tethered or  microsphere encapsulated growth factor 
delivery. Variables that determine efficiency of release profile include polymer used, its 
pore size, concentration and molecular weights of factors delivered and solvent the 
release profile is studied in. However, no direct correlation between delivery mode and 
elastogenesis has been established
147
.  
Several studies have demonstrated dose-dependent elastogenic induction of IGF-1 
in both confluent cell cultures and in vivo delivery to rats, primarily in terms of 
tropoelastin synthesis and mRNA expression. Elastogenic benefits of in vivo 
administration of IGF-1 to rats (1.2 mg/kg/day), was found to be tissue and age specific. 
While increased tropoelastin synthesis and matrix deposition was observed in the rat 
aorta, lung tropoelastin mRNA levels were unaffected. This phenomenon, though 
observed throughout the lifetime of the rat, was found to diminish with age
142-144
.  
Studies have also established the contribution of TGF-β family of growth factors 
to elastin synthesis during fetal development and in tissue repair. One such study 
examined the effects of TGF-β1 and TGF-β2 on human elastin mRNA abundance, 
promoter activity, and mRNA stability in cultured human skin fibroblasts and found that 
with varying concentrations of TGF-β1 or TGF-β2 for 24 h resulted in a dose dependent 
increase in the elastin mRNA steady-state levels, with a maximum enhancement of 
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approximately 30-fold being noted with 1 ng/mL. These results demonstrate that TGF-β1 
and TGF-β2 are potent enhancers of elastin gene expression and that this effect is 
mediated, at least in part, post-transcriptionally
38, 145
. In addition, TGF-β augments LOX-
mediated crosslinking of soluble tropoelastin into a mature, insoluble matrix layer
38
.  
Besides growth factors, various biomolecules such as LOX
 
helps to crosslink the 
tropoelastin to give elastic fibers
148
. In the absence of LOX, tropoelastin tends to 
associate with GAGs due to the presence of amino groups in the elastin lysine residues, 
which offer positive charges for binding with negative charges of GAGs
43
. Besides, in the 
absence of LOX, such electrostatic interaction could be important and prevent newly 
synthesized tropoelastin molecules from spontaneous random aggregation far from the 
cell surface. Elastogenic benefits of Cu ions/nanoparticles
149
, calcitriol and retinoic acid
 




HA as an Elastogenic Stimulator: HA is a type high molecular weight GAG found in the 
ECM of many tissues. It consists of N-acetyl-D-glucosamine (GlcNAc) and D-glucuronic 
acid (GlcA) repeats linked by a β1-4 glycosidic bond. The disaccharide units are linked 
by β1-3 bonds to form the HA chain
153-155
. HA is known to influence various physiologic 
functions such as morphogenesis, embryonic development, tissue stability, cell 
proliferation, remodelling, migration, differentiation, angiogenesis and wound healing. 
This is suggested to be achieved through its interaction with a set of HA-binding matrix 
and cell surface receptor proteins called hyaladherins
156-158
. Among them, CD44, a cell 
surface glycoprotein with a molecular weight of ~85 kDa, is known to play an important 
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role in HA binding to the cell surface
156, 159
. The presence of pro-inflammatory cytokines 
like IL-1, and growth factors like EGF, TGF-β and BMP-7, is further known to increase 
transcription levels of CD-44, therefore improving cell-HA interaction
154-155
. Studies in 
vascular, pulmonary and dermal tissues have reported a close association between GAGs 
such as HA and heparin sulfate, and proteoglycans such as versican
160
. Unlike GAGs like 
dermatan and chondroitin sulfates, HA was found to support elastic fiber formation by 
playing a key role in the synthesis, organization, and stabilization of elastin by VSMCs
42
. 
This is attributed, in part, to the role of HA in synthesis and organization of microfibrils 
(fibrillin), a precursor for elastic fiber deposition, and in part, to its binding of versican, 
which in turn interacts with microfibrillar proteins like fibulins-1 and-2, and elastin-
associated proteins to form higher-order macromolecular structures important for elastic 
fiber assembly
158
. Recent studies also provide evidence that due to the presence of 
charged lysine residues, soluble tropoelastin molecules are coecervated on the highly 
anionic surfaces of HA, to facilitate LOX-mediated crosslinking into an insoluble matrix. 
HA is also known to stabilize elastin fibers against degradation by elastases
43
. Several 
studies have also been conducted to explain the size-specific effects of HA. Native HA is 
a long-chain, stable polymer, with molecular weight > 1000kDa (HMW HA). It hydrates 
the ECM and binds growth factors and smaller GAGs. On the other hand, smaller 
fragments of HA like Low molecular weight HA (LMW HA) ~100 kDa, and HA 
oligosaccharides (HA-o) ~ 2-10 kDa, are capable of binding to cell surface receptors in a 
monovalent manner resulting in the stimulation of specific cell signaling cascades, thus 
influencing their metabolic functions
161
. LMW HA are synthesized from enzymatically 
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digested HMW HA and are found in association with proliferating ECs and SMCs. 




. Previous studies conducted in our lab have established size-specific effects 




Role of Mechanical Stimulation In Matrix Assembly: Mechanical conditioning is 
another consideration for tissue engineering vascular grafts. Elastin synthesis by vascular 
SMCs is very sensitive to magnitude, frequency, duration and type of strain applied
164-165
. 
Numerous studies have been conducted to study the effects of dynamic conditioning on 
elastogenesis. While shear stresses induce apoptosis and detrimental cell response in 
VSMCs, the application of cyclic mechanical stretch simulating distension experienced 
by medial SMCs in vivo significantly influence the phenotype, alignment, matrix 
deposition, and growth factor release by both native and cultured SMCs
58, 164-165
. Recent 
studies have demonstrated that SMCs, isolated from both rat and human aortae, respond 
positively to radial and cyclic strains of < 10% by improving collagen compaction, tensile 
strength, circumferential alignment of cells and matrix, and up to a 2-fold increase in 
elastin mRNA production 
57, 59, 164-166
. Changing the frequency of cyclic strains was found 
to play a more significant role in regulating the alignment of vascular SMCs in an intact 
actin filament-dependent manner; frequency of 1.25 Hz for cyclic strains between 2.5%-
10% was found to be most effective in influencing SMC response
167-169
. Cyclic stretch-
induced matrix synthesis has been found to be regulated by a tyrosine-kinase dependent 
TGF-β pathway
170
. A mentioned earlier, integrins play a primary role in 
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mechanotransductive effects of external stimuli on vascular cell response
85, 171
. Excessive 
strains of over 10% and beyond 5 Hz frequency have been found to induce apoptotic 
response mediated via integrins
164
.        
 
Scaffolding Materials for Elastic Matrix Engineering: Scaffolds provide a 3-D template 
for cellular infiltration and neo-tissue synthesis. Once the desired tissue is formed, the 
scaffold material must ideally degrade into non-toxic byproducts. Scaffolds can be 
broadly classified into (a) natural and (b) synthetic scaffolds. Apart from the type of 
scaffold used, various culture parameters like addition of biomolecules, cell type, 
duration of culture, application of mechanical stimuli etc., are interdependent and impact 
final outcomes of elastic matrix. Table.2.2 gives an overview of various scaffolds 
investigated so far in combination with these parameters towards elastic matrix outcomes.  
 
Targeted Delivery of Elastogenic Factors: In the previous sections, we discussed various 
biomolecules as that have been demonstrated, or have the potential for use in elastic 
matrix regeneration and repair. The primary considerations in translating their benefits 
demonstrated in vitro, into in vivo clinical use is determining an effective dose range, and 
more importantly the mode of delivery. This is especially true with the use of 
biomolecules that induce a variety of repose depending on their concentrations and tissue 
within AAA, at similar doses, TGF-β1 induces antagonistic and adverse reactions within 
TAA
60, 185
. It is therefore crucial to develop strategies that can specifically target a tissue 
site and have precise control over their delivery
186-188
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Table 2.2: Strategies using various combinations of scaffolds, dynamic stimulation, and 










  on which they are surface tethered, or through 
a combination of both
201-206
. Several factors such as topography, degradation products 
and their effects, carrier chemistry etc. play a critical role in efficient delivery as well as 
in regulating cell response
207-209
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chemistry closely regulate cell attachment via integrin signaling
210-211
. Biomolecules 
encapsulated within polymeric carriers, especially growth factors are sensitive to 
processing steps as well as the byproducts of polymer degradation, and can often result in 
loss of bioactivity
60, 212
. Along with scaffold chemistry, surface charge is also shown to 
influence release profiles as well as efficient uptake of released factor depending on the 
tissue site. For example, for targeted delivery within the vasculature, and scaffolds 
functionalized with a positive surface charge have shown to improve uptake and 
retention
213-214
.Cationic surfaces have shown to positively influence outcomes in elastic 
matrix engineering as well. It has been hypothesized that cationic functionalization 
enables interaction with hydrophobic domains in elastin and the crosslinking enzyme, 




While a lot of progress has been made towards vascular matrix engineering and in 
situ repair of compromised vessels, regeneration of elastic matrix is still insufficiently 
addressed. Nonetheless, various parameters summarized in this chapter, especially when 
used in combination, hold promise towards development of successful elastic matrix 









INVESTIGATING INDUCED ELASTOGENESIS BY VASCULAR SMCS IN AN 
IN VITRO 3-D COLLAGEN-GEL MICROENVIRONMENT 
 
3.1. INTRODUCTION 
As discussed in detail in the previous chapters, the elastic matrix is responsible for 
providing vessels the necessary recoil and compliance to accommodate blood flow, and 
at the same time also regulates vascular smooth muscle cell (SMC) behavior through 
mechano–transduction
1
, particularly during morphogenesis and disease progression
2
. 
Once injured, the elastic matrix is not repaired, due to (a) poor elastin precursor 
(tropoelastin) synthesis by adult cells, (b) inefficient recruitment and crosslinking of 
tropoelastin into an elastic matrix, and (c) further organization into elastic fibers
10
. The 
failure to reinstate a healthy matrix, when damaged by injury or disease, or when 
congenitally malformed or absent, can therefore severely compromise tissue homeostasis. 
This is one of the reasons why synthetic graft replacements (e.g. ePTFE) for such 
diseased segments, though capable of reinstating vessel elasticity and compliance, are 
unable to provide biologic stimuli to restore healthy vascular cell phenotype and tissue 
homeostasis. 
Alternative strategies to tissue engineer elastic vessel replacements using 
autologous adult vascular SMCs seeded on biodegradable scaffolds, natural or synthetic, 
have been challenged by poor elastogenicity of these cell types, and lack of knowledge of 
materials and methods to biomimetically replicate and enhance tropoelastin synthesis, 
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recruitment, crosslinking, and matrix assembly
10
. The problem of poor elastic matrix 
deposition is especially severe in cellular microenvironments within such tissue–
engineered constructs invariably rich in regenerated collagen, which switch SMCs to a 
less synthetic, and even less elastogenic phenotype
56
.    
Of potential benefit to overcoming the poor elastogenicity of adult vascular cells, 
our laboratory previously determined the synergistic benefits of HA–o and TGF–β1 to 
elastin precursor synthesis, elastic matrix deposition, and fiber formation by cultured 
adult rat and human SMCs
148, 184
. We also showed that TGF–β1 increases expression 
levels of mRNA for tropoelastin, and that of the matrix crosslinking enzyme, lysyl 
oxidase (LOX), while suppressing the activity of matrix degrading matrix 
metalloproteinases (MMPs) 
148, 217
. Negatively-charged HA is also thought to coacervate 
tropoelastin molecules for more efficient localized crosslinking and organization of these 
precursors into mature fibers, much like the role of glycosaminoglycans (GAGs) in a 
developing aorta
34, 42
. Our prior data also suggests that oligomeric forms of HA, 
specifically 4– and 6– mers, also enhance elastin mRNA expression. The presence of 
collagenous matrix is centric to replicating vascular tissue architecture and mechanics
48
, 
and vascular cells, regardless of the choice of scaffolds, robustly synthesize collagen
10, 27
. 
It is therefore imperative to examine the impact of a pre-existing collagenous 
microenvironment on the ability of the cells to synthesize fibrous elastic matrix on their 
own and also their response to provided elastogenic factors
56
. Towards utilizing the 
above factors to enable and enhance elastic matrix deposition within collagenous tissue, 
in the present study, we investigate the effect of these factors at different dose 
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combinations within statically loaded 3–dimensional (3–D) cellularized collagen 
constructs. 
 
 3.2. MATERIALS AND METHODS 
3.2.1. Isolation and Culture of Rat Aortic Smooth Muscle Cells 
Abdominal aortae were harvested from adult Sprague–Dawley rats according to 
animal protocols approved by the Medical University of South Carolina, where this work 
was performed. After scraping out the intima and the adventitia, the medial layers of the 
aortae were minced into 1–2 mm–long pieces, incubated first in DMEM–F12 (Gibco–
Invitrogen, Carlsbad, CA) containing 20% v/v fetal bovine serum (PAA Scientific, 
Dartmouth, MA), 1% v/v Penstrep (Thermo Scientific, Rockford, IL) and 175 U/ml 
collagenase II (Worthington Biochemicals, Lakewood, NJ) for one hour at 37 °C. The 
pieces were then incubated in a second digestion mixture containing the above solution 
supplemented with 0.25 mg/ml of elastase III (Worthington Biochemicals, Lakewood, NJ) 
for 45 minutes. The digestate was finally centrifuged at 200g for 5 minutes, and the pellet 
re–constituted and cultured in DMEM–F12 containing 20% v/v serum and 1% v/v 
Penstrep. Primary rat aortic SMCs (RASMCs) thus obtained, were cultured and passaged 
in T–75 flasks. Cells of low passage (P3 – P5) were used to seed the collagen constructs. 
 
3.2.2.  Fabrication of Cellularized Collagen Constructs 
The inherent nature of cell–seeded collagen to shrink and form a compacted gel 
was utilized to fabricate 3–D constructs. Collagen–cell mixtures were aliquoted within 
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rectangular (3.8 mm × 2 mm × 1.5 mm) silicone rubber (Smooth–On, Inc., Easton, PA) 
wells cast in 100 mm diameter glass petri–dishes
218-219
. The molds/dishes were steam–
sterilized at 121 ºC for 30 minutes. In order to obtain directed compaction of the collagen 
gels under static tension, polyurethane tubes anchored with stainless steel pins (both 
sterilized in 1 N HCl for 20 minutes and rinsed in sterile PBS) were anchored to the ends 
of each well.  
Acid–solubilized type I collagen (BD Biosciences, Bedford, MA) was mixed with 
5 × DMEM/F12 and 0.1 N NaOH and added drop wise to titrate the mixture to 
physiological pH. RASMCs (passages 3–5) were trypsinized, centrifuged, and re–
suspended in medium and added to the above solution to obtain a final concentration of 2 
mg/ml collagen, 1 × 10
6 
cells/ml, 20% v/v serum and 1% v/v Penstrep in DMEM–F12. 
All mixing was performed on ice to prevent premature polymerization of collagen when 
physiologic pH was attained. Equal volumes of this collagen-SMC mixture were then 
aliquoted into each well and cultured in a CO2 incubator at 37 °C. Within a few hours, the 
collagen–cell mixture started to gel and anchor around the polyurethane end holders. 
These holders prevented longitudinal gel contraction, but enabled contraction in a 




Figure 3.1: Statically loaded RASMC–seeded 3–D collagen gels. Gels, shown at day 




A sterile cocktail of HA–o and TGF–β1 (Peprotech, Rocky Hill, NJ) was 
exogenously supplemented in the growth medium, at six different dose combinations (0.1, 
1 and 10 ng/ml of TGF–β1, each with 0.2 and 2 µg/ml of HA–o). Since this is a 
pioneering study utilizing a combination of HA–o and TGF–β1 for elastic matrix 
synthesis by SMCs within 3-D cultures, there is lack of literature indicating appropriate 
doses for such a model. We have therefore extrapolated the dose range for the current 
study from our outcomes in 2-D cultures, and utilized a range to include concentrations 
of an order of magnitude lower and higher than that used in 2-D cultures in order to 
evaluate optimum conditions
37, 139, 220
. HA oligomer mixtures used in this study primarily 
consisted of 4–mers (~ 75%) with 6–mers and 8–mers forming the balance. They were 
prepared by digesting high molecular weight HA (1.5 × 10
6
 Da, Genzyme Biosurgery, 
Cambridge, MA) with testicular hyaluronidase (40 U/mg at 37 °C; Worthington 
Biochemicals, Lakewood, NJ) as we have described previously
163
. The constructs were 
cultured for 21 days and spent medium changed every two days. Spent medium from 
each well was pooled with aliquots previously removed from the same wells, and frozen 
at –20 °C until biochemically analyzed at the end of the culture period. 
 
3.2.3. Construct Compaction 
All constructs were photographed at regular intervals using a digital camera and 
their central widths measured using Image–J (NIH, Bethesda, MD) imaging software. 
The extent of contraction (compaction ratio) of each construct was measured as a 
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percentage difference in width of the well and the central width of the construct at day 21. 
At least three measurements were made on each construct. 
 
3.2.4. DNA Assay for Cell Quantification 
The DNA content of RASMCs within the collagen constructs was measured at 21 
days of culture to estimate to estimate increases to cell number relative to that at seeding. 
Briefly, the gels were detached from the holders and digested in 10 mg/ml proteinase–K 
(Gibco–Invitrogen, Carlsbad, CA) at 65 °C for 10 hours until the matrix structure was 
completely solubilized. The enzyme was inactivated by boiling the solution for ten 
minutes. The digested solution was then sonicated for 3 minutes on ice to lyse cells, and 
DNA content was measured using a flourometric assay. Cell numbers were calculated 
assuming  6 pg of DNA/ cell
221
. Results were represented in terms of cell proliferation 
ratio (cell count at 21 days/ initial seeding density) and as a fold–change in this ratio 
compared to control.  
 
3.2.5. RT-PCR for mRNA expression of Tropoelastin, Collagen and LOX 
Constructs were harvested in RNA-Later stabilization solution (Qiagen, Valencia, 
CA) after 21 days of culture, homogenized using a needle and syringe, RNA extracted 
using an RNeasy kit (Qiagen, Valencia, CA), and samples loaded onto RNeasy mini 
columns. Total RNA was eluted with 40 μL of RNase-free water, its concentration 
determined by absorbance measurement at 260 nm using a Ribo-green assay kit 
(Invitrogen, Carlsbad, CA). 200 ng of RNA was reverse transcribed with iScript cDNA 
54 
 
synthesis kit (Biorad, Hercules, CA) according to the manufacturers’ instructions. 
Samples (40 μL) were incubated at 42 ºC for 5 minutes and then reverse transcriptase 
(RT) inactivated at 85 ºC for 35 minutes. Gene expression for collagen, elastin and LOX 
were evaluated using 1 µl of cDNA with Power SYBR
®
Green Master Mix (Applied 
Biosystems, Foster, CA) (n = 6/case) in the ABI 7500 Real Time PCR System (Applied 
Biosystems). A comparative threshold method 
222
 was used to quantify the mRNA 
expression of these genes and was reported as 2
–∆∆Ct
, with 18s serving as the internal 
control. The sequences of all primers are listed in Table 3.1.  
 
3.2.6. Fastin Assay for Elastin Content 
Total elastin synthesized by RASMCs was measured using a commercially 
available Fastin assay kit (Accurate Scientific and Chemical Corporation, Westbury, NY). 
Three distinct elastin fractions were assayed for, namely, (a) tropoelastin, the soluble 
precursor of elastin synthesized by cells, present within medium fractions, (b) the less 
crosslinked, alkali–soluble matrix elastin, and (c) the highly crosslinked, alkali–insoluble 
matrix elastin. Volume fractions from the pooled culture medium were directly used to 
measure tropoelastin. To measure matrix elastin, the constructs were first treated with 0.1 
N NaOH at 95 °C for one hour and centrifuged. The resulting supernatant consisted of 
alkali–soluble matrix elastin, while the pellet comprised of alkali–insoluble matrix elastin. 
The soluble matrix fraction was neutralized with an equal volume of 6 N HCl at 110 °C 
for 16 hours, dried overnight, reconstituted in water and quantified using the kit. Since 
the Fastin kit measures only soluble, α–elastin (~ 60 kDa), the insoluble matrix pellet was 
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first solubilized with 0.25 M oxalic acid at 95 °C for one hour, and then filter–centrifuged 
with 10 kDa cut–off membranes (Millipore, Billerica, MA). The solubilized matrix 
elastin retained above the filters was then quantified with the assay kit. Tropoelastin and 
total matrix (alkali –soluble + –insoluble) thus measured were normalized to the cell 
count within respective constructs. The matrix yield (i.e. the ratio of matrix elastin/ 
(tropoelastin + matrix elastin) × 100) was calculated. 
 



























Primers) Reverse CCA GGT AGC TGG GGT TTA CA 
 
Table 3.1: Forward and reverse sequences of primers for rat ELN, LOX, and the house-
keeping gene, 18S 
 
3.2.7. Western Blotting for LOX and MMPs –2 and –9  
Western blotting was performed to semi–quantitatively compare the amounts of 
LOX enzyme protein and of the elastolytic MMPs –2 and –9, synthesized by RASMCs 
within constructs subjected to different treatment conditions.  At day 21, harvested 
constructs were ground into powder in liquid nitrogen, extracted in RIPA lysis buffer 
(750 µl, Invitrogen, Carlsbad, CA) with a protease inhibitor cocktail (Thermo Scientific, 
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Rockford, IL), and then assayed for total protein content using a BCA assay kit (Thermo 
Scientific, Rockford, IL)
223
. Volumes equivalent to 3 μg of protein were loaded under 
reduced conditions into 4–12% SDS PAGE gel for LOX analysis and 10% SDS PAGE 
gel for MMP analysis, along with a pre–stained molecular weight ladder (Invitrogen, 
Carlsbad, CA). The gels were then transferred wet onto PVDF membranes. Following 
this, the membranes were blocked in TBST (Tris–Buffered Saline with 0.01% v/v Tween 
20, pH 7.4) containing 5% w/v milk for an hour, immunostained using polyclonal 
antibodies (1:1000 for 1.5 hours) against LOX (Santa Cruz Biotechnology, Inc. Santa 
Cruz, CA), MMP–2 (Abcam, Cambridge, MA) and MMP–9 (Millipore, Billerica, MA), 
HRP–conjugated secondary antibody (1:10,000 for one hour) (GE Healthcare 
Biosciences, Pittsburgh, PA) and detected using an ECL–plus chemiluminogen detection 
kit (GE Healthcare Biosciences, Pittsburgh, PA). The blotted membranes were then 
stripped and re–probed with β–actin loading control (Abcam, Cambridge, MA). Bands 
were quantified using Image–J software (NIH, Bethesda, MD), expressed as relative 
density units (RDU) and normalized to control. Analysis was performed on bands 
generated from 3 blots per condition. 
 
3.2.8.  Gelatin Zymography for Detection of MMP–2 and –9 
Volumes containing 5 μg proteins from the digested constructs were loaded per 
lane of 10% gelatin zymograms (Invitrogen, Carlsbad, CA) and run alongside a pre–
stained protein ladder (10 kDa–190 kDa; Invitrogen, Carlsbad, CA), and purified protein 
standards of MMPs -2 and -9 (Anaspec, Fremont, CA), for 2 hours at 125 V. The gels 
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were then washed in 2.5% v/v Triton X– 100 for 30 minutes to remove SDS, following 
which they were incubated overnight in a substrate buffer to activate MMPs. The gels 
were then stained in Coomassie Brilliant Blue solution (Sigma, St. Louis, MO) for 45 
minutes and de–stained (40% v/v methanol, 10% v/v glacial acetic acid) for 1.5 hours 
until clear bands were visible against a blue background
223
. The band intensities were 
quantified using Image–J and expressed as RDU values of the experimental cases 
normalized to RDU values of control cultures. Analysis was performed on the bands 
generated from 3 gels per condition. 
 
3.2.9.  Visualization of Elastic Matrix and Mineralization 
At 21 days of culture, the constructs were fixed in 4% w/v formalin and 
embedded in paraffin. Tissue sections (5 μm thick) were then stained for elastin using a 
Verhoeff Van Gieson (VVG)–based elastic–stain kit (ScyTek Laboratories, Inc., Cache, 
UT).  To visualize elastin using immuno–fluorescence, the sections were incubated in 
0.05% w/v Pontamine sky blue (Sigma, St. Louis, MO) for 30 minutes, mounted using 
Vectashield containing DAPI (Vector Laboratories, INC. Burlingame, CA), cover–
slipped and observed with a visible–red (Texas red) fluorescent filter. Pontamine sky blue 
quenches the auto–fluorescence of elastin and collagen in the visible–green region of the 
emission spectrum, and transfers the auto–fluorescence of elastin alone to the red region 
of the spectrum
224
. Elastin–specific fluorescence of sections labeled in this manner was 
confirmed by detecting elastic matrix in separate sections from the same sample with a 
rabbit anti–rat elastin antibody. Sections were imaged using a fluorescent microscope and 
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alignment of elastic fibers in the constructs were quantified by calculating their angular 
standard deviation
225
. Length and angle of individual fibers were measured using Image 
Pro software (Bethesda, MD).  Elastin deposits with aspect ratio greater than 2 (long axis: 
short axis) were assumed to be fibers and only these were used for quantification.  
 The presence/absence of calcific deposits within constructs was ascertained by 
labeling sections with a Von Kossa–based calcium–staining kit (ScyTek Laboratories Inc., 
Cache, UT).   
 
3.2.10. Mechanical Testing of 3-D Constructs 
 Uniaxial mechanical testing was performed on constructs treated with 4 selected 
dose combinations: 0.1 ng/ml, 1 ng/ml and 10 ng/ml TGF-β1, each with 0.2 µg/ml HA-o 
(n = 10/ case) using Instron 5943 under a 10 N load cell.  Only 4 experimental cases were 
chosen to perform the mechanical testing based on the observations made using the 
various biochemical tests described above: 1) untreated control, 2) 0.2 μg/ml HA-o and 
0.1 ng/ml TGF-β1, 3) 0.2 μg/ml HA-o and 1 ng/ml TGF-β1, and 4) 0.2 μg/ml HA-o and 
10 ng/ml TGF-β1. The width of constructs was measured optically using a stereoscope, 
and thickness measurements using a liner variable differential transducer (LVDT). The 
constructs were gripped between serrated metal grips after wrapping the ends with three 
layers of paper towel and testing was performed in a saline bath maintained at 37 °C. 
Specimens were first preconditioned at a rate of 4 mm/s for 10 cycles followed by load to 
failure at an extension rate of 10 mm/min. Load vs. displacement and stress vs. strain 
curves were calibrated and elastic moduli calculated for each construct. Failure loads 
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were calculated if the specimens do not fail at the grips or due to other artifacts. Tensile 
modulus was calculated between 15%-30% strains (85 data points for all constructs). 
 
3.2.11. Statistical Analysis 
All quantitative results were analyzed from n = 6 independent repeats of each case and 
reported as mean ± standard deviation. Statistical significance between groups was 
determined from a one-way analysis of variance (ANOVA) and for  values ≤ 0.05. 
Power analysis of our prior data indicates that n = 6 replicates for cell/tissue cultures with 
3 independent measurements for each parameter, is sufficient to reliably detect 
quantitative differences in outcomes, with a power of ≥ 0.95 (i.e.,   = 0.05, i.e., 5% 






3.3.1. Cell Quantification 
As seen in Figure 3.2, cell numbers were highest (4.2 ± 0.8 –fold increases over 
21 days; 1.4 ± 0.1 –fold vs. non–factor treated control) in constructs cultured with the 
lowest dose combination of TGF–β1 (0.1 ng/ml) and HA–o (2 µg/ml), and lowest (1.96 ± 
0.23 fold increase over 21 days; 63 ± 13% of cell counts in control cultures at day 21) 
within constructs cultured with the highest dose of factors, i.e., TGF–β1 (10 ng/ml) and 







3.3.2. Elastic Matrix Content 
Elastic matrix outcomes were quantified in terms of mRNA expressions of 
tropoelastin and LOX, quantity of the soluble precursor i.e., tropoelastin, quantity of 
matrix components of elastin i.e., alkali-soluble and –insoluble elastin, and LOX protein 
content. As seen in Figure 3.3, mRNA expression of elastin remained unchanged relative 
to control in all treatment conditions ( > 0.4). Cells within the control constructs 
synthesized 4.4 ± 0.5 ng/cell of tropoelastin, 9.4 ± 3.4 pg/cell of matrix elastin, 
comprising 4.5 ± 1.8 pg/cell of alkali–soluble matrix elastin and 1.5 ± 1.1 pg/cell of 
alkali–soluble fraction. Tropoelastin synthesis per cell was unaffected by culture with 
TGF–β1 and HA–o, except at the highest provided dose combination (10 ng/ml TGF–β1 
and 2 µg/ml HA–o) at which significant increases (1.5 ± 0.2 – fold vs. control) were 
noted (Figure 3.4 A). Consistent with the tropoelastin content though, this difference was  
Figure 3.2: Effect of elastogenic factors on cell proliferation ratio. Cell numbers 
were calculated based on the estimate of 6 pg of DNA per cell, as calculated from 
DNA assay, at 0 and 21 days post–seeding, and their ratios determined and 
compared to. Differences were deemed to be significant from control cultures for 











most pronounced in the cases with highest TGF–β1 doses (up to 26.2 ± 2.4 fold increase 
compared to control). This increase was significantly higher compared to the lower dose-
Figure 3.3: Effect of treatment conditions of mRNA expression of elastin relative 
to control constructs. No significant differences were observed between different 
conditions (n = 6) 
Figure 3.4: Effect of TGF–β1 and 
HA–o on elastin synthesis. (A) 
Differences in synthesis of 
tropoelastin and total matrix 
elastin per construct in samples 
cultured with HA–o and TGF–β1 
relative to control cultures. (B) 
Effect of factor treatment on 
synthesis of alkali–soluble matrix 
elastin and crosslinked, alkali–
insoluble matrix elastin. (C) 
Effect of factor treatment on 
yields of matrix elastin, i.e. the 
fraction of total elastin amounts 
produced by cells that is deposited 
in the matrix. ‘*’ indicates 
differences from controls 
significant for p < 0.05, and ‘#’ 
between cases as indicated (n = 6 
for each case) 
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combinations as well (14.5 ± 3.4 in 0.1 ng/ml TGF–β1, and 11.2 ± 3.1 in 1 ng/ml TGF–
β1). Differences in addition of HA-o with equal doses of TGF–β1 were insignificant in 











On the other hand, elastic matrix deposition per cell was also significantly greater 
in most experimental cases compared to control, with greatest increases (5.4 ± 0.8 and 5.3 
± 1.1 – folds vs. control) noted in constructs cultured with the lower dose combinations 
of TGF–β1 (0.1 ng/ml) and HA–o (0.2 µg/ml or 2 µg/ml) (Figure 3.4 B). Also noted was 
that increases in matrix elastin, especially at the lower provided doses of factors, were 
Figure 3.6: Fold change in protein levels of LOX in cultures with TGF–β1 and HA–o  
factors compared to untreated control cultures, as determined by western blotting. 
Differences from control were deemed significant (*) for p < 0.05 (n = 3 per case). 
Figure 3.5: Effect of treatment conditions of mRNA expression of LOX relative to 
control constructs. Significant differences, indicated by ‘*’ were observed in all 
treatment conditions relative to control (n = 6), p < 0.05 
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associated more with increases in the less crosslinked, alkali–soluble matrix elastin 
fraction than with the more robustly–crosslinked, alkali–insoluble fraction. At the highest 
provided dose combinations, fold increases in both fractions compared to control were 
similar, i.e. the ratios of alkali- insoluble to –soluble elastin were the highest (Figure 3.4 
C). This finding was consistent with mRNA expression and western blotting analysis for 
LOX enzyme (31 kDa) synthesis within cultured constructs. mRNA expression of LOX 
was elevated in all treatment conditions relative to control ( < 0.05), with the highest 
increase in constructs with 10 ng/ml TGF-β1 with both doses of HA-o (2.56 ± 3.5 –fold, 
 < 0.001, relative to control), as seen in Figure 3.5. LOX protein content was also 
highest in constructs cultured with 10 ng/ml of TGF–β1 and 0.2 µg/ml of HA–o (3.5 ± 
0.5 –fold vs. control). LOX protein synthesis was elevated in all factor-treated cases 
compared to control (Figures 3.6 and 3.7). Matrix yields (Figure 3.4 C) were greatest in 
constructs cultured with the lower dose combination of factors, i.e. 0.1 ng/ml TGF–β1 






Figure 3.7: Effect of factors on enzyme synthesis and active forms. Representative 
immunoblots of (A) MMP–9 and (B) MMP–2 indicating the active and inactive 
protein bands for each case, and (C) LOX. (D) Representative gelatin zymogram of 
MMP–2 indicating the active and inactive bands 
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3.3.3. MMP Protein Analysis 
Figure 3.7 shows representative immunoblots of MMPs –2 and –9 and zymogram 
of MMP–2. Figure 3.8 compares MMP –2 and –9 amounts measured within collagen 
constructs treated with TGF–β1 and HA–o factors, with that measured within untreated 
control constructs.  
MMP 2 was detected on the Western blots as two distinct bands corresponding to 
the zymogen form (~ 72 kDa) and active form (~ 62 kDa). MMP–9 was also detected in 
its zymogen (~ 92 kDa) and active (~ 82 kDa) forms. The greatest increases in total 
(active and inactive forms) MMP–2 protein amounts over controls was observed within 
constructs cultured with the lower dose combinations of the factors In general, MMP–9 
synthesis was decreased in factor–treated constructs relative to control, though the 
decreases were greatest and statistically significant for constructs cultured with the 
highest TGF–β1 factor (10 ng/ml of TGF–β1 and 0.2 µg/ml or 2 µg/ml of HA–o) and 
with the lowest dose combination (0.1 ng/ml TGF–β1 and 0.2 µg/ml HA–o).  
Figure 3.9 compares active and inactive forms of MMP–2 in factor–treated 
constructs with that in control constructs. MMP–9 activity is not shown since the bands 
were absent or too faint to be reliably quantified. In general, MMP–2 zymogen levels 
were very low, both in control and factor–treated constructs, except those cultured with 
low doses of HA–o (0.2 or 2 µg/ml) and TGF–β1 (0.1 ng/ml). The quantities of the active 
form of MMP–2 were also mostly similar between constructs, excepting those cultured 
with low doses of HA–o (0.2 or 2 µg/ml) and TGF–β1 (0.1 ng/ml), in which significant 













3.3.4. Mechanical Properties of Constructs 
 The compaction ratio of constructs cultured with the various dose combinations 
of TGF–β1 and HA–o was less than that of control constructs cultured without the factors 
(Figure 3.10). Compaction ratios were the lowest in constructs that received one of the 
two lowest dose combinations, specifically, 0.1 ng/ml TGF–β1 and 2 µg/ml HA–o (46.57 
± 4.12 %, p < 0.05).  
 
Figure 3.8: Differences in total protein synthesis of MMPs –2 and –9 in experimental 
cases compared to control, as determined from immunoblotting of the two proteases. 
‘*’ indicates statistical difference compared to control for p < 0.05 (n = 3 per case) 
Figure 3.9: Effect of factors on MMP–2 quantities as determined by gelatin 
zymography. Data represents a fold change in relative density units of zymogram 
bands in experimental cases compared to control cultures. Significance in differences 








Tensile testing of constructs (Figure 3.11) revealed non-linear stress strain 
curves, typical of collagenous tissues. Addition of factors did not significantly alter the 
modulus of the constructs, in both the elastic toe region, as well as the plastic region. The 
highest elastic moduli were observed in untreated control constructs (740.7 ± 81.2 kPa), 
and the lowest in constructs with 0.1  ng/ml TGF–β1 and 0.2 µg/ml HA-o (632.6 ± 61.3 
kPa). However, these differences were not statistically significant, compared to control or 
between constructs. The toe region of the constructs at the start of load to failure test 
phase was inconsistent. Therefore tensile modulus at this region was not calculated. 
Almost all constructs failed at the grips, and therefore the yield properties could not be 
accurately and consistently determined. 
 
3.3.5.  Visualization of Elastic Matrix  
VVG staining for elastin (Figure 3.12) and immuno–fluorescence labeling after 
Pontamine sky–blue quenching (Figure 3.13) showed the presence of elastic fibers in all 
the constructs treated with factors, although due to the limited thickness of the sections,  
Figure 3.10: Percentage change in central widths of constructs at day 21 compared to 
day 0 (n = 6 per case). * indicates significance of differences compared to control 















the continuity and total length of individual fibers could not be ascertained. Elastic fibers 
were more abundant and appeared more complete towards the edges of the constructs.  
Elastic fiber alignment, calculated in terms of angular standard deviation, did not 
differ between the various culture conditions (Figure 3.14 A). However, there were a 
significantly greater number of elastic fibers (Figure 3.14 B) present in all cultures that 
received the elastogenic factors, (except cultures that received 1 ng/ml of TGF–β1 and 2 
µg/ml of HA–o).    Von Kossa staining (Figure 3.15) for calcific deposits indicated lack 
of matrix mineralization in all constructs. 
Figure 3.11: Effect of select doses of treatment conditions on tensile properties of 
constructs. (A) Representative stress vs. strain curves of constructs at the 4 treatment 
doses. Toe regions were not consisently seen in all constructs. All constructs failed at 
the grips. Tensile modulus calculated between 15%-30% strains were not statiscally 




Figure 3.12: Representative images of 5 µm sections stained for elastin with modified 
VVG at 20 × magnification (scale bar = 200 µm).  Elastic fibers are stained purple and 
surrounding collagen is stained pink 
Figure 3.13: Representative fluorescence micrographs of construct sections 
showing distribution of nuclei in green (A), elastin/elastic fibers in red (B), and the 
overlay of the two (C). Paraffin embedded sections were treated with Pontamine sky 
blue to quench autofluorescence of collagen and shift that of elastin to the red 






Attempts at engineering elastic tissue constructs, such as vascular replacements, 
thus far, have been challenged by poor ability of post–neonatal cell types to synthesize 
tropoelastin and crosslink the precursors into a fibrous matrix
227-228
. It is also evident 
Figure 3.14: Elastic fiber alignment in collagen gel constructs represented by 
angular standard deviation in degrees (A) and no. of aligned fibers (B). ‘*’ represents 
significance in difference from control cultures 
Figure 3.15: Von Kossa staining for mineral deposits. The absence of any black 
spots/deposits indicates lack of  TGF–β1–induced matrix mineralization in the dose 




from literature that the extracellular microenvironment critically influences cell 
phenotype and behavior. In this context, a large body of work attests to the contractile 
phenotype of SMCs within the intact vessel wall, and the switch to a more synthetic (i.e. 
proliferative and ECM–generating) phenotype, when these SMCs are isolated and 
cultured in vitro
56, 141
, either on tissue culture polystyrene (TCPS), or within scaffolds 
created from one of the many natural (e.g. fibrin
227
) or synthetic (e.g. Polyglycolic acid 
(PGA)
52
) polymers. From the standpoint of elastin regeneration, vascular SMCs in 
contact with these scaffolds have been found to enhance tropoelastin synthesis. Although 
the cellular scaffolds may provide the initial framework for cell adherence and 
proliferation, the expectation is that the scaffold would gradually biodegrade, and cell–
synthesized ECM would accumulate and assume primary load–bearing roles. Key among 
these ECM proteins is collagen, which cells are able to abundantly and preferentially 
synthesize and deposit, beginning at a fairly early stage in culture. While such collagen 
fiber deposition is favorable from the standpoint of replicating the 3–D collagenous 
matrix within the aorta, there is also significant and irrefutable evidence that this 
microenvironment promotes a more quiescent, contractile phenotype amongst SMCs 
(compared to other scaffolding materials like PGA and fibrin), which is not particularly 
conducive to their ability to synthesize elastin and lay down elastic matrix structures
49, 52-
53, 229
.  Thus, efforts to engineer soft elastic tissues, such as vascular tissues, will 
tremendously benefit from an elastin–regenerative stimulus that can overcome the 
unfavorable microenvironment for elastin synthesis imposed by a collagenous matrix, 
standard to most applications.  
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Previously, our lab established the elastogenic benefits of TGF–β1and HA–o 
towards increasing tropoelastin precursor production and crosslinked–matrix deposition 
by RASMCs
37, 148, 217, 230
. However these studies were performed on RASMC layers 
cultured on 2–D TCPS surfaces, on which SMCs are known to assume a more 
proliferative, synthetic phenotype than what they exhibit within intact vessels. In order to 
translate the specific benefits of the above mentioned factors to a culture model more 
closely evocative of a collagenous 3–D matrix microenvironment, naturally present 
within decellularized vascular tissue–based scaffolds, and that generated by cells seeded 
on other scaffolds, we studied the effect of the above mentioned factors on adult 
RASMCs seeded within 3–D collagen constructs maintained under static tension.  
Relative to untreated control constructs, cell numbers within constructs cultured 
with HA–o and TGF–β1 were in general slightly greater, with the significant differences 
being only for the intermediate factor doses. A significant attenuation in the increase in 
cell count was noted only at the highest provided dose (i.e. 10 ng/ml of TGF–β1 and 2 
µg/ml of HA–o). While these results are  consistent with observations of other groups, 
wherein increasing TGF–β1 concentrations was found to lower cell densities
231
, the 
results contrast substantially from our previous observations of a dose–dependent 
inhibition of SMC proliferation on TCPS surfaces
184
. The present results suggest that (a) 
interaction with the collagenous ECM alters SMC behavior compared to 2–D cultures, 
and (b) such collagen–SMC interaction de–sensitizes the cells to TGF–β1 and HA–o, 
attested to by a significant decrease in cell number only at the highest provided doses. It 
is also apparent from our results that similar to our recently published observations in 2–
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D cultures, TGF–β1 effects dominate with a biphasic dose–dependent proliferative 
response to TGF–β1 at both HA–o doses
232
. However, from the standpoint of a tissue 
engineering application, wherein growth in tissue mass is contingent on increased 
availability of ECM–generating cells, the HA–o/TGF–β1 dose combination that provides 
greater impetus to SMC proliferation (i.e. 0.1 ng/ml of TGF–β1 and 0.2 or 2 µg/ml of 
HA–o), is most desirable.  
Within a collagenous 3–D matrix, SMCs are likely to switch to a more contractile 
phenotype characterized by reduced ECM synthesis, which has been previously 
reported
49, 52-53, 229
. Concurrently, our results indicated that within 3–D collagen 
constructs, HA–o and TGF–β1 together had mostly no effects on tropoelastin synthesis. 
The sole exception was the highest factor dose which induced a moderate, but significant 
increase. While this lies in complete contrast with our prior published studies in 2-D 
culture, wherein we noted even the lowest dose combination of factors we test here, to 
induce multi–fold increase in tropoelastin synthesis compared to non–additive controls, 
and the differences could be attributed to a switch in SMC phenotype between 2-D and 3-
D cultures.  
HA–o and TGF–β1 in this study appear to influence the process of tropoelastin 
crosslinking and matrix deposition to a greater extent than tropoelastin synthesis itself; 
the enhancement of elastic matrix deposition appears to be the predominant effect of the 
factors, though in the absence of information as to an exact mechanism by which the 
factors elastogenically induce the cells, this currently remains an unsubstantiated 
observation. As seen in Figures 4A and 4B, at both HA–o doses (i.e. 0.2 and 2 µg/ml), a 
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classic biphasic TGF–β1 dose response is seen with regard to elastic matrix deposition, 
with significant (~ 5 fold) increases noted at the lowest tested TGF–β1 dose (0.1 ng/ml) 
and much smaller increases noted at higher TGF–β1 doses. Our results also suggest that 
at higher doses, HA–o reduces this biphasic elastic matrix synthesis response to TGF–β1; 
especially at higher TGF–β1 doses (i.e. 1 and 10 ng/ml), increasing HA–o dose led to a 
significant increase in elastic matrix deposition. Matrix elastin increases were primarily 
associated with enhanced deposition of the less crosslinked alkali–soluble fraction.  
In the majority of cases, we found the factors to enhance significantly relative to 
controls, the synthesis of LOX enzyme, which is believed to play a central role in 
crosslinking tropoelastin into a mature elastic matrix.  This is in agreement with our prior 
published findings
37, 233
  where we showed HA–o/TGF–β1 to enhance mRNA expression, 
protein synthesis and activity of the elastin crosslinking enzyme. However, the most 
significant increase in LOX synthesis was observed in cell cultures treated with 0.2 μg/ml 
of HA-o and 10 ng/ml of TGF-β1 (see Figures 3.6 and 3.7). Likewise, in comparing 
ratios of amounts of alkali-insoluble (i.e., highly crosslinked) matrix elastin to amounts of 
the alkali-soluble fraction (see Figure 3.4), we find that the ratios are far less than 1, for 
all cases, especially for cultures treated with the lower doses of the factors, but greater 
than 1 in the singular case wherein LOX synthesis was most significantly enhanced (i.e., 
0.2 µg/ml of HA-o and 10 ng/ml of TGF-β1). We thus hypothesize that the increases in 




A very interesting observation is that the matrix yield (i.e. mass % of total elastin 
output crosslinked into a matrix) in control collagen constructs is much lower (~ 0.2%) 
than what we have observed with the same cell type in 2–D cultures on non-collagenous 
substrates (10–15%). While we have shown a multi-fold increase in matrix yields in the 
presence of TGF–β1 and HA–o factors, most significantly at the lowest tested doses, the 
yields remain < 1%.  One possible reason for the low levels of elastic matrix deposited, 
which will confirm in a future study, might be over-production of GAGs such as 
chondroitin sulfate by the SMCs, which as studies by Hwang et al.
38
 and Allison et al.
39
 
have shown, to inhibit elastin synthesis and assembly, and shown to correlate with 
increased collagen matrix deposition.  Regardless, despite the likely LOX–mediated 
crosslinking of tropoelastin in the presence of HA-o and TGF-β1, the poor elastic matrix 
yields obtained in this study  indicate that there is room for improvement in terms of 
enhancing the deposition of the more robustly crosslinked, and hence the more stable 
alkali–insoluble elastic matrix fraction.  
In the context of enhancing elastin matrix within 3–D collagenous constructs, 
leading to tissue engineering of a clinically sufficient, implantable tissue, it might thus be 
necessary to seed the scaffolds at much higher cell densities to overcome the poor matrix 
yield obtained per cell (even when elastogenically induced) or alternatively co–deliver 
elastin–crosslink–promoting factors (e.g. LOX or LOX–activity enhancing copper 
nanoparticles), which we have shown to be very useful for the purpose
148-149
.     
MMPs –2 and –9 represent a class of Zn
2+
 dependent gelatinases that degrade 
matrix proteins, specifically elastin
12
. Since intact elastic fibers serve as nucleation sites 
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for organization of new elastic matrix structures, and since net accumulation of elastic 
matrix is dependent on much attenuated matrix degradation relative to its regeneration, 
minimizing MMP production/activity is desirable
83
. In this context, our study showed 
that the lowest, but the most elastogenic dose combination of TGF–β1 and HA–o 
significantly attenuate MMP–9 synthesis, but enhance MMP–2 production by SMCs. At 
the highest provided dose, also deemed to be elastogenic, but less so, MMP–9 production 
was negligible and MMP–2 levels were similar to untreated controls. Likewise, active 
forms of MMP–2 protein was enhanced at the lowest TGF–β1 and HA–o dose 
combinations, and remained unaffected at higher doses. While it is yet undetermined as 
to whether the above mentioned increases in synthesis of MMP–2 protein quantities (both 
zymogen and active forms) at the lowest tested TGF–β1 and HA–o doses are significant 
enough on absolute terms to actually compromise the matrix; if it is so, providing MMP–
inhibiting culture conditions, or alternatively, providing the higher, non–MMP–
enhancing factor dose might be a desirable approach.  
Another favorable observation of culturing SMCs within statically loaded 
collagen gels was the high degree of alignment in the synthesized elastic fibers, as seen in 
Figure 3.14. While the degree of alignment was more or less uniform irrespective of the 
culture conditions, all cultures that received the elastogenic factors, except those with 1 
ng/ml of TGF–β1 and 2 µg/ml of HA–o, consisted of significantly larger number of 
aligned fibers compared to non-additive control cultures.  
TGF–β1, when over–expressed, especially in a sustained manner, can induce 





However, our study did not show any calcification, even in constructs cultured with the 
highest dose of 10 ng/ml TGF–β1. 
 
3.5. CONCLUSIONS 
 This study demonstrates elastogenic induction of RASMCs with HA–o 
and TGF–β1 factors within non-elastogenic 3-D constructs of statically loaded collagen 
gel constructs. While a much higher dose combination than that shown useful in earlier 
studies within 2-D cultures is necessary to enhance both tropoelastin and matrix synthesis, 
compared to other studies performed on SMCs in collagen gels, we have demonstrated 
that synthesis of significant amounts of matrix elastin is possible in the presence of these 
factors. A major challenge to our ability to obtain the optimum amount of elastin, that 
engineering of tissue constructs for human use demand, is the rather poor elastic matrix 













IMPACT OF DYNAMIC CONDITIONING ON INDUCED ELASTOGENESIS BY 
CELLS IN 3D COLLAGENOUS MICROENVIRONMENTS 
 
4.1. INTRODUCTION 
In the previous chapter we demonstrated that EF-stimulation of adult vascular 
cells towards de novo synthesis of elastic matrix components can be achieved even in a 
quiescent 3D collagenous microenvironment not particularly conducive to elastogenesis. 
We also showed that cell alignment achieved in the predominant direction of applied 
static strain, positively influenced orientation and alignment of both the pre-existing 
collagen matrix, and the cell-synthesized elastic matrix. However, due to the particular 
design of the 3D collagen gel system that applies strain along the longitudinal axis, the 
orientation of the synthesized matrix is tangential to the circumferential orientation 
exhibited in vivo by the elastic arteries. In this study, we therefore wanted to further 
modify this 3D model system such that the orientation of cells, and as a result, the 
synthesized elastic matrix would mimic that contained in vascular tissues. Several studies 
have demonstrated the benefits of cyclic mechanical stretch towards inducing orientation 
of SMCs. Studies have also demonstrated that cells behave differently under uniaxial 
tension within 3D constructs similar to that incorporated in our previous study
57, 234
, 
compared to when they are cultured within tubular constructs. While cells are shown to 
orient in the direction of uniaxial tension, cells within tubular constructs experience radial 
and circumferential stretch, and orient in a direction perpendicular to stretch, therefore 
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conforming to circumferential alignment, similar to that seen in vivo. We therefore chose 
to use a tubular collagen gel model to which cyclic distension could be applied with the 
aim of achieving circumferential orientation of cells and thereby, enabling deposition of 
newly synthesized elastic matrix in a circumferential orientation as in intact blood 
vessels.  
The three important factors that influence mechano-transductive response by 
cells, and as a result, cell phenotype and final matrix output, are strain amplitude, 
frequency and duration of cyclic stretch
164, 235
. To date, most studies utilizing cyclic 
stretch parameters have primarily used strain levels of > 2.5%, and a majority of them 
have used 10% strains
57, 59, 166, 236
. However, most of these studies were also targeted 
towards generating small diameter vascular tissue equivalents that typically respond to 
much higher strains than do elastic arteries
5
. Moreover, the synthesis and enzymatic 
activity of the predominant elastolytic protease MMP-2, has been reported to increase at 
higher strains
237-238
. While it is argued that MMP-2 is important for matrix 
reorganization
237
, its enzymatic activity can at the same time however, also degrade 
newly synthesized elastic matrix, and prevent its maturation and assembly within the 
scaffolds
10, 83
. Another limitation of applying these higher strains, especially in a 
collagenous hydrogel environment that has not yet completely been remodeled to have 
sufficient fibrillar matrix, is the irrecoverable creep that the scaffold would experience 
under repeated cyclic loading
59
. This would also lead to the cells perceiving constantly 
changing levels of strains, and not the set strain levels intended to transduce the cells. 
Alternatively, studies have also demonstrated the importance of frequency of strain 
79 
 
perceived by cells, and that changing the frequency of cyclic strains was found to play a 
significant role in regulating the alignment of vascular SMCs in an intact actin filament-
dependent manner
167-168
. In order to minimize the detrimental effects of high strain levels, 
and at the same time promote cell and matrix alignment, we therefore chose to subject 
SMC-seeded tubular collagen constructs to 2.5% cyclic strain applied at frequencies of 
0.5 Hz, 1.5 Hz and 3 Hz for 21 days of culture. The doses of the EFs used to 
elastogenically stimulate cells in this study, were based on the results obtained in Chapter 
1, where the dose combination of 0.1 ng/ml TGF-β1 and 0.2 μg/ml HA-o was concluded 
to be most elastogenic. In light of results of other studies in our lab that human aortic 
SMCs (HASMCs) respond to elastogenic stimulation by EFs
239
, we transitioned to study 
of these cell types to render our outcomes more clinically relevant.  
 
4.2. MATERIALS AND METHODS 
4.2.1. Design, Construction and Principle of Operation of Bioreactor for Dynamic 
Cell Culture 
A bioreactor was constructed to deliver cyclic, tangential strains to the tubular 
collagen gel constructs and the SMCs seeded within it. The set up (Figure 4.1.) consisted 
of (a) tubular tissue-culture-chambers with centrally placed silicone tubing (around which 
the collagen gel constructs would compact) connected to (b) compressible metallic 
bellows distended cyclically by (c) a stepper motor whose motion was controlled by (d) a 
custom-programmed motor-controller. The motor and controller were powered by a 
standard 3 amp power supply. The system was fabricated at the Device Prototype Core 
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(Design, Electronics and Polymer cores) at the Cleveland Clinic. All bioreactor parts 
were either made in house at the Device Prototype Core, or purchased from Cole Parmer 
(Vernon Hills, IL) or McMaster Carr (Aurora, OH).  
 
Principle of Operation: The segment of the bioreactor that was filled with water (from 
the sealed end of the bellows to the sealed ends of silicone tubes within the culture 
chamber in Figure 4.1) was a closed, air-tight unit, within which the inner silicone tubes 
are the only compliant parts.  
Figure 4.1: Bioreactor set-up for applying 2.5 % stains. The tissue culture chamber with 
inner silicone tubing (a), is connected via a manifold to the bellows (b), which are in turn 
coupled to the shaft (c) of the DC motor (d). The forward and backward movement of the 
shaft of the motor is controlled by the motor controller (e), powered by an external power 
supply (f). The volume spanning the region within the silicone tubing starting from the 
tissue culture chamber, to the end of the bellow is a closed loop into which sterile water is 




The system therefore worked on the principle that when the bellows are 
compressed by the motor shaft, the change in volume will be experienced only by the 
elastic silicone tubes and compensated by a resultant change in diameter of the tube. This 
cyclic change in diameter therefore induced circumferential strains on the SMCs cultured 
within the collagen-gel constructs surrounding the tube. 
 The increase in volume within the silicone tubes in order to deliver the required 
strains is proportional to distance travelled by motor shaft to compress the bellows which 
will displace that same change in volume, resulting in generation of strains at the silicone 
tube. It was crucial to ensure that the system was completely devoid of any air bubbles 
and maintained airtight throughout the culture duration in order to deliver accurate strains 
to the constructs. 
 
Tissue Culture Chamber: The tissue culture chamber of the bioreactor (Figure 4.2) 
consisted of tubular compartments, 5 cm length, 8 mm diameter each, cast out of silicone 
rubber. Silicone rubber tubes (4 cm length, 4 mm outer diameter, 1 mm thickness) were 
inserted across the length of each compartment, and held taut in place by friction. 
Silicone rubber is easy to sterilize and provides a non-adherent surface to prevent cell-
attachment. The collagen gel constructs were polymerized and contracted within these 
chambers such that a 5 ml volume of the collagen-cell mixture would be equally 
distributed around the circumference of central silicone tubing.  The compartments with 
the silicone tubes were sealed at one end with lour fittings, and connected to a 6-channel 
polycarbonate manifold at the other end, which was in-turn connected to the bellows of 
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the bioreactor. A leur-lock was fitted to either ends of the manifold to remove air and fill 
the circuit with sterile water. All parts of the system directly in contact with the culture 













Figure 4.2: Tissue culture chamber of the bioreactor showing 6 parallel culture chambers 
with central silicone tubing around which the sell-seeded collagen gels would contract 
 
 
Motor Controller and Generation of Strains: Stainless steel bellows were mechanically 
coupled to the shaft of the stepper motor (EZStepper, All Motion, Union City, CA), such 
that as the shaft rotates clock-wise or anti-clockwise, the bellows compress or expanded 
proportionately. The speed of rotation, number of steps moved forward or backward by 
the shaft, and the minimum and maximum limits (of shaft movement and current drawn) 
were controlled by the stepper motor-controller supplied with the motor, custom-
programmed to deliver the required strains and frequencies. The compressibility of 
bellows and the stepper motor specifications were set such that the system would deliver 
a maximum of 5% strain at 5 Hz frequency, sufficient to meet the requirements of our 
study. The motor was first programmed to generate linear motion according to the 
83 
 
manufacturer’s instructions. The parameters in the program were then set up in order to 
deliver the 2.5 % strains at the three chosen frequencies of 0.5 Hz, 1.5 Hz and 3 Hz. Each 
bioreactor set up delivered cyclic strains to 6 collagen gel constructs cultured in parallel 
(as seen in Figure 4.2). In order to confirm the settings and optimize the parameters, test 
runs of the strain delivery in the chambers were performed under a stereoscope (Olympus 
SZ61; Olympus, Center Valley, PA) connected to a CCD camera (Infinity-2, Electron 
Microscopy Sciences, Hatfield, PA). The strain in the silicone tubes were recorded, 
calculated using Image J software (NIH, Bethesda, MD) and confirmed based on the 
difference in outer diameter per cycle for the three frequencies.  
The motor, shaft and the bellows were enclosed in a plastic casing for ease of 
handling. The controller was connected to a PC with its software via a USB cable and to 
start and stop the program alone, but not at other times. Each bioreactor was individually 
connected to an external power supply (0-30 V, 1-3 amps). The system drew less than 0.3 
amps and its running voltage was ~ 20 V. During tissue culture, only the tissue culture 
chamber with its connections to the bellows and motor were placed inside a sterile CO2 
incubator maintained at 37 °C, while the controllers and power supplies were placed 
outside. 
 
4.2.2. Fabrication of Tubular Collagen Gel Constructs 
Before starting the cultures, the single-use central silicone tubing within each 
tissue culture chamber (Figure 4.2) was first inserted and held taut in place to prevent 
sagging. A leak test was then performed to ensure that there were no holes in the tubing 
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and it did not pop out of the chamber at the strains delivered. The chambers containing 
the silicone tubes were then steam sterilized (121 °C, 45 minutes). Parts (b) and (c) 
(mentioned in Section 4.2.1) were then assembled and attached to the polypropylene 
manifold. A leak test was separately performed for these parts to ensure a tight seal. Even 
though the closed circuit (containing bellows, manifold, silicone tubing and the 
connecting parts, Figure 4.1) in which water is stored to deliver the strains, is isolated 
from the cultures, it was ensured that they were maintained relatively clean as well. To do 
this, after the leak test, the entire circuit was incubated with 70% v/v ethanol (10 minute 
 3 change) and then rinsed in sterile water (3 ) . These parts were then attached to the 
tissue culture chamber inside a sterile hood. Sterile water was then slowly pumped into 
the closed circuit via the leur locks using a syringe to completely fill the volume with 
water. A leak test was again performed to ensure a tight, closed loop to remove any 
residual air bubbles. The set up was positioned upright overnight in the sterile hood, 
during which time any residual air bubbles from the circuit arose, to be easily removed by 
slowly pumping in more sterile water into the circuit. 
Acid solubilized rat tail collagen-I was brought to neutral pH and kept on ice as 
described in Section 3.2.2. Adult healthy human aortic SMCs (HASMCs) (Cell 
Applications, San Diego, CA) were trypsinized at passage 4 and mixed with the collagen 
solution at a final concentration of 0.5  10
6
 cells/ml and 2 mg/ml collagen. Due to the 
high collagen gel volumes and number of replicates, cell seeding density used in this 
study was 50% of that used in the experiments using rat cells detailed Chapter 3. 
Preliminary studies performed to test the extent of contraction between 1  10
6





 HASMC/ml indicated comparable degrees of contraction when evaluated 5 
days after seeding. The lower cell seeding density is also relevant in the context of our 
studies since prior studies have suggested that tropoelastin synthesis tends to be higher on 
a per cell basis with lower cell densities
28
. An aliquot of the cell-collagen mixture (5 ml) 
was then added slowly to each culture chamber such that the mixture uniformly 
distributed itself around the circumference of the tube. Culture medium was changed 
after 24 hours. At 48 hours, the medium was changed yet again and fresh medium with 
the stated EF doses (Table 4.1), and dynamic culture conditions were provided. Day one 
of the culture was therefore corresponding to 72 hours post-seeding of the constructs. 
Optimized EF doses of 0.1 ng/ml TGF-β1 and 0.2 μg/ml HA-o were added exogenously 
to the culture medium, similar to that described in Chapter 3. The five experimental and 
control conditions are listed in Table 4.1. Constructs that did not receive EFs and were 
cultured under static conditions (no EFs, static) were considered to be biological controls 
for all normalization purposes. Culture medium was changed every two days and spent 
medium was removed, pooled with prior aliquots from the same well, and frozen at -20 
°C for later analysis.  
After 21 days of treatment, i.e., 24 days post-seeding, the constructs were 
harvested for analysis. The constructs were first rinsed in three quick changes of sterile 
PBS. Each construct was then cut with the silicone tube, removed from the chamber, and 
placed into a dish containing sterile PBS. Constructs were transversely cut into four equal 
parts to be further processed for the various biochemical assays listed below. 
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Mechanical testing and PCR were performed on a different set of constructs, than 
those cultured for biochemical analysis discussed in the following sections. RT-PCR was 
performed on approximately  0.8 cm segments of the same constructs seeded for 
mechanical testing. In the procedure followed for other assays, for each batch of 
trypsinized cells, an equal number of constructs were seeded for each culture condition, 
including treatment controls. However, for these analyses, we staggered seeding and 
harvesting of constructs corresponding to individual test cases by a few days. All factors 
related to initial seeding that may contribute to any variability of construct outcomes such 
as cell count, final pH, volumes pipetted etc., were however maintained the same. 
Group 
0.1 ng/ml TGF–β1+ 0.2 
μg/ml HA-o 
Frequency of 2.5% 
Cyclic strain (Hz) 
No EFs, static (control) - Static 
EFs, static + Static 
EFs + 0.5 Hz + 0.5 
EFs + 1.5 Hz + 1.5 
EFs + 3 Hz + 3 
 
Table 4.1: Experimental conditions: impact of dynamic conditioning on induced 
elastogenesis in 3D tubular collagen gel constructs 
 
4.2.3. Compaction of Tissue Constructs 
All constructs were photographed weekly and their lengths and central widths 
measured using Image J software (NIH, Bethesda, MD). At least 5 measurements for 
central width and 3 measurements for the length were made per construct. Construct 
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compaction was measured and reported as the aspect ratio (length : outer diameter) on the 
day of harvest.  
 
4.2.4. DNA Assay for Cell Quantification 
One segment of each construct was snap-frozen in liquid nitrogen and lyophilized 
for 24 hours, following which dry weights of the segments were measured. The segments 
were then digested in 750 μl of 5mg/ml proteinase-K (Gibco–Invitrogen, Carlsbad, CA) 
in a 65 °C water bath for 10 hours. The samples were then boiled for 10 minutes above 
75 °C to neutralize the enzyme. After cooling the samples down to room temperature (~ 
25 °C), they were sonicated on ice 5 second cycles for 45 seconds, with a 10 second lag 
between each sonication cycle. DNA content was then measured in these samples using a 
Hoechst-dye based flourometric assay as described in Section 3.2.4
221
. Cell count was 
measured based on the estimate of 6 pg DNA/cell, and was normalized to mg weights of 
constructs (n = 6/case).  
 
4.2.5. RT-PCR for mRNA Expression of SMC Phenotypic Markers and Matrix 
Proteins 
One segment of each construct (n = 6/case) was cut into 1 mm thick pieces and 
snap frozen until processing. Samples were reconstituted in RLT buffer provided with the 
RNeasy mRNA isolation kit (Qiagen, Valencia, CA) with 1% v/v 2-mercaptoethanol and 
homogenized using  a 21-guage needle and syringe. mRNA was isolated from the 
homogenized samples as per the instructions provided in the RNeasy kit manual.  Isolated  
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Primers) Reverse AGGTGGCTATTCCCAGTGTG 
Fibrillin- 1 
(FBLN1) 



















Primers) Reverse CCAGGTAGCTGGGGTTTACA 
Collagen-1 
(COL1A1) 































Primers) Reverse GAGGTCCTTCCTGATGTCAA 
Caldesmon 
(CALD1) 




Biosystems) Reverse CGAATTAGCCCTCTACAACTG 59.7 
Osteopontin-1 
(OPN1) 




Biosystems) Reverse ACTTACTTGGAAGGGTCTGTG 59.8 
 




RNA (120 ng) was converted into cDNA using iScript cDNA synthesis kit (Biorad, 
Hercules, CA), as outlined in Section 3.2.8. Gene expressions of various SMC markers 
such as SMA, caldesmon and osteopontin, elastic matrix proteins such as elastin, 
fibrillin-1, fibulin-5 and LOX, and MMPs -2 and -9, were estimated in 1 μl cDNA (in 
duplicates), using the comparative threshold method with 18 s as the normalizing gene, as 
described in the previous chapter. Primers for all genes were either purchased as 
optimized primer sets from Real Time Primers (Elkins Park, PA), or designed using the 
NIH software PerlPrimer
®
, as listed in Table 4.2. 
 
4.2.6. Fastin Assay for Elastin Content 
One segment from each construct was lyophilized for 24 hours and their dry 
weights were measured. Lyophilized constructs were first digested in 1 ml of 0.1 N 
NaOH for 1 hr in a 98 °C water bath to convert alkali-soluble matrix elastin into an α-
elastin form in order to be measured using the Fastin assay kit (Accurate Scientific and 
Chemical Corporation, Westbury, NY). The samples were then centrifuged at 5000 rpm 
for 10 minutes, and supernatants collected to analyze for alkali-soluble elastin content 
(200 µl per sample in duplicates). The pellets were resuspended in 500 μl of 0.25 M 
oxalic acid and digested for 1 hr in a 98 °C water bath to convert alkali-insoluble matrix 
elastin into the α-elastin form. Digested samples were then filter–centrifuged with 10 kDa 
cut–off membranes (Millipore, Billerica, MA) at maximum speed for 10 minutes. The 
solubilized matrix elastin retained above the filters (40–50 µl) were then reconstituted to 
a total volume of 1000 μl and then quantified with the assay kit (300 µl per sample in 
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duplicates). Matrix elastin content measured as alkali-soluble and –insoluble elastin was 
reported after normalizing to mg dry weights of construct (duplicate readings, n = 
6/case).  
 
4.2.7. Western Blotting for Cellular and Matrix Proteins 
One segment from n = 3 constructs from each case were lyophilized, and the cut 
into small pieces to speed up homogenization. Cold RIPA lysis buffer (750 µl, 
Invitrogen, Carlsbad, CA) with a protease inhibitor cocktail (Thermo Scientific, 
Rockford, IL) was then added to each of the samples, following which they were 
homogenized on ice for 10–15 minutes (until the pieces appeared to have been 
homogenized). The samples were then agitated at 4 °C for 2 hours to completely 
homogenize and solubilize the proteins. The digested samples were then centrifuged at 
10,000 rpm for 20 minutes, and supernatants collected for further analysis. A BCA assay 
was performed to measure total protein concentration in each sample using a 
commercially available kit (Thermo Scientific, Rockford, IL).  
Western blotting was performed to compare expression of phenotypic markers of 
contractile SMCs such as smooth muscle α-actin (SMA; an early-stage marker), Smooth 
muscle-22-α (SM22; a mid-stage marker), myosin heavy chain (MHC; a late-stage 
marker), and calponin and caldesmon (both mid-stage markers), elastic matrix proteins 
such as LOX, fibrillin-1 and fibulins -4 and -5, and matrix proteases MMPs-2 and -9. 
Volumes equivalent to 5 μg protein were loaded under reduced conditions into 4–12% 
SDS PAGE gels for LOX, fibulin, SMA, SM22, calponin and caldesmon, with MES 
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running buffer, and 10% SDS PAGE gels for MMPs, fibrillin and MHC with MOPS 
running buffer, along with a pre–stained molecular weight ladder (either 3.5 kDa–250 
kDa, or 10 kDa–190 kDa). The gels were then transferred onto nitrocellulose membranes 
using an iBlot
®
 Transfer system according to the manufacturer’s instructions. Blots were 
then blocked for one hour using a commercially available blocking solution (Li-Cor, 
Lincoln, NE), then incubated overnight in primary antibodies, and one hour in secondary 
antibody solutions (Li-Cor). Blots were imaged using an Odyssey
®
 Imaging System (Li-
Cor) which enabled the simultaneous measurement of 2 proteins in the same blot. β-actin 
was used as a normalizing protein for every blot. All primary antibodies were purchased 
from Abcam (Cambridge, MA), except LOX, fibrillin-1 and fibulin-5 (Santa Cruz, CA), 
and MMP-9 (Millipore, Billerica, MA), and all western blotting supplies purchased from 
Invitrogen (Carlsbad, CA), unless otherwise mentioned.  
Protein band intensities were measured using Image-J (NIH, Bethesda, MD) 
software in terms of RDU, normalized to the corresponding β-actin bands in the same 
blots and reported as a fold change in normalized RDU values relative to treatment 
control samples. Samples from three biological replicates were analyzed for each protein, 
except for the SMC markers (n = 1 blot each), whose bands were not quantified.  
 
4.2.8. Gelatin Zymography for Detection of Enzyme Activities of MMPs -2 and -9 
Gelatin zymography (as described in Section 3.2.8) in was performed on the 
RIPA buffer lysed samples as described in Section 3.2.7. Volumes equivalent to 6 μg 
protein were loaded into each lane of a 10 % gelatin zymogram (Invitrogen, Carlsbad, 
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CA), alongside a pre-stained protein ladder (10 kDa–190 kDa; Invitrogen, Carlsbad, CA), 
and purified protein standards of MMPs -2 and -9 (Anaspec, Fremont, CA). Gels were 
developed and destained to estimate the activity of MMPs-2 and -9 proportional to the 
extent of gelatin digestion bands in the gels. Band intensities were quantified and 
reported as outlined in Sections 3.2.8 and 4.2.7. Band intensities of samples from n = 3 
biological replicates were used to analyze results.  
 
4.2.9. Visualization of Elastic Matrix 
One segment from each experimental case was fixed and paraffin-embedded as 
detailed in Section 3.2.9., at the Imaging Core of the Cleveland Clinic. Sections (10 µm 
thick) were deparaffinized, epitope-retrieved in 10 mM citrate buffer in a 100 °C water 
bath for 40 minutes. Sections were then blocked in 5% v/v goat serum for 30 min, 
immunolabeled for elastin (1:100 primary, overnight, 4 °C) and fibrillin-1 (1:50 primary, 
overnight, 4 °C), with Alexa Flour
®
-633 (Invitrogen, Carlsbad, CA) secondary antibody 
(1:1000, 1 hour RT). The labeled sections were mounted in Vectashield with DAPI 
(Vector Laboratories, INC. Burlingame, CA) to stain for nuclei, cover-slipped and 
visualized under a Cy5 filter for elastin and fibrillin. Both cross-sections and 
longitudinal-sections of the constructs were labeled and imaged.   
Additionally, 30─µm cross- and longitudinal-sections were stained using a 
commercially available VVG-based staining kit (ScyTek Laboratories Inc., Cache, UT) 
to visualize elastic fibers.   
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Longitudinal and cross section of one construct from each treatment condition 
were also processed for Transmission Electron Microscopy (TEM). Constructs harvested 
at 21 days of culture were fixed in 2.5% v/v gluteraldehyde and 4% v/v 
paraformaldehyde in 2% w/v sodium cacodylate buffer for 6 hours at RT and 6 hours at 4 
°C, and stored in cacodylate buffer until further processing . Samples were then post–
fixed in 1% w/v osmium tetroxide and 1% uranyl acetate (1 hour), and dehydrated in a 
graded ethanol series (50–100 % v/v). Fixed cell layers were embedded in Epon 812 resin 
and placed on copper grids embedded in pure Eponate for sectioning. Sections (85 nm 
thickness) were cut using a diamond knife, and stained with uranyl acetate and lead 
citrate. Sections were imaged using a Philips CM12 electron microscope operated at 60 
kV. 
 
4.2.10. Mechanical Testing of Constructs 
Tensile properties of the tubular collagen constructs were analyzed on 0.8 cm wide ring 
sections of the constructs as outlined by Isenberg. et.al.
59
 and Lee. et.al.
169
. Segments (2-
3) from each of the 6 biological replicates per case were harvested. The initial diameter 
and thickness of specimens were measured on smaller ring sections (2-3 mm width) 
flanking each test specimen using an upright Olympus histology microscope (Pittsburgh, 
PA) and its accompanying imaging software, DP2. Multiple specimens (3-4) were 
imaged to take these measurements per biological replicate. Tensile testing was 
performed using an Instron BioPuls 5988 system (Norwood, MA) with a 10 N load cell, 
and in a 37 °C PBS bath. The ring specimens were held in place for the testing via 2 
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stainless steel hooks, which were placed between the metal grips of the instrument. The 
initial runs performed on test samples indicated that the constructs began to show plastic 
deformation and failure at very low loads, i.e., < 1 N. Therefore, unlike the method 
outlined in the Nerem study, pre-conditioning was not performed on these constructs. 
Load to failure tests were performed at rate of 10 mm/min. The gauge was calculated 
when the construct was truly in tension. This was done by dividing the circumference of 
the construct by 2, and then subtracting the circumference of the stainless steel hooks 
(half of the top and the bottom, equating to the full circumference of one hook). The 
thickness was considered to be twice the thickness of the construct, since the stresses 
were experienced by both sides of the ring. Tensile modulus and yield properties were 
determined from the engineering stress and strain values, plotted from the load vs. 
displacement data generated by the instrument. Modulus was calculated as the linear 
slope of the stress-strain curve, i.e., the section spanning a 20%-30% strain range with the 
highest modulus. A 10%-15% (i.e., 0.32 mm displacement) offset was used to calculate 
the yield point to determine the stress strain values.  
 
4.2.11. Statistical Analysis 
All quantitative results were analyzed from n = 6 independent biological replicate 
cultures and measurements made in triplicates, unless otherwise indicated, and reported 
as mean ± standard deviation. Statistics was performed with the help of SPSS software 





4.3.1. Compaction of Tissue Constructs 
The aspect ratios (length : O.D.) of constructs in all treatment and control 
conditions were ~ 11 (Figure 4.3). No significant differences were found between 
groups. It should be noted that there were 1-2 constructs that exhibited aspect ratios 
between 8 and 9, indicating higher degrees of longitudinal contraction, but these 













Figure 4.3: Effect of application of cyclic stretch with EFs on construct compaction. 
Constructs in different treatment conditions were contracted to similar levels 
 
4.3.2. Cell Quantification 
DNA assay performed on tubular collagen constructs (n = 6) indicated all 
constructs to have similar cell densities 21 days after treatment (Figure 4.4). Cell 
densities per mg dry weight of construct was found to range between (1.2 ± 0.6)  10
5
  
cells for cases with mechanical strains at 1.5 Hz, to (2 ± 0.8)  10
5 
 for cases at 0.5 Hz. 
Differences in cell counts between different treatment conditions were found not to be 
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statistically significant. Application of strains did not seem to have a positive or a 
















Figure 4.4: Effect of addition of EFs and dynamic conditioning on cell density after 21 
days of treatment. No significant differences were observed between different treatment 
conditions 
 
4.3.3. Analysis of SMC Phenotypic Markers 
RT-PCR of SMC phenotypic markers SMA, caldesmon and osteopontin was 
performed to evaluate the effects of treatment with EFs under static and dynamic 
conditioning (Figure 4.5). While the addition of EFs did not seem to affect the 
expression of early-stage contractile marker within static constructs, SMA within static 
constructs (1.21 ± 0.3 –fold,  = 0.97, relative to control), a bimodal increase was 
observed with the addition of cyclic strains with increasing frequencies. A 2.23 ± 0.4 -
fold increase from control was noted for constructs treated with EFs + 0.5 Hz ( = 0.004, 
relative to control, and 0.02 to static EFs). This was further increased to 4.13 ± 1 -fold in 
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constructs treated with EFs at 1.5 Hz, relative to control and static EFs constructs (ρ < 
0.001 for both). However, increasing frequency to 3 Hz brought this expression down to 
levels similar to that in control (1.93 ± 0.23 -fold, ρ = 0.06), and static constructs with 
EFs (ρ = 0.19). SMA gene expression was significantly higher in constructs with EFs 
under 1.5 Hz relative to all treatment conditions ( < 0.001).  
mRNA expression of caldesmon in static constructs with or without EFs remained 
unchanged (1.17 ± 0.28 –fold,  = 0.9). Relative to control, its gene expression was 
increased to similar extents in constructs with EFs under frequencies of 0.5 Hz (1.9 ± 0.4 
–fold) and 1.5 Hz (2.2 ± 0.3 –fold), ρ < 0.001. This increase was statistically significant 
compared to static EFs constructs as well (ρ ≤ 0.003). Similar to the trend seen in SMA 
gene expression, caldesmon gene expression in constructs with EFs under 3 Hz was again 
brought down to levels similar to static constructs with or without EFs (1.13 ± 0.34, 
relative to control, ρ > 0.95).  
Expression of osteopontin remained relatively unchanged among both sets of 
static constructs, and dynamic constructs with EFs under 0.5 Hz and 1.5 Hz (ρ > 0.72). 
On the other hand, it was elevated significantly in constructs with EFs under 3 Hz 
frequency (2.6 ± 0.7 –fold, ρ < 0.001, relative to control). This increase was statistically 
significant compared to all other treatment conditions tested in this study (ρ < 0.001).  
Western blotting was performed to detect protein quantities of contractile SMC 
phenotypic markers (Figure 4.6). Similar to that seen with RT-PCR, band intensities of 
SMA, calponin and SM22 were highly pronounced in all cases that received dynamic 
stimulation, and appeared similar in both static constructs. Those of MHC appeared more 
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Figure 4.5: Change in mRNA expressions of SMC phenotypic markers with addition of 
EFs and cyclic strains relative to control. Frequency-dependent regulation of gene 
expressions of SMA, caldesmon and osteopontin were observed. ‘*’ represents 
significant difference from control, ‘#’ from static EFs, ‘+’ from EFs + 3 Hz, and ‘$’ 













Figure 4.6: Representative western blots of contractile SMC phenotypic markers, along 
with normalizing protein, β-actin. Contractile marker band intensities appeared to be 





4.3.4. Elastic Matrix Synthesis 
RT-PCR was performed to evaluate the effects of EFs and cyclic strains applied at 
different frequencies on mRNA expressions of genes encoding various elastic matrix 
proteins such as elastin, fibrillin-1, fibulin-5 and LOX (Figure 4.7). mRNA expression of 
elastin was greatly influenced with the addition of EFs as well as by change in cyclic 
strain frequencies. Within static constructs, addition of EFs significantly increased elastin 
gene expression to 4.8 ± 0.4 –fold ( < 0.001), relative to control. Application of cyclic 
strains in addition to EFs showed a bimodal behavior in elastin gene expression with 
increasing frequencies. Constructs stretched at 0.5 Hz showed an increase of 3.1 ± 0.5 –
fold relative to control ( = 0.001). While this increase with 0.5 Hz was lower than that 
seen with static constructs treated with EFs ( = 0.003), application of strain at 1.5 Hz 
significantly increased elastin gene expression further to 6.67 ± 1.5 –fold relative to 
control (  ≤ 0.002 relative to all treatment conditions). On the other hand, at 3 Hz, 
elastin gene expression was brought down to levels similar to that with untreated controls 
(1.3 ± 0.2 -fold,  = 0.97, relative to control).  
mRNA expression of fibrillin-1 was also influenced by the frequency of applied 
strain. Relative to control, while a 2 ± 0.6 –fold increase was observed in static constructs 
with EFs ( = 0.007), this was not mirrored under cyclic strain frequencies of 0.5 Hz 
(1.38 ± 0.41 –fold,  = 0.7) and 3 Hz (1.7 ± 0.32 –fold,  = 0.1). However, at 1.5 Hz 
stretch frequency, fibrillin-1 gene expression was increased to 1.8 ± 0.5 –fold relative to 
control, which was deemed statistically significant ( = 0.045). It is important to note that 
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among the 4 EF-treated constructs (both static and strained), differences in gene 
expression were not statistically significant ( > 0.1).  
Addition of EFs or change in cyclic strain frequencies did not appear to influence 
mRNA expression of fibulin-5. Its expression levels in all treatment conditions, both 
static and dynamic, were similar to that in untreated static control constructs ( > 0.7). 
mRNA expression of LOX showed similar trends as that seen with elastin. 
Addition of EFs to static constructs increased its gene expression to 2.8 ± 1.1 -fold 
relative to control ( = 0.005). Application of strains at 0.5 Hz and 3 Hz did not 
significantly alter its expression relative to control ( > 0.7). However at the median 
frequency of 1.5 Hz, it was elevated by 2.7 ± 1.2 –fold ( = 0.01), relative to control. The 
increase seen with addition of EFs to static constructs and those stretched at 1.5 Hz, were 
statistically similar to each other ( = 0.99) and to those stretched at 0.5 Hz ( > 0.07), 









Figure 4.7: Effect of addition of EFs and varying cyclic strain frequency on mRNA 
expression of genes encoding elastic matrix proteins, elastin, fibrillin-1, fibulin-5 and 
LOX. Significant differences represented by '*' from control, '#' from static EFs, '$' 














Figure 4.8: Effect of EFs treatment under static and stretched conditions on matrix 
elastin content. Matrix elastin measured in terms of alkali-soluble and -insoluble elastin 
and normalized to cell count (A) and mg dry weight of constructs (B). Significant 
differences represented by ‘*’ relative to control, and ‘$’ relative to all treatment 
conditions, for p ≤ 0.05 
 
Matrix elastin content was measured using a Fastin assay kit, in terms of alkali-
soluble and –insoluble elastin. As seen in Figure 4.8, addition of EFs did not 
significantly improve alkali-soluble matrix elastin content in static cultures ( = 0.97). 
However, application of cyclic strains in the presence of EFs did significantly improve 
alkali-soluble matrix elastin output in a frequency-dependent manner. Relative to control, 
constructs treated with EFs and stretched at 0.5 Hz frequency increased alkali-soluble 
matrix content up to 2-fold (12.5 ± 3.3 μg/mg, compared to 5.8 ± 2.9 μg/mg in control,  





treatment under at 1.5 Hz cyclic strains. Up to 5-fold increase relative to control, and 3-
folds relative to static constructs with EFs was seen with application of stretch at 1.5 Hz 
(26.2 ± 9.6 μg/mg,  < 0.001 relative to both sets of static treatment). Application of 
stretch at 3 Hz however appeared to decrease elastic matrix output (3.8 ± 0.4 μg/mg). 
However, it is important to note that the differences in alkali-soluble elastin content were 
statistically insignificant among all treatment conditions ( > 0.1), except in constructs 
treated with EFs at 1.5 Hz where significantly greater quantities were deposited relative 
to all other conditions ( < 0.001). Insoluble matrix elastin content did not appear to 
benefit by the addition of cyclic strains despite treatment with EFs. There was a 1.8 fold 
increase observed in the static cultures treated with EFs alone (3.9 ± 0.6 μg/mg vs. 2.2 ± 
0.4 μg/mg in static controls,  = 0.026). Constructs that received cyclic strains with EFs 
synthesized similar quantities of alkali-insoluble elastin under all three frequencies 
compared to untreated control ( > 0.9).  
Western blotting analysis of other proteins constituting elastic matrix such as 
LOX, fibrillin-1 and fibulins -4 and -5 were not reliably detected at the protein 
concentrations tested (5 µg). It was found out from the manufacturers of the antibodies, 
that for the detection of fibulin in western blots, at least 50 μg protein was required, 
which was much higher than the protein yields obtained in our studies.  
 
4.3.5. MMP -2 Production and Activity  
RT-PCR, western blotting and zymography were performed to analyze the 
expression, synthesis and activity of proteases specific to elastic matrix degradation 
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synthesized by SMCs, i.e., MMPs -2 and -9. As seen in Figure 4.9, relative to control, 
mRNA expression of MMP-2 remained unchanged within constructs treated with EFs 
under static conditions and with cyclic stretch applied at 0.5 Hz and 1.5 Hz ( > 0.5). 
However, under EF-treatment with cyclic stretch at 3 Hz, there was a 1.9 ± 0.3 –fold 
increase in MMP-2 mRNA expression, relative to control. This increase was statistically 
significant relative to all treatment conditions ( ≤ 0.001). However, as seen in Figures 
4.10 A and B, western blotting performed to estimate total protein content of zymogen 
and active forms of MMP-2 did not reveal any significant differences among the 
treatment conditions, both static and dynamic. On the other hand, zymography (Figures 
4.11 A and B) performed to estimate activity of secreted MMP-2 enzyme, showed more 
than 3-fold increase in band intensities of the zymogen form of the protease in all EF-
treated constructs, relative to control ( < 0.02). This increase in zymogen content was 
similar in all EF-treated conditions, both static and dynamic ( > 0.4). On the other hand, 
no significant differences in zymogram band intensities of  the active form of protease 









Figure 4.9: Effect of varying cyclic strain frequency and addition of EFs on MMP-2 
mRNA expression relative to control. Increase in MMP-2 gene expression was significant 










Figure 4.10: Effect of addition of EFs under static and dynamic conditions on MMP-2 
protein content. (A) Representative immunoblots showing zymogen and active forms of 
MMP-2 protein, with normalizing protein, β-actin. (B) Semi-quantitative analysis of 
differences in band intensities of the 2 forms of MMP-2 protein relative to control. No 





Figure 4.11: Effect of addition of EFs and change in cyclic stretch frequency on MMP-2 
enzyme activity. (A) Representative zymogram showing MMP-2 band intensities at both 
active and zymogen forms. (B) Semi-quantitative analysis of change in MMP-2 enzyme 
activity relative to control. ‘*’ indicates significant difference from control for p ≤ 0.05 
 
4.3.6. MMP -9 Production and Activity 
mRNA expression of MMP-9 was uniformly low in all constructs, and their Ct 
values were at or below the detection limits of the instrument, at the cDNA 
concentrations tested. Therefore, it was difficult to discern differences between treatment 
conditions, if any existed. Similarly, bands corresponding to either active or inactive 
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forms of the protease were undetected by zymography, at the protein concentrations 
tested (5 µg/case). However, western blotting analysis of MMP-9 (Figures 4.12 A and B) 
showed increase in band intensities of both active and zymogen forms of the protease in 
EF-treated constructs subjected to cyclic stretch at frequencies of 1.5 Hz and 3 Hz. 
Relative to control, 1.6 ± 0.5 –fold increase in both active and inactive forms of MMP-9 
were seen under 1.5 Hz ( < 0.05). With application of stretch at 3 Hz, relative to control, 
increase of 1.7 ± 0.5 –fold for zymogen, and 1.4 ± 0.1 –fold for active MMP-9 were seen 
( < 0.04). This increase with application of 1.5 Hz and 3 Hz was statistically significant 
compared to static EFs and  EFs + 0.5 





Figure 4.12: Effect of change in cyclic strain frequency and addition of EFs on MMP-9 
protein content. (A) Representative immunoblot of MMP-9 showing active and zymogen 
forms of the enzyme. (B) Semi-quantitative analyssis of fold-change in RDU of band 
intensities of both forms of the protein relative to control. Significant differences are 
represented by ‘*’ from control, ‘#’ from static EFs, and ‘+ from EFs + 0.5 Hz, for , for p 
≤ 0.05 
 
4.3.7. Matrix Ultrastructure 
Cross- and longitudinal- sections of all treatment conditions were labeled for 
elastin and fibrillin proteins. As seen in Figures 4.13 through 4.15, cells and fibers were  
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Figure 4.13: Effects of EF-treatment and variation of strain frequency on matrix 
assembly and orientation. Representative images of 30 µm-thick longitudinal-sections 
(A) and cross-sections (B) of all constructs stained with modified VVG. Elastic fibers, 
stained purple to black, within cyclically strained constructs appear oriented more 
towards the longitudinal direction, than in the circumferential direction. Alignment in the 
longitudinal direction appears more random with increase in strain frequency, indicating 
initiation of alignment perpendicular to applied strain. Circumferential alignment can be 
seen closer to the lumen (L) within strained constructs, which does not appear to have 
uniformly translated across the thickness of the constructs. More number of elastic fibers 
appear to be present in constructs treated with EFs compared to those without. Scale bar 








Figure 4.14: Effects of EF-treatment and cyclic strain frequency variation on synthesis 
and assembly of fibrillin. Representative images of 10 µm thick longitudinal- (A) and 
cross- (B) sections of constructs immunolabeled for elastin (red) and nuclei (blue). 
Longer fibers of elastin are seen in the longitudinal direction than circumferentially, 
similar seen in Figure 4.13. White arrows indicate longitudinal direction of constructs. 





Figure 4.15: Effect of EF-treatment and varying frequency of stretch on fibrillin 
assembly and orientation. Representative fluorescent images of 10 µm thick longitudinal- 
(A) and cross- (B) sections of constructs immunolabeled for fibrillin (red) and nuclei 
(DAPI). White arrows indicate longitudinal direction of constructs. ‘L’ = lumen. 10  
magnification.    
Application of stretch was found to improve orientation in the circumferential 
direction in the regions closer to the silicone tubing, and progressively decreased in 
regions further away from it. However, in the longitudinal direction, as seen in both in 





elastic fibers were found in all the cases. Another important observation to be made is 
that the distribution of these fibers is not uniform across the width or circumference of 
the constructs; they appear to be denser in some regions more than others. 
Immunolabeling of elastin and fibrillin (Figure 4.14 and 4.15) showed that these proteins 
were mostly found associated with each other.  
TEM was also performed on both cross- and longitudinal- sections. 
Representative images of longitudinal sections from a construct treated with EFs + stretch 
at 1.5 Hz are shown in Figure 4.16. Once again, what appears to be elastin assembly on 
fibrillin scaffolds (indicated by arrows) are seen in some regions within longitudinal-
sections, but were hardly observed in the cross-sections. Cell morphology appeared 
normal across most regions in the section and cell membranes appeared intact. 
 
Figure 4.16:  Representative TEM images of constructs conditioned with EFs and cyclic 
stretch at 1.5 Hz. Initiation of elastic matrix deposition (indicated by red arrows) can be 
seen between adjacent cells. Collagen is indicated by black arrows. Scale bars = (A) 1 






4.3.8. Mechanical Properties of Constructs 
As mentioned in Section 4.2.2 of this chapter, mechanical testing was performed 
on a different set of samples than that seeded for biochemical assays discussed above. 
While all seeding procedures were kept constant, we observed that in the constructs 
seeded under the dynamic conditioning at 0.5 Hz and 1.5 Hz, the two constructs located 
in wells at each end of the tissue culture chambers, contracted much less than the ones 
seeded in the middle. We attribute this to user error that may have arisen either due to 
presence of residual ethanol vapors in the chambers or unequal mixing of cell-collagen 
solution prior to seeding. While this anomaly resulted in a decrease in mRNA yields, it 
did not affect the overall outcomes of our PCR results. However, the mechanical 
properties of these constructs cultured on either ends were quite different than the ones 
cultured in the three chambers towards the center. We have therefore reported results 
both including and excluding these constructs (Figures 4.17 and 4.18). We also observed 
a higher degree of circumferential non-homogeneity compared to previous culture sets, 
which is likely to have had a significant impact on the mechanical testing outcomes.   
Tensile modulus was calculated over 0.873 mm displacement, corresponding to 
20% - 30% strain in the constructs (Figure 4.18 A). Prior to excluding the end constructs, 
the tensile modulus was calculated to be 1.59 ± 0.97 kPa for constructs cultured at 0.5 Hz 
with EFs, and 1.93 ± 1.08 kPa at 1.5 Hz strains with EFs. The static constructs without 
EFs showed a modulus of 2.30 ± 0.39 kPa, and 2.12 ± 0.81 kPa for those with EFs. After 
eliminating the anomalous end constructs, the modulus was found to be 1.81 ± 1.06 kPa 
for 0.5 Hz and 2.48 ± 0.51 kPa for 1.5 Hz, compared to 2.41 ± 0.37 kPa for static 
111 
 
controls, and 1.67 ± 0.33 kPa for static cultures with EFs. The differences in the tensile 
modulus between cases were found to be statistically insignificant both with and without 
inclusion of the end constructs.  
As seen in Figure 4.18 B, yield properties were found to be lowest in constructs 
with EFs at 0.5 Hz. While the yield stress showed significant decrease compared to static 
constructs after eliminating the end constructs (1.16 ± 0.54 kPa,  = 0.019), decrease in 
yield strain was significant prior to eliminating them (1.41 ± 0.12,  = ). Differences in 
yield properties among all other constructs remained statistically insignificant. 
Since the testing was started when the constructs were technically not in tension- 
i.e., in their original diameters, the toe region seen in the stress-strain curves primarily 
represent the phase where the constructs are being stretched up to a length at which they 
begin to experience true tension. We believe that any elastic properties of the constructs 
contributed by the synthesized elastic matrix may be masked by this phenomenon within 
this region. Therefore, unlike that reported by the Nerem group, we believe that 
calculating the modulus within this toe region does not provide accurate information 
regarding the elastic properties of the constructs. We have therefore calculated the tensile 
and yield properties beyond the toe region, once the constructs were in true tension.  
 
4.4. Discussion 
Among the various hemodynamic forces present in the vasculature, cyclic 
circumferential strains are the most prevalent forces perceived by vascular smooth 
muscle cells
5
. Cyclic strains are therefore also most influential in regulating 
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mechanotransduction-mediated effects in VSMC phenotypic state, matrix synthesis and 
orientation
164, 235
. Various cell surface receptors have been identified that respond to 
different components of external stimuli. For example, Liu et.al., have shown that strain 
frequency-dependent modulation of VSMC alignment is regulated by integrin β-1 
receptors that activate a p38-mitogen-activated protein kinase (MAPK) pathway
167
. 
Alignment is elicited first in the cytoskeletal actin filaments, which ultimately results in 
cellular orientation. It has also been reported that such alignment is highly frequency 










Figure 4.17: Representative stress vs. strain curves of n = 6 samples per treatment 
condition. The initial toe region corresponds to the phase during which constructs are 
truly brought under tension. All constructs demonstrated a linear phase, where their 
tensile properties were determined. Soon after the constructs started to fail, they 
continued to display plastic deformation, until they completely failed. The end constructs 
that did not contract as much as the ones centrally placed.  
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Figure 4.18: Effect of EF-treatment and cyclic strain frequencies on mechanical 
properties of HASMC-seeded tubular collagen gel constructs. Tensile and yield 
properties are represented excluding the anomalous end constructs. (A) Tensile modulus 
corresponding to 20%-30% strains, were found to be similar in all treatment conditions. 
Yield properties (B) and (C) were not improved by cyclic strains or addition of EFs. ‘*’ 
represents significant difference from untreated static controls, ‘#’ from static EFs, ‘§’ 
from EFs+1.5 Hz and ‘+’ from EFs+3 Hz, for p ≤ 0.05  
 
Most studies conducted so far that have explored the role of cyclic stretch to 
improve cell alignment and matrix output have utilized physiological levels of 10% strain 
at 1 Hz frequencies
57, 59, 166, 236
. These studies were also aimed towards tissue engineering 
small diameter vascular grafts that typically experience higher strains than elastic 
arteries
5
. However, as noted by the Tranquillo group, cells under these conditions in vivo 
usually remain in a quiescent, non-proliferative and non-matrix producing states
59
. In one 
of their studies, they have further noted no changes in cell proliferation, alignment or 
matrix production between 2.5% and 10% strains
59
. Moreover, reconstituted collagen 
gels, such as that used in this study, behave like viscoelastic fluids prior to forming 
mature fibrils. Therefore, when subjected to long-term cyclic loading, they can succumb 
to irreversible creep, especially at higher strain amplitudes
59
. Wernig et.al., have shown 
that the same integrin β-1 receptors involved in cell alignment, also mediate stretch-
induced apoptosis at strains greater than 10%
171




expression of matrix degrading MMPs such as MMPs-2 with higher strain amplitudes
237-
238
. While it can be argued that the presence of these MMPs might be required to initiate 
matrix remodeling, their activity can at the same time also adversely cause the 
degradation of newly synthesized elastic matrix
10, 83, 172
. In the current study, we therefore 
utilized lower strain values of 2.5% and varied the frequency rates to evaluate its effects 
on cell behavior and induced elastic matrix outcomes.   
Cell densities after 21 days of treatment were found to be comparable between the 
static and dynamic cultures. This was in accordance with other studies that have reported 
similar observations within collagen gel scaffolds
28, 236
. It has been noted that under 10% 
strains, cell proliferation appears to be dictated by the scaffold in which the cells are 
grown. For example, while Kim et.al., noted increased cell proliferation at 7% strains in 
PGA scaffolds
57
, Isenberg et.al. noted no changes in cell densities between 2.5% and 
10% strains
59
, or between static and dynamic cultures within tubular collagen scaffolds. 
In contrast to the results reported on rat cells in the previous chapter, addition of EFs did 
not increase cell numbers in this study.  
Several studies have also shown that cyclic stretch can maintain a healthy 
contractile phenotype of SMCs. SMCs in culture are known to typically switch to a more 
synthetic, proliferative and matrix-producing phenotype, compared to that seen in vivo. 
While this phenotypic switch to produce matrix is crucial from the stand point of tissue 
engineering and regenerative medicine, excessive expression can also lead to abnormal 
proliferation and undesirable matrix output, as seen in a diseased environment such as 
that in AAAs. Maintaining a balance between a healthy and a synthetic phenotype is 
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therefore the key to carefully regulate desirable cellular response. Cyclic stretch is known 
to improve the expression of various contractile phenotypic markers of SMCs such as 
SMA, caldesmon and MHC, while at the same time, also increase matrix output. In our 
study, mRNA expressions of the 2 contractile markers tested- SMA and caldesmon 
appeared to be influenced more by change in frequency, than with the addition of EFs. 
While addition of EFs to static constructs did not significantly change gene expression of 
the above contractile markers, a bimodal trend was observed with increase in frequency 
of applied strain. This trend was far more pronounced in SMA gene expression, which 
showed a  moderate 2-fold increase with stretch at 0.5 Hz, increased further up to 4-fold 
at 1.5 Hz, and at 3 Hz, dropped down to levels similar to that within static constructs. 
Caldesmon expression was moderately increased with stretch at 0.5 Hz and 1.5 Hz, but 
not at 3 Hz. On the other hand, gene expression of osteopontin, a marker for osteogenic 
differentiation of SMCs suggestive of an activated phenotype, was elevated up to 2-fold 
within constructs stretched at 3 Hz alone. However, no differences were noted relative to 
control in other constructs treated with EFs, both static and dynamic. This is in contrast to 
other studies that have reported that the expression of osteopontin that is generally 
increased within 3-D cultures, is down regulated by the addition of cyclic stretch
240
. 
TGF-β1 is known to induce osteogenic differentiation of SMCs at concentrations > 10 
ng/ml
139
. While the doses utilized in our study were a 100-fold lower, it is likely that at 
frequencies as high as 3 Hz, the addition of TGF-β1 could induce such osteogenic 
expression. mRNA expression of elastin appeared to be influenced both by the addition 
of EFs and changing frequencies of cyclic stretch. While addition of EFs increased elastin 
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mRNA expression up to 5-fold within static constructs, a bimodal frequency-dependent 
change was seen under cyclic stretch. Up to a 3-fold increase was seen with stretch at 0.5 
Hz, which was significantly elevated up to 6-fold at 1.5 Hz, but lowered to levels 
comparable to static constructs without EFs at 3Hz. Similarly, the 2-fold increase mRNA 
expressions of fibrillin-1 and LOX within EFs-treated static constructs, relative to 
control, were mirrored in stretched constructs under 1.5 Hz frequencies alone. This trend, 
together with that seen with variation in gene expressions of SMC markers, suggests that 
EF-mediated alternations in gene expressions are closely regulated under varying 
dynamic environments. This is further substantiated with observations made in elastic 
matrix output within different treatment conditions in this study. Within static constructs 
treated with EFs, despite the up-regulation in elastin gene expression, alkali-soluble 
matrix elastin content was not significantly greater than untreated controls. However, EF-
treatment under cyclic strains at 1.5 Hz, significantly improved alkali-soluble matrix 
elastin output up to 5-fold, relative to static constructs with or without EFs. Further, while 
mRNA expression of elastin and genes encoding other elastic matrix proteins were lower 
in EF-treated constructs stretched at 0.5 Hz and 3 Hz relative to static EFs, alkali-soluble 
elastin content between the three groups were comparable. Moreover, despite the 2-fold 
increase in LOX and fibrillin-1 gene expressions seen relative to control within static EFs 
and EFs + 1.5 Hz constructs, we could not detect their presence at the protein levels. 
Fibrillin-1 is an important component of the microfibrillar scaffolds on which 
tropoelastin units are coecervated, and LOX is a Cu
2+
 dependent enzyme that crosslinks 
tropoelastin molecules. Their synthesis and activity are therefore important determinants 
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in generating a mature, crosslinked elastic matrix. In the light of limited synthesis of 
these proteins, despite increase in their gene expressions, crosslinking new elastin 
precursors were likely limited. This could potentially have contributed to the low levels 
of alkali-insoluble elastin measured in all treatment conditions.  
Analysis of elastic matrix degrading gelatinases, MMPs -2 and -9, showed 
different trends at the gene expression level compared to that at the enzyme level. MMP-
2 gene expression was up-regulated up to 2-fold relative to control in EF-treated 
constructs stretched at 3 Hz alone, and was comparable to static controls within all other 
constructs. However, both the total protein content as well as enzyme activity of MMP-2 
were comparable among all treatment conditions. This finding is in contrast to that 
observed by other groups, wherein both gene expression and enzyme activity of MMP-2 
have been reported to increase under cyclic stretch relative to static controls
237-238
. This 
difference could be attributed to the use of low strains of 2.5% in our studies, compared 
to the 10% strains used in other studies. It is also likely that at these strains, EFs-mediated 
decrease in MMP-2 enzyme activity is being facilitated. While the differences in protein 
content and enzyme activity remained insignificant, it is important to note that the thick 
bands corresponding to active enzyme in the zymograms indicated high levels of enzyme 
activity for protein concentrations as low as 5 μg/lane. On the other hand, mRNA 
expression of MMP-9 was uniformly low in all treatment conditions. However, moderate 
increase (~ 1.5 –fold) in its protein content, both zymogen and active forms, were  seen in 
constructs treated with EFs and stretched at 1.5 Hz and 3 Hz. 
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The matrix ultrastructure and orientation of cells in the scaffolds were contrary to 
what we had hypothesized. As noted in the VVG stained slides and IF images, at the 
strain and frequencies provided, the cells and elastic fibers all appear to be oriented more 
in the longitudinal direction, than in the circumferential direction. Several studies have 
reported lower degrees of orientation and random alignment at 2.5% strains, compared to 
higher strains of 10%. However, what we note in this study is a uniform orientation in the 
longitudinal direction. Further, the longitudinal orientation closely resembles what was 
observed in the static cultures reported in Chapter 3. The increase in expression of 
various SMC contractile markers and changes in levels of matrix elastin however indicate 
that the cells have responded to the presence of external mechanical stimuli. The cross 
sectional views of constructs treated with stretch do indicate higher levels of 
circumferential orientation on the surface closest to the silicone tubing, compared to the 
regions further away from it. This indicated preliminary levels of orientation, not 
completely transferred to the entire thickness of the collagen gel. As a result of this 
orientation, the mechanical tests that were performed on ring sections of the constructs 
also did not show significant differences in tensile or yield properties. The low modulus 
of ~ 2 kPa seen in all test conditions could also be explained by the apparent influence of 
treatment conditions on matrix orientation more in the longitudinal direction and less in 







In this study we have demonstrated a positive influence of application of dynamic 
stimulation along with EFs up to 1.5 Hz frequency. Both increases in mRNA expression 
of proteins involved in elastic matrix assembly as well as increase in alkali-insoluble 
matrix elastin content was observed and found to be highest in the constructs treated with 
EFs and stretched at frequency of 1.5 Hz. Alkali-insoluble matrix elastin remained 
unchanged with the addition of EFs along with dynamic stimulation. While a 
circumferential orientation was not obtained as expected, a high degree of longitudinal 

















IMPACT OF MMP─INHIBITION ON OUTCOMES OF INDUCED 




In the studies described in the previous chapters, we reported on the elastogenic 
benefits of TGF–β1 and HA-o to adult SMCs, both rat and human, cultured under static 
and dynamic conditions. In these studies, however, it was noted that the fraction of 
matrix elastin deposited in the highly crosslinked alkali-insoluble elastin form was low, 
and the expression and activity of the elastolytic enzyme MMP-2 continued to be high, 
regardless of the treatment condition. In an attempt to improve deposition of crosslinked 
mature elastic matrix and reduce its degradation, critical to enhancing accumulation and 
fiber formation, in this study, we sought to evaluate if suppression of MMP-2 activity in 
the cultured constructs improves the above mentioned synthesis.  
Doxycycline (DOX) is a modified tetracycline compound that has been widely 
administered as a broad-spectrum antibiotic
126
. Known to be a non-specific MMP 
inhibitor, systemic delivery of DOX has been clinically shown to reduce the rate of AAA 
growth and progression of disease
45-47
. Studies exploring the mechanisms of MMP 
inhibition have found DOX to significantly reduce activity of both elastolytic (MMPs -2, 
-9) and non-elastolytic (MMPs -1,-3,-8,-12) proteases, both at the transcription and 
translation steps of protein synthesis
127-128
. Several groups have also specifically 
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evaluated its effects on gelatinases, i.e., MMPs -2 and -9, proteases that are up-regulated 




Preliminary studies conducted in our lab tested effects of DOX on SMCs isolated 
from a CaCl2 model of rat AAA, over a dose range of 0.1 μM–10 μM. The DOX was 
added exogenously with culture medium. Of these, the highest dose of 10 μM was found 
to be highly cytotoxic, while the lower doses of 0.1 μM and 1 μM did not impede cell 
proliferation over 21 days of culture. For this study, we therefore delivered the lower 
DOX doses of 0.1 μM and 1 μM, and exogenously supplemented it to the culture medium 
along with previously determined, effective dose combination of EFs (see Chapter 3). In 
the study described in Chapter 4, the dynamic conditioning regime found to promote 
highest elastogenic activity was 2.5% cyclic strain applied at a frequency of 1.5 Hz. The 
two DOX doses with EFs were therefore provided to both static HASMC-seeded tubular 
collagen gel constructs, and constructs stretched cyclically to 2.5% strains at 1.5 Hz for 
21 days. 
 
5.2. MATERIALS AND METHODS 
All steps involved in fabrication and culture of constructs, assay time points and 
methods of construct harvest, methods of biochemical analysis, imaging, and statistical 
analysis were performed in a manner similar to that described in Section 4.2 of Chapter 
4. Doxycycline solutions were prepared fresh prior to each media change. Mechanical 
testing was not performed on these constructs.  
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The different treatment conditions are listed in Table 5.1. Of these, the static 
controls, static + EFs and EFs + 1.5 Hz construct samples were reused from those 
cultured for the study in Chapter 4. These samples were either 1) re-assayed along with 
the samples obtained from those cultured with DOX in this study (DNA assay, Fastin 
assay, zymography western blotting of MMPs -2 and 9), or 2) experiments for both 
studies were performed simultaneously (RT-PCR and western blotting for SMC 




TGFβ1 (0.1 ng/ml)/ 




No EFs (Control) - - - 
EFs, static - + - 
EFs + DOX, static (1) 
 
+ - 
EFs + DOX, static (2) 0.1 + - 
EF, dynamic 1 + + 
EFs + DOX, dynamic (1) 0.1 + + 
EFs + DOX, dynamic (2) 1 + + 
 




5.3.1. Construct Compaction  
As shown in Figure 5.1, the aspect ratios of constructs (length : O.D) at 21 days 
after treatment with DOX and EFs were found to be 11 ± 2.3, similar to that seen in 
constructs without DOX and in no EF controls. This indicates that the degree of 
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contraction was higher in the transverse direction than longitudinally (as length/O.D is ~ 
11, which indicates length >> O.D).  
 
5.3.2. Cell Quantification 
After 21 days of treatment, cell numbers were normalized to mg dry weights of 
lyophilized constructs. While cell numbers appeared to increase under dynamic 
stimulation in constructs with or without DOX, this increase was statistically significant 
only in constructs with 0.1 μM DOX (2.01 ± 0.62  10
6 
) and EFs compared to static 
controls without DOX or EFs ( = 0.006) (Figure 5.2). Differences were statistically 
insignificant between all other treatment conditions. This indicates that the addition of 
DOX with EFs under static or stretched conditions did not adversely affect cell growth, 
either in terms of cell proliferation or cell death, compared to untreated static controls.  
 
5.3.3. Analysis of SMC Markers 
RT-PCR (n = 6) and western blotting (n = 1) of SMC phenotypic markers were 
performed to analyze the effect of treatment conditions on phenotypic changes to SMC 
(Figure 5.3). mRNA expressions of contractile phenotypic markers of SMCs – SMA  
(early-stage marker) and caldesmon (mid-stage marker), and synthetic, activated marker, 
osteopontin, were analyzed in the different treatment conditions. 
Figure 5.3 A shows the fold change in mRNA expression of SMA in the different 





















ontrols, SMA mRNA expression remained unchanged in all static constructs treated with 
or without DOX. Addition or increasing concentration of DOX did not alter this 
expression ( > 0.06). On the other hand, cyclic stretch significantly increased its 
expression in all treatment conditions ( < 0.001 compared to static controls). This 
Figure 5.1: Effect of treatment conditions on construct compaction after 21 days. 
Graph above shows similar extents of contraction among all treated conditions, 
under both static and dynamic conditions 
Figure 5.2: Effect of DOX + EFs on cell densities after 21 days of treatment, 
under static and stretched conditions. Plot above shows addition of DOX + EFs 
under both static and dynamic conditions did not significantly alter cell densities 
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increase was highest in dynamic constructs with EFs alone, where 4.13 ± 1 –fold increase 
was seen compared to controls ( < 0.001). This increase was also mirrored in all 
dynamic constructs treated with EFs or EFs + DOX, compared to their corresponding 
static constructs treated with similar concentrations of the same factors ( < 0.001). 
Addition of 0.1 μM DOX with EFs to stretched constructs appeared to slightly lower 
SMA expression compared to stretched constructs with EFs alone ( = 0.003). However, 
as was seen with static constructs, increasing concentration of DOX in stretched 
constructs did not alter SMA mRNA expression ( = 0.27).   
Figure 5.3: Effect of stretch on SMC phenotypic markers compared to static cultures 
in the presence of DOX + EFs. (A) mRNA expression of SMA significantly increased 
with application of stretch compared to static constructs. (B) mRNA expression of 
caldesmon similarly increased within cyclically stretched constructs. (C) mRNA 
expression of osteopontin remained unaffected in all treatment conditions, except in 
stretched EFs constructs alone. (D) Representative immunoblots of SMC contractile 
phenotypic markers showing increase in protein content with addition of stretch. 
Significant differences for p ≤ 0.05 are indicated by ‘*’ relative to control, ‘#’ from 
static EFs, ‘&’ between the groups indicated, and ‘+’ from all DOX + EFs –treated 
constructs, both static and dynamic 
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Figure 5.3 B shows fold changes in mRNA expression of caldesmon compared to 
controls. Similar to the trends observed with mRNA expression of SMA, that of 
caldesmon remained unchanged within all statically treated constructs ( > 0.49), but 
increased to 2.2 ± 0.45 -fold with incorporation of stretch ( < 0.001), compared to 
controls. Addition or increasing concentration of DOX did not alter its expression 
between conditions within both static ( > 0.93) and stretched constructs ( > 0.98). 
However, addition of stretch to constructs treated with similar concentrations of EFs or 
EFs + DOX significantly increased its expression compared to corresponding static 
constructs ( < 0.02).  
As seen in Figure 5.3 C, mRNA expression of the synthetic, activated SMC 
phenotype marker, osteopontin, was not significantly increased or decreased compared to 
control in any of the treatment conditions ( > 0.2). While addition of EFs alone (both 
static and stretched) appeared to slightly increase this expression, the differences were 
statistically insignificant ( > 0.2). However, compared to stretched constructs with EFs 
alone, addition of DOX at both doses, appeared to lower this expression, in both static ( 
< 0.02) as well as stretched ( < 0.005) constructs. Differences with increase in DOX 
concentration (both static and stretched) were insignificant ( > 0.8). 
Western blotting (Figure 5.3 D) of contractile phenotypic markers SMA, SM22α, 
calponin and MHC showed an increase in band intensities in all stretched constructs 
compared to the static constructs. Bands for caldesmon were undetected at the protein 




5.3.4. Elastic Matrix Content 
RT-PCR for gene expressions of elastin, fibrillin-1, fibulin-4 and LOX, Fastin 
assay for quantifying matrix elastin (alkali -soluble and –insoluble), and western blotting 
of fibrillin-1, fibulin, and LOX were performed to evaluate the effects of the treatment 
conditions on elastic matrix output.  
As seen in Figure 5.4 A, mRNA expression of elastin was significantly increased 
in all treatment conditions compared to control ( < 0.01). Among the static constructs, 
the highest increase was seen in those with 1 µM DOX + EFs (6.1 ± 0.97,  < 0.001), 
compared to control. However, among the 3 sets of static cultures treated with or without 
DOX, no statistical difference was observed ( > 0.15). The mRNA expression was 
pronounced to a greater extent among the stretched constructs than their static 
counterparts (6.7 ± 1-fold compared to control,  < 0.001).  Similar to that seen with the 
static constructs, addition of DOX + EFs at the 2 doses to stretched constructs induced 
similar increases in mRNA elastin expression compared to stretched constructs with EFs 
alone ( = 1).  As seen in Chapter 4, with respect to control, addition of stretch to 
constructs treated with EFs alone resulted in a 6.7 ± 1.5 –fold increase in elastin mRNA 
expression, which was significantly higher than the 4.8 ± 0.4 –fold among static EFs 
constructs ( = 0.006). However, addition of stretch did not improve the already high 
mRNA expression among the DOX-treated cultures at either doses ( > 0.15).  
The mRNA expression of fibrillin-1, the microfibrillar scaffolding protein of 
elastic matrix, was increased to similar extents of approximately 2-fold in almost all 
treatment conditions compared to controls ( > 0.12), as seen in Figure 5.4 B. However, 
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this increase was statistically significant only in 3 treatment conditions compared to 
control- static EFs (2 ± 0.6 –fold,  = 0.02), and 0.1 µM DOX + EFs –treated constructs, 
both static (2.1 ± 0.6,  = 0.01) and stretched (2 ± 0.6,  = 0.04). No significant 
differences in expression were observed between all other treatment conditions. The 
mRNA expression of fibulin-4 (Figure 5.4 C) also remained unchanged in all treatment 
conditions compared to control ( > 0.85). mRNA expression of LOX appeared to be 
elevated in all treatment conditions (Figure 5.4 D). However, this increase was also 
significant only in 3 treatment conditions- static constructs with EFs alone (2.82 ± 1.1,  
= 0.004), stretched constructs with EFs alone (2.68 ± 0.42,  = 0.01), and stretched 
constructs with 1 µM DOX + EFs (2.43 ± 0.42,  = 0.047). Like that observed in 
expressions of fibrillin-1 and fibulin-5, differences in mRNA expression of LOX between 
treatment conditions, both static and stretched, were insignificant ( > 0.098). 
Matrix elastin content was measured in terms of the less crosslinked alkali-soluble 
elastin, and the highly crosslinked alkali-insoluble elastin, as seen in Figure 5.5. 
Compared to control, alkali-soluble matrix elastin content was significantly elevated in 
all treatment conditions, both static ( < 0.047) and stretched ( < 0.001). Within static 
constructs, the addition of DOX + EFs at both doses resulted in further increase in alkali-
soluble elastin content compared to those with EFs alone (26.2 ± 9.5 µg/mg,  = 0.05 
with 0.1 µM DOX + EFs, and 30.6 ± 9.3,  = 0.001 with 1 µM DOX + EFs). Addition of 
stretch further increased alkali-soluble elastin content. Up to 2-fold increase was noted in 














 in not improve the already high levels of alkali-soluble elastin content (> 26 µg/mg in all 
cases,  > 0.47 between the 4 DOX + EF –treated constructs). Similarly, among the 3 sets 
of stretched constructs, with or without DOX, differences were insignificant ( > 0.46). 
The presence of the highly crosslinked, alkali-insoluble matrix elastin content was found 
to be similar in almost all treatment conditions (1.9 ± 0.8 µg/mg,  > 0.19), with or 
without DOX or stretch. Stretched constructs with 0.1 µg/mg DOX + EFs, were the only 
condition that showed a significant increase in alkali-insoluble elastin content compared 
to all other constructs (3.8 ± 1.9,  < 0.04). 
 
Figure 5.4: Evaluation of changes in mRNA expression of different elastic matrix 
proteins under static and dynamic conditions with the addition of DOX and EFs 
(A) elastin, (B) fibrillin-1, (C) fibulin-5, and (D) LOX. '*' represents significant 











Western blotting of the elastic matrix proteins fibrillin-1, fibulins -4 and -5, and 
LOX did not result in consistently detectable or quantifiable bands. This is likely due to 
the low protein concentrations (5 µg) that these were tested with. 
 
5.3.5. MMP-2 Production and Activity 
RT-PCR, western blotting and zymography were performed to analyze the effects 
of DOX + EFs under static and stretched conditions. As seen in Figure 5.6, constructs 
treated with DOX + EFs significantly decreased MMP-2 mRNA expression under both 
static and stretched conditions, compared to those without DOX ( < 0.01), at both the 
doses provided. Within static constructs, compared to control, MMP-2 mRNA expression 
was significantly decreased to 0.24 ± 0.05 –fold and 0.22 ± 0.1 –fold with 0.1 µM DOX 
Figure 5.5: Effects of addition of DOX and EFs on elastic matrix content under static 
and dynamic conditions. Alkali -soluble elastin elevated in all treatment conditions 
compared to control. Alkali-insoluble matrix elastin remained unchanged in almost all 
cases, except in 0.1 M DOX + EFs. '*' represents significant difference from control, 
‘#’ from static EFs, and ‘$’ with respect to every treatment condition, for p ≤ 0.05) 
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+ EFs and 1 µM DOX + EFs respectively ( < 0.001 for both).  This decrease was also 
significant compared to static constructs treated with EFs alone ( < 0.01), whose MMP-
2 mRNA expression was 0.7 ± 0.18 –fold compared to control ( = 0.02). The difference 
in expression between DOX-treated and –untreated constructs was significant under 
dynamic stimulation as well ( < 0.001 for stretched EFs compared to both doses of 
stretched DOX + EFs). MMP-2 mRNA expression within stretched constructs with EFs 
alone were comparable to control (0.98 ± 1.8 –fold,  = 1). However, with the addition of 
0.1 µM DOX + EFs and 1 µM DOX + EFs, this was brought down to 0.36 ± 0.08 –fold 
and 0.31 ± 0.07 –fold respectively ( < 0.001 for both). While MMP-2 mRNA expression 
appeared to increase with stretch, this increase was significant in constructs treated with 
EFs alone ( = 0.03). Differences in its expression between static and dynamic constructs 








Figure 5.6: Changes in mRNA expressions of MMP-2 under static and dynamic 
conditions, with DOX + EFs, and EFs alone, relative to control. Significant decrease 
observed with addition of DOX + EFs under both static and dynamic conditions. '*' 















Western blotting of MMP-2 (Figures 5.7 A and B) did not show any significant, 
treatment-specific differences in intensities of bands corresponding to both zymogen and 
active forms of the protein ( > 0.63). However, zymography (Figures 5.8 A and B) 
showed significant decrease in enzyme activity of MMP-2 as a function of DOX dose, 
under both static and stretched conditions. Within static constructs, fold-change in RDU  
 
Figure 5.7: Effect of addition of DOX + EFs on MMP-2 protein content under static 
and dynamic conditions relative to control. (A) Representative immunoblots of active 
and zymogen forms of MMP-2 in all treatment conditions. (B) Semi-quantitative 
analysis of MMP-2 protein represented as fold change in RDU relative to control. No 















values of active MMP-2 enzyme bands relative to control, were significantly decreased to 
0.45 ± 0.18 –fold with 0.1 µM DOX + EFs, and further decreased to 0.25 ± 0.13 –fold 
with 1 µM DOX + EFs ( < 0.001 for both). This decrease in MMP-2 enzyme activity 
under both DOX doses tested was significant relative to static constructs treated with EFs 
alone as well ( < 0.001). Increase in DOX dose (with EFs) to 1 µM significantly 
Figure 5.8: Change in MMP-2 enzyme activity with addition of DOX and EFs under 
static and stretched conditions relative to control. (A) Representative zymogram 
showing bands corresponding to active MMP-2 enzyme. Bands corresponding to 
zymogen form of the enzyme were undetected. (B) Fold change in MMP-2 active 
enzyme compared to control. Significant decrease observed proportional to increase 
in DOX concentration in both static and dynamic constructs. ‘*’ represents significant 
difference from control, ‘#’ from static EFs, ‘@’ from 0.1 µM DOX + EFs static, ‘&’ 
from dynamic EFs and ‘$’ compared to every treatment condition, for p ≤ 0.05  
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decreased enzyme activity compared to 0.1 µM DOX + EFs ( = 0.008). Similarly, while 
application of stretch did appear to increase MMP-2 enzyme activity, this trend was 
mirrored under dynamic conditioning as well. Within stretched constructs, relative to 
control, the active enzyme band intensities were significantly decreased to 0.81 ± 0.1 –
fold with 0.1 µM DOX + EFs ( = 0.048), and 0.59 ± 0.2 with 1 µM DOX + EFs ( = 
0.001). Again, this decrease was significant compared to stretched constructs treated with 
EFs alone ( < 0.04) whose band intensities were comparable to control (1 ± 0.09 –fold, 
 = 0.7, relative to control). Similar to that seen within static constructs, decrease in 
enzyme activity within stretched constructs was also proportional to increasing DOX 
concentration ( = 0.005 between 0.1 µM and 1 µM DOX + EFs, dynamic constructs). 
Zymogen forms of MMP-2 (72 kDa) enzyme were undetected in all treatment conditions 
at the protein concentrations tested (5 µg) in both western blots and gelatin zymograms. 
 
5.3.6. MMP-9 Production and Activity 
mRNA expressions of MMP-9 for constructs in all groups were extremely low 
and barely above the detectable limits of the instrument, at the cDNA concentrations 
tested. It was therefore not possible to discern differences in its gene expression between 
different groups, if any existed. Western blotting of MMP-9 (Figures 5.9 A and B) 
showed a dose-dependent decrease in band intensities of active MMP-9 protein, with 
decrease in intensity being proportional to increase in DOX concentration (with EFs), 
under both static and dynamic conditioning. Within static constructs, relative to control, 
RDU values of MMP-9 active protein bands were decreased to 0.64 ± 0.16 –fold ( = 
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0.02) with 0.1 µM DOX + EFs, and further down to 0.44 ± 0.07 –fold ( = 0.01) with 1 
µM DOX + EFs. Compared to static constructs treated with EFs alone (whose band 
intensities were 0.95 ± 0.01 –fold,  = 0.71, relative to control), significant decrease in 
MMP-9 active protein band intensity was observed with 1 µM DOX + EFs alone ( = 













Figure 5.9: Effect of addition of DOX and EFs on MMP-9 protein content, under static 
and dynamic conditions. (A) Representative immunoblots of MMP-9 active protein in 
different treatment conditions. Bands corresponding to zymogen form of protein were 
undetected. (B) Semi-quantitative analysis of MMP-9 active protein represented as fold 
change in RDU relative to control. Significant decrease seen with addition of DOX + 
EFs in both static and dynamic constructs. ‘*’ represents significant difference from 
control, ‘#’ from static EFs, and ‘@’ between conditions indicated, for p ≤ 0.05 
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Application of stretch appeared to increase MMP-9 active band intensities in all 
constructs, relative to the corresponding static constructs treated with similar 
concentrations of DOX or EFs. These differences were however statistically significant in 
constructs with 1 µM DOX + EFs alone ( = 0.047 between static and dynamic). In all 
stretched constructs, MMP-9 intensities remained lower than control; 0.6 ± 0.06 –fold ( 
= 0.01) for EFs + stretch alone, 0.72 ± 0.15 –fold for 0.1 µM DOX + EFs + stretch ( = 
0.048), and 0.66 ± 0.18 –fold for 1 µM DOX + EFs + stretch ( = 0.02). Among the 3 
sets of constructs under dynamic conditioning, with or without DOX, MMP-9 band 
intensities were comparable ( > 0.8). Bands corresponding to zymogen forms of MMP-9 
were undetected in western blots at the protein concentrations tested. Both active and 
inactive forms of MMP-9 enzyme were undetected in gelatin zymograms.  
 
5.3.7. Matrix Ultrastructure 
Matrix ultrastructure appeared similar to the static and dynamic constructs 
evaluated in Chapter 4, as seen in Figures 5.10 through 5.12. Cells and synthesized 
matrix were oriented more in the longitudinal direction, than circumferentially. Elastin 




The studies conducted in Chapters 3 demonstrated the elastogenic benefits of 





















Figure 5.10: Elastic matrix assembly and orientation in response to with DOX and 
EFs under static and dynamic conditions. Representative (A) longitudinal- and (B) 
cross- sections (30 µm thick) of constructs show more elastic fibers (stained 
purple to black) deposited within DOX + EFs- treated constructs. Cells and matrix 
appear to be oriented more in the longitudinal direction, than circumferential. 







Figure 5.11: Effects of treatment with DOX, EFs and dynamic stimulation towards 
elastin synthesis and assembly. Representative fluorescent micrographs of 10 µm-
thick (A) longitudinal- and (B) cross-sections of constructs immunolabeled with 
elastin (red) and nuclei (blue). Longer fibers of elastin are seen in the longitudinal 
sections. Addition of DOX, under both static and dynamic conditions appears to 
have improved elastic matrix output. White arrows indicate longitudinal direction 








Figure 5.12: Effects of treatment with DOX, EFs and dynamic stimulation 
towards synthesis and assembly of fibrillin. Representative fluorescent 
micrographs of 10 µm-thick (A) longitudinal- and (B) cross-sections of constructs 
immunolabeled with fibrillin (red) and nuclei (blue). White arrows indicate 





serve to enhance net accumulation of newly synthesized elastic matrix and improve its 
quality, especially in the form of more mature fiber formation. In the current study, we  
constructs. In Chapter 4, we were able to replicate these results within adult human SMCs, 
and further enhance matrix alignment with the application of cyclic stretch as reported in 
Chapter 4. That these observations were made within collagenous microenvironments, 
not particularly conducive to elastogenesis, by inducing inherently non-elastogenic adult 
SMCs, is highly encouraging. One of the observed shortcomings of the tested methods 
was the continued lack of synthesis and organization of highly crosslinked, mature alkali-
insoluble matrix elastin. At the same time, the expression, synthesis and activity of 
MMP-2, a major elastolytic protease
83
, was found to remain consistently high in both 
studies. We therefore hypothesized that suppression of MMP-2 can therefore evaluated 
the benefits of utilizing DOX, a modified tetracycline reported to be a non-specific MMP 
inhibitor
130
, supplemented with EFs, in improving elastic matrix outcomes via 
suppression of MMPs. 
Progression of AAA disease appears to be related to two factors, namely, a) 
chronically high levels of matrix protease activity, primarily MMPs -2 and -9, initiated by 
inflammatory cells infiltrating the site of tissue injury
16, 55, 241
, and b) the inability of the 
native vascular cells to preserve and restore disrupted vascular wall matrix, especially 
elastin
10, 18, 79
. Systemic delivery of Doxycycline has been clinically useful to attenuate 
MMP-mediated disruption and loss of elastic matrix
46, 126
. As a result, progression of 
disease is suppressed, and in a few cases even reverted, by preserving the existing elastic 
matrix within the AAA wall
46, 126








also been linked to likely dose-dependent effects such as frequent gastrointestinal tract 
disturbances, cutaneous photosensitivity and irreversible dental discoloration
242
. Besides, 
systemic inhibition of MMPs is not desirable since it plays key roles in normal tissue 
remodeling and turnover as well
83
. Localized delivery of DOX using osmotic pumps in 
AAA rodent models has been attempted and showed DOX to retain therapeutic benefits 
at concentrations 100-fold lower than that delivered systemically
243-244
. However, when 
we delivered similar concentrations to SMCs in 2D cell culture, we found DOX to be 
cytotoxic at concentrations as low as 10 μM, but to promote cell proliferation at lower 
concentrations. Other studies have also indicated a dose-dependent inhibition of cell 
attachment and proliferation by DOX 
245-246
. In the current study, at concentrations as low 
as 0.1 and 1 μM, we did not observe any changes in cell densities compared to those 
without DOX treatment, both static and stretched. These differences may be due to one or 
more of the following factors, namely a) reduced DOX dose on a per cell basis within the 
current 3D model owing to much higher cell-seeding density, compared to that in 2-D 
culture, b) limitation to diffusion of DOX into constructs, effectively reducing doses 
perceived by cells, and c) the presence of a collagenous environment that is inherently 
deterrent to cell proliferation, potentially normalizing the proliferative capacity of cells 
across treatment conditions.  
DOX-mediated suppression of gelatinases has shown to be achieved by inhibition 
both at the level of mRNA expression of proteases
127-128
, as well as during protein 
synthesis, and inducing irreversible loss of enzyme activity post-synthesis
131, 247
. Liu et.al. 





. At the concentrations tested in our study, we witnessed a marked suppression in 
MMP-2 mRNA expression as well. This suppression was higher in the DOX + EFs 
treated cultures, than those treated with EFs alone, both under static and stretched 
conditions. In the static cultures, up to a 5-fold decrease in MMP-2 mRNA expression 
was found with the addition of 1 μM DOX, and a 4-fold suppression for 0.1 μM. Even 
within cyclically stretched constructs, where the stretch-induced increase in MMP-2 
mRNA expressions are known to occur
170
, its gene expression was found to be decreased 
to levels statistically similar to that found within static cultures treated with DOX + EFs. 
However, this decrease in expression was not found to be dose-dependent, with similar 
levels of MMP-2 mRNA suppression seen in both DOX doses tested, with or without 
stretch. It is important to note that the DOX doses tested in this study were several orders 
of magnitude lower than what has been shown to inhibit MMP-2 gene expression
127-128
. It 
is likely that within a 3D collagenous environment, where cells inherently secrete 
proteases for tissue remodeling
170, 237
, inhibition of MMP at the level of gene expression, 
in the presence of such low concentrations of inhibitors, could get normalized. This 
normalizing effect is further substantiated by the finding that MMP-2 mRNA expression 
was suppressed to similar, and not proportional extents, within static and stretched 
constructs. On the other hand, at the protein level, both active and zymogen forms of 
MMP-2 were found to be similar under all treatment conditions, indicating that at the 
levels tested, DOX did not inhibit protein synthesis, despite the apparent decrease in 
MMP-2 mRNA expression. In contrast however, enzyme activity of MMP-2, as 
evaluated by zymography, was found to decrease proportionally with increase in DOX 
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concentrations, in both static and dynamic constructs. This suppression was however 
more pronounced within static constructs (up to 2- and 4- fold decrease with 0.1 µM and 
1 µM DOX + EFs respectively), than within stretched constructs (up to 1.5- and 2- fold 
with 0.1 µM and 1 µM DOX + EFs respectively), likely due to increase the phenomenon 
of tissue remodeling-mediated increase in MMP-2 expression mentioned above. Several 
groups, including Liu et.al.,
248
 have also shown that DOX alters the conformation of both 
the zymogen and the active enzyme by binding enzyme-associated Ca
++131
. This makes 
the proteins more susceptible to proteolysis, resulting in their fragmentation into smaller 
molecular weight fractions and an irreversible loss of enzyme activity
131-132
. While we 
did not observe MMP-2 fragments in either western blots or the zymograms, our results 
nonetheless substantiate the hypothesis that DOX further inhibits MMP-2 activity at the 
enzyme-activity level as well. It is likely that the phenomenon of fragmentation occurs at 
higher DOX concentrations than that tested here, or that even if the fragments were 
formed in our study, their concentrations were too low to be detected. It is important to 
note that the MMP-2 gene expression and enzyme activity were far more suppressed in 
constructs treated with DOX + EFs, than that within EFs alone, indicating that DOX 





 have also been reported to also induce.   
MMP-9 mRNA expression at concentrations tested were very low to begin with, 
which made discerning differences between cases difficult. The low mRNA expression 
could also indicate why we did not observe bands corresponding to zymogen form of 
MMP-9 at the concentrations tested. However, western blotting did reveal differences in 
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total protein content of active MMP-9 enzyme. This was found to be lowered 
proportional to increase in DOX concentration, both in static and dynamic constructs. 
This further substantiates that the concentrations of DOX tested in this study were 
effective in suppressing protease activity.  
Addition of DOX also increased mRNA expression of elastin as well as alkali-
soluble matrix content, compared to untreated controls as well as constructs treated with 
EFs alone, in both static and dynamic constructs. Differences in mRNA expression of 
elastin appeared to be more pronounced between static and dynamic constructs, than 
between the two doses. mRNA expression of other elastic matrix proteins was found to 
be similarly increased (up to 2 fold) in all EF treated cultures, with or without DOX. 
Interestingly, unlike that seen in constructs treated with EFs alone, alkali-soluble matrix 
elastin content was found to be similar in all EF + DOX-treated constructs, and was not 
found to be influenced by varying concentration or application of stretch. This could 
likely be due to the similar levels of mRNA expression as well as total protein content of 
MMP-2 seen among all DOX + EFs –treated constructs.  
Several studies have indicated that DOX-mediated suppression of MMPs 
additionally occurs through the suppression of JNK pathway
133, 249
. Within AAAs, 
suppression of JNK has also been shown increase expression and synthesis of various 
matrix proteins, especially LOX, via a TGFβ-1 activated pathway
250-253
. Thus, it is 
pertinent to expect that DOX would enhance LOX bioavailability as well. LOX 
expression in our study, while elevated in EF-treated constructs (both static and dynamic) 
relative to static control, does not appear to be enhanced further upon addition of DOX. 
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TGFβ-1, which is added along with DOX in this study, is also known to enhance LOX 
mRNA expression and improve activity of the crosslinking enzyme
38
. It is possible that 
any DOX-mediated regulation of LOX expression may be limited and thus be masked by 
the addition of TGFβ-1 in our cultures. It is also important to note that our studies were 
conducted on healthy SMCs and in concentrations much lower than that reported in other 
studies. The combined suppression of MMP activity and increase in alkali-soluble matrix 
elastin was translated into higher quantities of alkali-insoluble matrix elastin only in one 
of the treatment conditions- 0.1 μM DOX + EFs with stretch. The levels remained 
comparable to static controls in all other cases. It is likely that the formation of the highly 
crosslinked alkali-insoluble elastin requires higher expression of elastic matrix 
scaffolding proteins i.e., fibrillin-1, fibulins and LOX, than that obtained in our studies. 
Matrix ultrastructure also appeared similar to constructs treated with EFs alone. As noted 
in Chapter 4 studies, cell and fiber alignment were once again in the longitudinal 
direction, and not in the circumferential direction. This is likely due to the low strains of 
2.5% applied to the constructs in this study.  
 
5.5. Conclusions 
Supplementation of HASMC-collagen constructs with DOX and EFs improved 
elastic matrix output in terms of higher quantities of alkali-soluble matrix elastin. 
Expression and activity of both MMPs -2 and -9 were found to be suppressed in both the 
DOX-doses tested. Improvements in insoluble-elastin content was observed in one of the 




EVALUATION OF ELASTOGENIC EFFECTS DUE TO LOCALIZED, 




In the previous chapter, we demonstrated that the treatment of adult SMCs within 
collagen constructs with EFs and DOX improve outcomes of induced elastogenesis. 
While these studies mimic an in vivo tissue microenvironment, the EFs and DOX were 
supplemented exogenously to the culture media. There are two limitations to such 
delivery. First, the direct translation of such exogenous delivery and its cell-regulatory 
outcomes cannot be achieved in vivo at the site of proteolysis and disease, in a manner 
similar to that demonstrated in these studies. Second, it is unclear whether diffusional 
limitations exist for EF access into the tissue constructs, and to what extent induced 
elastogenesis is limited by this factor. In the context of in situ matrix repair, it is thus 
important to obtain localized, controlled delivery of therapeutic agents, whose 
concentrations and bioavailability can be closely regulated to achieve significant and 
predictable cellular response. Nanoparticulate delivery of active agents via polymeric 
carriers has been widely used for various in vivo drug delivery applications
254-256
. 
Compared to other delivery modes such as those involving the use of microparticles, 
nanoparticles (NPs) offer several advantages such as higher surface area/unit volume, 
achieving higher release, better tissue infiltration and interaction at the cellular level due 
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to their nano-range sizes comparable to cells, and generation of comparatively lesser 
byproducts of polymeric degradation that can adversely impact activity of agents 
encapsulated within
257-259
. In this study, we have utilized the in vitro tubular collagen gel 
model, as optimized in the previous chapters, to evaluate the effects of localized delivery 
of elastogenic factors from poly (lactic-co-glycolic acid) (PLGA)  nanoparticles (NPs).  
It is important to note that in this study, we have evaluated the effects of co-
delivery of only TGF-β1 and DOX, and excluded HA-o from the study. Nanoparticulate 
formulations for  HA-o delivery are currently being developed in our lab, and were 
therefore not available to be included in this study. Accordingly, a direct comparison of 
the results of Chapters 4 and 5 are therefore not possible. We have thus included in this 
study, an additional control case in which TGF-β1 and DOX were exogenously delivered 
at concentrations similar to that released from the NPs. All other culture conditions were 
kept constant among the different treatment cases.  
   
6.2. MATERIALS AND METHODS 
6.2.1. Synthesis of TGFβ-1 and DOX loaded Nanoparticles 
Two different sets of Poly (dl-lactic-co-glycolic acid) nanoparticles (PLGA; 50:50 
lactide : glycolide; inherent viscosity 0.95-1.20 dL/g in hexafluoroisopropanol; Durect 
Corporation, Birmingham, AL) nanoparticles were synthesized – one with TGF-β1 (28 
kDa) (R & D Systems, Minneapolis, MN) and another with DOX (Sigma, St. Louis, MO). 
A double-emulsion/solvent evaporation method was utilized to obtain PLGA NPs loaded 
with either of the water soluble factors
213-214
. Nanoparticles were synthesized with 0.25% 
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w/v polyvinyl alcohol (PVA), which acts as an anionic surfactant and a stabilizer
213
. 
Particle size and ζ-potential were evaluated using a NICOMP 380 ZLS analyzer. Size 
homogeneity of the synthesized particles was confirmed using TEM. In order to obtain 
the target concentration of factors (as optimized in Chapters 4 and 5) released from the 
NPs, 2 different drug-loading concentrations for DOX, and 3 for TGF-β1 were tested. 
DOX was loaded at 2% and 5% w/v, while TGF-β1 was loaded at 1000 ng, 2000 ng and 
5000 ng per mg of PLGA. Blank NPs were synthesized in manner similar to the factor-
loaded NPs, but without the addition of any factors.  
 
6.2.2. Release Profile of Factors from NPs 
Release of DOX and TGF-β1 (agents) from NPs was evaluated in PBS at 37 °C 
over 21 days. TGF-β1 NPs were suspended in PBS at a concentration of 10 mg/ml, while 
DOX loaded NPs were tested at 0.2 mg/ml and 0.5 mg/ml. In order to measure the 
concentration of the agents released from the NPs at each time point, the nanoparticles 
were first centrifuged at 14,000 rpm for 30 minutes at 4 °C, and supernatants collected 
for analysis. Fresh, 1 ml aliquots of PBS were added post-centrifugation to replenish the 
volumes for further study of release. The collected aliquots of supernatant from the TGF-
β1- NP preparations were frozen at -20 °C until analysis. The concentration of TGF-β1 
was measured in these aliquots using a commercially available enzyme-linked 
immunosorbant assay (ELISA) kit (R & D Systems, Minneapolis, MN). Concentration of 
DOX in supernatant aliquots similarly obtained by processing DOX NPs, were not frozen 
but measured immediately after each centrifugation cycle using UV-spectrophotometry 
149 
 
(SpectraMax M2, Molecular Devices, Inc., Sunnyvale, CA) at absorbance of λ = 273 
nm
259-260
. Concentrations were determined based on calibration curves of known DOX 
concentrations incubated in PBS for similar time points. Based on the cumulative release 
curves plotted for all cases, the optimum NP formulation was chosen for each factor, such 
that a total of 0.5 mg/ml NPs would be used to release agents within the collagen gel 
constructs over 21 days of culture. 
 
6.2.3. Formulation of NP-loaded Collagen Constructs 
Acid-solubilized rat-tail collagen was brought to physiological pH as detailed in 
Section 4.2.2.  Following this, the 2 sets of NPs were added at a final concentration of 0.5 
mg/ml. 5  10
5
 HASMCs/ml were then added to this viscous mixture, mixed well by 
gentle pipetting, and then added to the culture chambers of the bioreactors. The 
bioreactors were sterilized and set up as detailed in Sections 4.2.1 and 4.2.2.  Day 1 of 
culture was set to 24 hours after seeding the constructs since the factors from NPs were 
expected to initiate release of active agents immediately after seeding. The three 
treatment conditions tested, i.e. constructs with exogenous delivery (control; EDC), blank 
NPs (BNP) and agent-loaded NPs (ANP), and are listed in Table 6.1. Cyclic stretch was 
provided to all the 3 conditions at 2.5% strain and 1.5 Hz, as optimized in Chapter 4.  
DOX and TGF-β1 were exogenously supplementation to one set of constructs as delivery 
mode controls. The concentrations of exogenous delivery were equivalent to that released 
by the NPs at similar time points along (determined from their release curves in PBS) 
with DMEM/F12 (Media Core, Cleveland Clinic, Cleveland OH), 10 % v/v FBS (PAA 
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Scientific, Dartmouth, MA) and 1% v/v PS (Thermo Scientific, Rockford, IL). Constructs 
with blank NPs or agent-loaded NPs were cultured in above culture medium with no 
exogenous factors. Culture medium was changed every 2 days, and spent media pooled 
for each construct and frozen at -20 °C until analysis. Constructs were harvested 21 days 
after seeding, rinsed 3  in sterile PBS, and processed for various biochemical assays.  
 
6.2.4. Retention of NPs within Collagen Gels 
In order to verify that the NPs were retained in the gels, and not eluted out during 
compaction of constructs, a pilot study was performed on PLGA NPs loaded with Cy5-
tagged bovine serum albumin (BSA; NanoCS, New York, NY). N = 3 constructs were 
seeded each with 3 different NP concentrations - 0.1 mg/ml, 0.2 mg/ml and 0.5 mg/ml, 
and harvested at 3 time points – day 3, day 7 and day14. Constructs were visualized 
under a fluorescence microscope using a Cy5 filter (Olympus, Pittsburgh, PA) to gauge 
retention on the day of harvest.  Additionally, a DNA assay was also performed at days 3, 
7 and 14, to estimate the effect of NPs on cell proliferation. A minor difference between 
the NPs used in this pilot study, and the ones used to deliver DOX/TGF-β1, as discussed 
in this chapter, concerns the surfactant used to synthesize the NPs. Di-dodecyl-dimethyl-
ammonium bromide (DMAB), a cationic amphiphile, that imparts a net positive charge 
was used to synthesize NPs in the pilot study. As will be elaborated further in the 
Discussion section of this chapter (Section 6.4), although the surfactants may not directly 
influence release itself, DMAB, may have associated with released TGF-β1, resulting in 
decreased detection with ELISA. Hence, in subsequent experiments, we used PVA, 
which provides a net negative charge, as a surfactant. Despite the difference in 
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surfactants used, we believe that the pilot study can be used as a reliable indicator to 
estimate NP retention within the gels. This is since removal of NPs is likely to occur 
either during bulk fluid exclusion during  
gel compaction, or subsequently by diffusion. 
Table 6.1:  Experimental conditions-nanoparticulate delivery of elastogenic agents 
 
6.2.5. Compaction of Tissue Constructs 
All constructs were photographed at regular intervals and compaction of 
constructs was calculated and represented as an aspect ratio of length : O.D. on day 21 of 
harvest. 
 
6.2.6. DNA Assay for Cell Quantification 
As detailed in Section 4.2.4, 1/4
th
 segment of the each of the harvested constructs 
were flash-froze, lyophilized for 24 hrs and digested in 5 mg/ml proteinase-K (Gibco–
Invitrogen, Carlsbad, CA) for 10 hours. Samples were then centrifuged at 14,000 rpm to 
pellet any possible NPs, and supernatants sonicated prior to performing the Hoechst 
33258 dye (Gibco–Invitrogen, Carlsbad, CA) -based flourometric DNA assay
221
. Cell 
Group Mode of delivery of  DOX and TGF-β1 
Exogenous Delivery Control (EDC) Supplemented with culture medium 
Blank NPs (BNP) - 
Agent-loaded NPs (ANPs) 




numbers were calculated based on the estimate of 6 pg DNA/cell, and normalized to mg 
tissue weights for comparison, (n = 5/case).  
 
6.2.7. RT-PCR for mRNA Expression of SMA Phenotypic Markers and Matrix 
Proteins 
Rinsed segments of constructs were cut into small 1–2 mm long pieces and stored 
in RNAlater solution until processing, and RNA isolated using RNeasy kit (Qiagen, 
Valencia, CA), as detailed in Section 4.2.5. Briefly, samples were transferred to 500 μl 
RLT buffer (supplied with the kit) with 1% v/v 2-mercaptoethanol (Sigma, St. Louis, 
MO), homogenized using needle and syringe, and manufacturer’s instructions followed to 
isolate RNA into 50 μl of RNAase-free water. RNA content was measured using a Ribo-
green assay kit (Invitrogen, Carlsbad, CA), and 250 ng total RNA was reverse transcribed 
into 40μl cDNA, as detailed in Section 4.2.5. RT-PCR was performed for SMC markers 
such as SMA, caldesmon and osteopontin, elastic matrix proteins such as elastin, 
fibrillin-1, fibulin-5, LOX and collagen, and MMPs -2 and -9. Gene expressions were 
estimated in 1 μl cDNA (duplicate readings, n = 5 per sample), using the comparative 
threshold method with 18 s as the normalizing gene, as described in Chapter 1
261
. Primer 
sequences and source for the above genes are listed in Table 4.2 in Chapter 4.  
 
6.2.8. Fastin Assay for Elastin Content 
Lyophilized construct segments were digested in 0.1 N NaOH to solubilize alkali-
soluble matrix elastin, followed by in 0.25 M oxalic acid to obtain solubilized alkali-
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insoluble matrix elastin, as described in Section 4.2.6. Digested samples were once again 
centrifuged at 14,000 rpm for 30 minutes to eliminate any possible contamination from 
NPs. Digested aliquots (250 μl) were used to assay for alkali-soluble elastin, and 175 μl 
for alkali-insoluble elastin using the Fastin assay kit (Accurate Scientific and Chemical 
Corporation, Westbury, NY), as mentioned in Section 4.2.5.   
 
6.2.9. Western Blotting for Cellular and Matrix Proteins 
Lyophilized segments of constructs were cut into small 1-2 mm long pieces and 
500 μl of  RIPA lysis buffer (Invitrogen, Carlsbad, CA) with a protease inhibitor cocktail 
(Thermo Scientific, Rockford, IL) was added  to homogenize samples and solubilize 
proteins, as described in Section 4.2.7. A BCA assay (Thermo Scientific, Rockford, IL) 
was performed to measure concentration of total protein in all samples. Western blotting 
was performed to detect the phenotypic markers of contractile SMCs (n = 1/case) such as 
smooth muscle α-actin (SMA; an early-stage marker), Smooth muscle-22-α (SM22; a 
mid-stage marker), myosin heavy chain (MHC; a late-stage marker), and calponin and 
caldesmon (both mid-stage markers), elastic matrix proteins (n = 3/case) such as LOX, 
fibrillin-1 and fibulins -4 and -5, and matrix proteases (n = 3/case) MMPs-2 and -9. All 
blots were simultaneously labeled for the protein of interest and for the normalizing 
protein, β-actin. Protein content of 10 μg per sample was used to immunoblot the above 
proteins. Antibody concentrations and incubation time points corresponding to different 
steps in immunoblotting are detailed in Section 4.2.7. To semi-quantitatively represent 
the differences in elastic matrix proteins and proteases content between different 
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conditions, samples from n = 3 biological replicates per condition were assayed. Band 
intensities of the protein of interest calculated in RDU were first normalized to β-actin 
values, then normalized to the condition with exogenous factor delivery (treated as 
biological control), and represented as fold change in RDU values compared to the above 
condition.  
 
6.2.10. Gelatin Zymography for Detection of Enzyme Activities of MMPs -2 and -9 
 Gelatin zymography was performed to semi-quantitatively estimate differences 
the enzyme activities of the proteases MMPs -2 and -9, between the treatment conditions 
(n = 3/case). Protein samples (10 μg) homogenized in RIPA buffer as discussed in 
Section 6.2.9., were loaded into each lane of a 10% gelatin zymogram. As described in 
Section 4.2.8., zymography was performed on n = 3 biological replicates, and enzyme 
activity was represented as a fold change in RDU values relative to EDC constructs 
(control).   
 
6.2.11. Visualization of Elastic Matrix 
Constructs harvested after 21 days of treatment were rinsed 3 times in PBS, and 
0.5 cm long constructs were fixed in 4% w/v paraformaldehyde for 6 hours at RT and 6 
hours at 4 °C. Samples were then dehydrated and embedded in paraffin wax as detailed in 
Section 4.2.9. Histology was performed on 30 μm-thick cross- and longitudinal- sections 
using an Elastic stain kit (Laboratories Inc., Cache, UT) to visualize the ultrastructure of 
elastic matrix content in the constructs. IF was performed on 10 μm cross- and 
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longitudinal- sections, imaged using an fluorescence microscope under Cy5 filter 
(Olympus, Pittsburgh, PA) to detect elastin and fibrillin. The labeled sections were 
mounted in Vectashield with DAPI (Vector Laboratories, INC. Burlingame, CA) to stain 
for nuclei, and cover-slipped prior to imaging and visualization.  
Longitudinal sections (1 mm thick) of harvested constructs were fixed in 2.5% 
w/v gluteraldehyde and 4% w/v paraformaldehyde in sodium cacodylate buffer for 24 
hours, and then processed for TEM, as described previously in Section 4.2.9.  
 
6.2.12. Statistical Analysis 
All experiments were performed on n = 5 biological replicates per treatment 
condition, unless mentioned otherwise. Histology, IF and TEM were performed on 
segments from n = 1 construct per condition. All quantitative and semi-quantitative 
results are represented as mean ± standard deviation per condition. One-way ANOVA 
was performed  to calculate statistical significance in differences between treatment 
condition. Conditions were deemed to be significantly different for  values ≤ 0.05.  
 
6.3. RESULTS 
6.3.1. Nanoparticles Size and Release Profiles 
Hydrodynamic diameters of both TGF-β1 and DOX loaded NPs, and blank NPs 
synthesized were found to be within 300 ± 30 nm diameter and had a surface charge of 
30 ± 5 mV. Figure 6.1 shows the release curves of DOX and TGF-β1 from NPs in PBS 
over 21 days. In the studies discussed in Chapters 4 and 5, 0.1 ng/ml of TGF-β1 with 
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either of the DOX concentrations of 0.1 μM or 1 μM, were found to promote the most 
significant elastogenic outcomes. Based on the release curves of the two agent-loaded 
NPs, the formulations that most closely matched these concentrations were 2000 ng/mg 
loading of TGF-β1 when added at 0.3 mg/ml, and 5% DOX loading when added at 0.2 
mg/ml to the collagen-cell mixture. It is important to note that while the cumulative 
release of DOX from NPs over 21 days of treatment was similar to that optimized in 
exogenous delivery (5.61 μg/ml over 21 days), TGF-β1 released from the 2000 ng/mg 
formulation was ~ 10 fold lower. To account for this, we included exogenous delivery 
controls (EDC), to which DOX and TGF-β1 were supplemented exogenously to the 
culture medium. Equivalent concentrations corresponding to the release of TGF-β1 from 
2000 ng/mg loading (Figure 6.1 A), and DOX from and 5% loading at 0.2 mg/ml 






6.3.2. Nanoparticle Retention and Effects on Cell Density 
Cy5-tagged BSA loaded PLGA NPs were added at concentrations of 0.1 mg/ml, 
Figure 6.1 A: TGF-β1 Release Profile showing an initial burst phase followed by a 
sustained plateau phase. Based on the concentration released from 3 NP formulations, 











0.2 mg/ml and 0.5 mg/ml to HASMC-seeded collagen gel constructs, and were cultured 
for 3, 7 and 14 days. As seen in Figure 6.2, NPs at all three concentrations were retained 
within the gels at until day 14. DNA assay was performed to estimate cell densities at the 
different time points to estimate the effects of the different NP concentrations on cell 
proliferation (Figure 6.3). At day 14, cell proliferation appeared comparable in constructs 
Figure 6.1 B: DOX Release Profile. Based on the concentrations released from 
the 2 formulations of DOX-loaded PLGA NPs, a 5% w/v loading was chosen for 
subsequent studies  
Figure 6.2: Cy5-tagged BSA NPs (white specs) retained within collagen gel tubes at 
day 14. NPs added at the 3 concentrations - 0.1 mg/ml, 0.2 mg/ml and 0.5 mg/ml 
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with 0.1 mg/ml and 0.2 mg/ml NPs (1.7 ± 0.05 and 1.6 ± 0.25 –fold compared to day 1 of 
seeding). This was slightly less pronounced in constructs with 0.5 mg/ml NPs (1.4 ± 
0.16 –fold). However, the increase in cell densities with increasing culture durations in all 
treatment conditions indicated that the NPs did not adversely hinder cell proliferation. 
Based on these findings, and the results obtained from the release curves of agents from 
NPs (Figure 6.1), NP concentration of 0.5 mg/ml was chosen for further studies to test 









6.3.3. Compaction of Tissue Constructs 
After 21 days, constructs in all treatment conditions were found to have a length : 
O.D. aspect ratio of 8.4–9.5 (Figure 6.4). No significant differences were observed in the  
 
Figure 6.3: Cell density in collagen constructs with different NP concentrations, harvested at 3 
time points. None of the 3 concentrations tested ha detrimental effects on proliferation rates 
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extent of compaction between the different treatment conditions ( = 0.91 for both sets of 


















Figure 6.4: Construct compaction after 21 days of treatment. Addition of NPs did 
not alter aspect ratios over 21 days of treatment. Compaction was comparable 
among the three cases 
Figure 6.5: Effects of addition of NPs on cell density. No significant 
differences were observed in the cell densities of constructs with or without NPs 
160 
 
6.3.4. Cell Quantification 
The cell densities after 21 days of culture were found to be similar under all 
treatment conditions. Addition of NPs did not seem to adversely impact cell proliferation. 
Average cell densities, as represented in Figure 6.5, were found to be around 1.5 ± 0.25 
 10
5
 cells/mg construct. No significant differences were observed compared to EDC ( 
= 0.93 for BNP, and 0.22 for ANP). 
 
6.3.5. Analysis of SMC Markers  
RT-PCR was performed to evaluate the mRNA expressions of  SMA and 
caldesmon, the contractile SMC markers, and osteopontin, the synthetic/activated SMC 
phenotypic marker (Figure 6.6). Expression of the contractile markers was found to be 
maintained even with the addition of NPs compared to EDC ( = 0.97 and 0.93 for SMA, 
and 0.99 for caldesmon, for BNP and ANP). Osteopontin expression was also not 
elevated with the addition of NPs, and was not found to be statistically different from 
EDC ( = 0.08 for BNP and 0.07 for ANP).  
Western blotting was performed to estimate the differences in synthesis of various 
proteins that indicated the maintenance of a contractile, non-activated phenotype of 
SMCs over the 21 day period– SMA, calponin, caldesmon, SM22α and MHC (Figure 
6.7). For 10 μg protein concentrations, band intensities for all the contractile markers 
relative to their β-actin band intensities were found to be similar in all 3 treatment 
conditions. This demonstrates that a healthy contractile phenotype of cells was 
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6.3.6. Elastic Matrix Content 
The mRNA expressions of various genes corresponding to proteins constituting 
the elastic matrix were determined using RT-PCR –elastin, fibrillin-1, fibulin-5 and LOX 
(Figure 6.8). mRNA expression of elastin was decreased 3 ± 0.1 -fold (   0.001) in 
Figure 6.6: Effects of NP addition on SMC phenotypic response. mRNA expressions of 
SMC phenotypic markers SMA, caldesmon and osteopontin remained comparable to 
EDC constructs  
Figure 6.7: SMC phenotypic marker expression in response to NP delivery. 
Representative western blots of contractile SMC phenotypic markers indicate that 
phenotypic behavior of SMC was not altered by the addition of NPs  
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BNP constructs compared to EDC. This decrease was significantly bridged in ANP 
constructs ( = 0.002 compared to BNPs), which showed only a 10% decrease in elastin 
expression compared to EDC. Statistical comparison of elastin expression between 
exogenous and NP delivery of agents revealed no significant differences ( = 0.512). 
Similar trends were seen in differences in mRNA expressions of fibrillin-1 and fibulin-4. 
Expression of these genes were decreased up to 4-fold in constructs with Blank NPs (  
0.001 compared to exogenous control for both  genes). ANP constructs showed similar 
expression levels of fibulin-4 ( = 0.99), and a slight decrease in fibrillin-1 expression 
(1.5 ± 0.1 -fold,   0.001) compared to EDC constructs. The mRNA expression of LOX 
on the other hand, showed higher expression for both sets of constructs treated with NPs 
compared to EDC. While this difference was not significant in BNP constructs (1.5 ± 0.3 
-fold compared to exogenous controls,  = 0.16), the 1.7 ± 0.5 -fold increase within 
ANPs was statistically significant compared to EDC ( = 0.05). In addition to gene 
expression of  the above elastic matrix proteins, mRNA expression of collagen-1 was also 
estimated in the different treatment conditions.  A slight decrease in collagen-1 
expression compared to EDC was observed in constructs treated with NPs, but this 
decrease was statistically insignificant ( = 0.1 for BNP constructs and 0.19 for ANPs).  
A Fastin assay was performed to estimate the elastic matrix content in terms of 
alkali –soluble and –insoluble elastin within the 3 sets of constructs (Figure 6.9). Alkali–
soluble matrix elastin content within ANP constructs (20.01 ± 1.81 μg/mg) were found to 
be similar to that in EDC controls (20.97 ± 1.87 μg/mg,  = 0.73 ). These levels were 
significantly greater (up to 2-fold) than in BNP construct (9.62 ± 2.34 μg/mg,   0.001 
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compared to exogenous treatment controls). On the other hand, quantities of alkali–
insoluble matrix elastin was found to be barely above the detection limits of the assay kit 
within the sample volumes tested (around 0.5 μg/mg for all 3 conditions). They were 
statistically insignificant between the 3 conditions ( = 0.98 for BNP constructs and 0.64 









Western blotting was performed to estimate the levels of LOX, fibrillin-1 and 
fibulin-4. As seen in Figure 6.10, band intensities of LOX protein were found to be 
significantly higher in the constructs treated with NPs, both blank and agent-loaded, 
compared to EDC. Their intensities for treatment controls in the 2 subsequent biological 
replicates were too low to be reliably quantified. Therefore statistical comparison 
Figure 6.8: Effects of NP based delivery on mRNA expressions of elastic matrix 
proteins- elastin, fibrillin-1, fibulin-5, LOX and collagen-1. Expression of LOX was 
elevated in both BNP and ANP constructs. Expression of elastin was comparable 
between the 2 delivery modes, and that of fibrillin and fibulin was moderately lowered. 
'*' represents significant difference from EDC, '#' from BNP and '$' from every treatment 
condition for p < 0.05 
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representing differences in LOX protein content have not been performed. At the 10 μg 













6.3.7. Analysis of MMPs -2 and -9  
Gene expressions of the 2 gelatinases MMP-2 and -9 were determined using RT-
PCR. As seen in Figure 6.11, MMP-2 gene expression was significantly increased with 
Figure 6.9: Differences in elastic matrix content between the 2 delivery modes. Elastic 
matrix content measured in terms of alkali -soluble and -insoluble elastin remained 
comparable between NP-based and exogenous delivery of agents. '$' represents 
significant difference from every treatment condition for p < 0.05 
Figure 6.10: Effects of NP-based delivery on LOX protein content. Representative 
western blot of LOX protein in the 3 treatment conditions. LOX content appears to be 




the addition of NPs. Constructs with Blank NPs showed an average of 4.25 ± 0.6 -fold 
increase in MMP–2 expression compared to EDC (  0.001). The addition of factors 
within NPs lowered this expression 1.8-fold compared to Blank NPs (  0.001). MMP–2 
expression was 2.4 ± 0.3 -fold higher in ANP compared to EDC (  0.001). On the other 
hand, expression of MMP–9 was decreased in both sets of constructs treated with NPs. 
However this decrease was not statistically significant ( = 0.06 for BNP constructs, and 
0.18 for ANP). It is important to note that the Ct values for MMP–9 were only slightly 
above the reliable detection limits of the instrument for the cDNA concentrations tested. 









Western blotting was performed to estimate the amount of MMP protein present 
in the constructs. As seen in Figures 6.12 A and C, the zymogen form of MMP–2 
Figure 6.11: Outcomes in mRNA expression of MMPs -2 and -9 with delivery mode. 
A significant upregulation in MMP-2 is seen with the incorporation of NPs, while 
MMP-9 expression appears to have been suppressed. '*' represents significant 
difference from EDC, '$' with every treatment condition, for p < 0.05 
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corresponding to the 72 kDa bands, was found to be lower in BNP constructs compared 
to other 2 treatment conditions (3 ± 0.9 -fold compared to EDC,  = 0.03). Differences in 
band intensities between the 2 sets of constructs with NPs, with and without factors, were 
found to be insignificant ( = 0.19). In contrast, the band intensities for active MMP–2 
enzyme corresponding to 66 kDa were found to be higher in both sets of NP-treated 
constructs (1.7 ± 0.4 fold increase,  = 0.05 for BNP constructs, compared to EDC). No 
statistical difference in band intensities of active MMP–2 between exogenous and NP 






Figure 6.12: Outcomes in protein quantities of MMPs -2 and -9 in response to 
agent delivery mode. (A) Representative immunoblots of MMPs -2 and -9 along 
with normalizing protein β-actin. Semi-quantificatitative comparison of zymogen 
and active forms of MMP-2 protein (B) show an increase relative to EDC. However 
incorporation of agents within NPs appears to have brought down these levels 
relative to BNP. However,  and MMP-9 active enzyme (C) levels are significantly 






On the other hand, as seen in Figures 6.12 B and C band intensities 
corresponding to the 82 kDa active MMP–9 enzyme were found to be significantly 
decreased to similar extents in both sets of NP-treated constructs compared to exogenous 
supplementation (4.5-fold with  = 0.001 for both NP-treated constructs with and without 
agents). Zymogen forms of MMP–9 protein were undetected at the concentrations tested. 
Zymography was performed to estimate the activity of the gelatinases present in 
the constructs (Figure 6.13). The enzyme activity of MMP–2 was found to be 
significantly elevated in the constructs with NPs compared to EDC. A 2.8 ± 0.9 fold 
increase ( = 0.03) in MMP–2 zymogen, and 3.5 ± 0.5 fold increase ( = 0.001) in active 
enzyme was found in BNP constructs compared to EDC. This activity was decreased 
with the delivery of agents in ANP constructs, where up to a 2-fold increase was found in 
the intensities of both zymogen ( = 0.2) and active enzyme ( = 0.01), compared to 
EDC. On the other hand, as seen in Figure 6.13 A and B, at the protein concentrations 
Figure 6.13: Zymography of MMPs -2 and -9. (A) Representative zymograms 
showing both active and inactive forms of MMP-2 enzyme, and only active form of 




tested, bands corresponding to active MMP–9 enzyme were detected only in EDC 
constructs. They were not detected in either of the NP-treated constructs in any of the 3 
biological replicates tested. Zymogen bands of  MMP–9 enzyme were undetected in all 3 
conditions.   
 
6.3.8. Matrix Ultrastructure 
Elastic matrix components elastin and fibrillin-1 were immunolabeled in 10 μm 
cross and longitudinal sections of the 3 treatment conditions, and visualized using a 
fluorescence microscope under a Cy5 filter. As seen in Figures 6.14 and 6.15, cells and 
elastic matrix fibers appeared to be far more oriented in the longitudinal direction than 
circumferentially, in all treatment conditions. Signs of circumferential orientation were 
observed in the regions closer to the lumen of the constructs. Clumps of elastin and 
fibrillin were found in both cross and longitudinal sections, indicating that the 
synthesized fibers might be oriented in all directions. Elastin and fibrillin appeared to be 
mostly co-localized. Appearance and orientation of elastic fibers as seen in IF, were 
confirmed in the 30 μm sections that were stained for elastin using a modified VVG 
staining kit. Elastic matrix was undetected in the longitudinal sections imaged using TEM.  
 
6.4. DISCUSSION 
 In studies discussed in the previous chapters, and in prior work conducted in our 
lab, we have demonstrated the elastogenic inductibility of adult vascular SMCs by 
various exogenously supplemented EFs (TGF-β and HA-o)
37, 173, 184
. While the use of 
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these EFs have shown tremendous potential in stimulating de novo synthesis of elastic 
matrix in culture, it is important to evaluate strategies for their controlled and sustained 
delivery in a localized manner for final clinical application of regenerative repair of 
elastic matrix at sites of proteolytic disease such as AAA.  
This evaluation is crucial especially since the outcomes of factors we have 
evaluated in our studies are highly dose-dependent. For example, the regulatory effects of 
growth factors like TGF-β are critically dependent on precise control of delivered dose as 
they can induce extremely contrasting outcomes depending on the concentration
220
. 
While at concentrations below 10 ng/ml, it can suppress abnormal cell proliferation and 
aid in synthesis and assembly of elastin and elastic matrix components
37, 262
, at higher 
concentrations it can induce a synthetic, osteogenic switch of SMC phenotype and induce 
Figure 6.14: Representative images of Elastic staining of 30 μm thick cross- (CS) 
and longitudinal- (LS) sections of collagen (stained pink) constructs after 21 days of 
treatment. Orientation of cells and elastic fibers (stained purple/black, indicated by 
red arrows) seen in the logitunal direction. Cells and matrix appear to orient in the 





.  Moreover, the outcomes of TGF-β supplementation is also highly 
site dependent
185
.  For example, while the use of TGF-β has positively influenced elastic 
matrix synthesis by SMCs from AAA disease models,  TGF-β at similar concentrations 
has been shown to adversely impact thoracic AAs
60-61
. In fact, the use of TGF-β 
antagonists such as losartan has been shown to regress thoracic AAs
263-264
.   
A B 
Figure 6.15: Effect of agent delivery mode on outcomes of elastic matrix assembly 
and ultrastructure. Representative fluorescent micrographs of 10 µm thick (A) 
longitudinal- and (B) cross –sections of constructs immunolabeled for elastin (red, 
top panel), fibrillin (red, bottom panel) and nuclei (blue). All three treatment 
conditions showed detectable levels of both proteins. Both fibrillin and elastin 
distribution appears comparable between EDC and ANP constructs. Orientation in 
the longitudinal direction appeared more than circumferentially. White arrows 
indicate longitudinal direction of constructs. ‘L’ = lumen. Magnification = 10  
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Several studies have also demonstrated substantial benefits in therapeutic 
outcomes of localized, controlled delivery of factors over systemic delivery.  For example, 
many groups have evaluated various localized delivery methods for DOX, and have 
shown pronounced decrease in MMP activity and preservation of elastic matrix at 
concentrations even 100 fold lower than that used for systemic delivery
243, 253
. This has 
the potential to overcome several undesirable side effects of  systemic delivery of DOX 
for AAA treatment
242, 245
. Moreover, systemic inhibition of MMPs is undesirable since 
they participate in normal matrix remodeling and turnover as well
83
. 
In the current study, we have therefore utilized the tubular collagen model 
optimized in the previous chapters, to evaluate the outcomes of localized delivery of 
DOX and TGF-β from nanoparticles, over their exogenous delivery.  This in vitro model 
allowed the benefits of assessing the direct response of SMCs to polymer-based delivery 
of previously optimized elastogenic factors in a controlled microenvironment. PLGA 
(50:50 blend) chosen as the polymeric nano-carrier of factors, offers several benefits as 
an ideal drug delivery vehicle.  
PLGA is one of the most biocompatible polymers widely used for a variety of 
drug delivery applications
265-267
. It undergoes hydrolytic degradation into lactic acid and 
glycolic acid, which have not shown to induce adverse cell response, both in vivo and in 
vitro
259, 268
. PLGA is also easy to formulate and characterize
258
, and has been shown to be 




. It is also one of the very few 
biomaterials approved by FDA for a variety of clinical applications
265




The surface charge of nanoparticles has shown to play a role in mediating the 
bioavailability of factors as well as in regulating cellular response, both in vitro and in 
vivo. Various studies have pointed towards the benefits of utilizing cationically surface-
charged nanoparticles for vascular applications
213-214
, especially from the standpoint of 
enhancing elastic matrix deposition. It has been suggested that the presence of cationic 
amphiphiles attract the negatively charged LOX molecules, while at the same time repel 
positively charged elastases
215
. This has been further illustrated in studies that have 
utilized cationic amphiphiles such as DMAB which were shown to increase LOX protein 
synthesis and significantly suppress expression and activity of proteases such as MMPs -
2 and -9
216, 273
. In the current study, we thus initially formulated and tested DMAB-
modified PLGA NPs. However, the concentration of TGF-β1 released from these NPs 
was extremely low, possibly due to interaction between the DMAB particles and the 
growth factor. However, we were able to overcome this problem and obtain detectable 
and consistent quantities of TGF-β1 released from anionically modified NPs. 
Accordingly, in this study we have utilized anionic nanoparticles for the delivery of both 
DOX and TGF-β1. While surface charge modification did not affect DOX release 
profiles, DOX-loaded NPs were also synthesized using PVA to maintain consistency 
between the NPs releasing both these agents.  
Likely due to their failure to repel elastases, anionic NPs (both with and without 
agents) resulted in a marked increase in the mRNA expression, protein synthesis as well 
as enzyme activity of MMP–2. However, it was also observed that the delivery of agents 
from the NPs resulted in a marked decrease in overall MMP–2 mRNA expression relative 
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to BNP constructs, and a decrease in   protein content of active MMP-2 enzyme to levels 
seen in EDC constructs, This suggests a positive influence of addition of agent-loaded 
NPs. The MMP-2 enzyme activity was similarly lowered in ANP constructs compared to 
BNP constructs, but remained higher than those with exogenous factor treatment.  
In contrast however, the mRNA expression, total protein content and enzyme 
activity of MMP-9 was found to be significantly lowered with the addition of NPs, with 
or without agents. Zymogen bands for MMP-9 enzyme were completely undetected in 
both sets of the NP-treated constructs.  In addition to this, the lack of difference in the 
MMP-9 protein levels, as seen in immunoblots (Figure 6.10) between blank and agent-
loaded NPs suggests that MMP-9 inhibition may be influenced significantly more by the 
PVA-modified anionic NPs, than the addition of agents. This finding is contrary to what 
has been suggested in the literature regarding the positive influence of cationic 
amphiphiles for elastic matrix deposition, and therefore in corollary a negative influence 
of anionic amphiphiles.  
On the same lines, LOX protein content was found to be significantly higher in 
constructs treated with NPs, both with or without agents. Protein bands corresponding to 
LOX in our immunoblots showed extremely low to negligent quantities in constructs with 
exogenous factor delivery. This was consistent with the mRNA expression of LOX, 
which also showed higher expression in constructs with NPs. While mRNA expression 
was not significantly different between BNP and EDC, their comparable expression 
levels combined with the significantly higher levels of active LOX protein within NP-
treated constructs seems to suggest that LOX production is also somehow triggered by 
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the PVA modified NPs. It is likely that the decrease in MMP-9 mRNA expression as well 
as its diminished enzymatic activity has in a way improved LOX protein availability. To 
our knowledge, no direct correlation between MMP-9 inhibition or LOX up-regulation 
with the use of PLGA NPs or its surface modification with anionic amphiphiles has been 
reported in literature so far. Further investigation in is regard is warranted and its 
understanding would definitely help improve targeted in situ matrix repair strategies. 
Similarly, alkali-soluble matrix elastin content was found to be similar in both 
exogenous and NPs delivery of factors. While these levels were 2 fold lower in constructs 
with Blank-NPs, it is important to note that the ~ 9 μg/mg levels of alkali-soluble matrix 
elastin content was similar to that observed in constructs evaluated in the previous 
chapters that were cultured without EFs or DOX. This contrasting observation however, 
seems similar to proposed physical effects of Hyaluronic acid (HA) in elastic matrix 
assembly
274-275
. Native HA is a highly anionic glycosaminoglycan (GAG) present in the 
ECM of various tissues
95
. It facilitates synthesis of fibrillin microfibrils and directs elastic 
fiber assembly by binding versican (a proteoglycan) with elastin-associated proteins
42, 160
. 
HA also appears to stabilize elastin fibers against elastase degradation, once formed
43
. In 
addition to this, HA is known to enhance formation of mature matrix elastin by 1) 
coacervating soluble tropoelastin via their positive lysine residues and 2) facilitating lysyl 
oxidase (LOX)-mediated oxidation and crosslinking of tropoelastin into insoluble elastic 
fibers
42-43
. Studies from our lab have also confirmed such up-regulation
 
and demonstrated 
elastogenic synergy between HA oligomers (~ 756 Da) and growth factors such as TGF-
β1
37, 44
. It is likely that the anionic NPs behave in a manner similar to anionic HA. 
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However, despite the increase in LOX content and comparable levels of alkali-
soluble matrix elastin, the mature alkali-insoluble matrix elastin content was found to be 
extremely low and statistically similar under all treatment conditions. This is likely due to 
the low mRNA expressions of fibrillin-1 and fibulin-4, the microfibrillar proteins key to 
elastic fiber assembly, combined with the high expression and enzymatic activity of 
MMP-2. The low alkali-insoluble matrix elastin yields could also be contributed by the 
fact that the concentration of TGF-β1 delivered in this study was ~ 10 fold less than that 
we previously showed to be elastogenic. Concurrently, analysis of matrix ultrastructure 
of constructs did not reveal obvious differences between the three treatment conditions. 
Similar to that observed in Chapters 4 and 5, the ultrastructure of all constructs showed a 
higher degree of longitudinal orientation than circumferential alignment, again likely due 
the application of low strains. Circumferential alignment of cells and matrix were found 
in regions closer to the lumen of the constructs. 
Addition of NPs did not adversely affect cell proliferation or the expression of 
contractile phenotypic markers of SMC. These levels were comparable in all treatment 
conditions.  
One of the limitations of this study was the lack of direct visualization of NPs in 
the cultured constructs, since they were not tagged with any dyes in order to minimize the 
effects of any external influences. NPs were assumed to be retained in the constructs 
based on the pilot study performed with DMAB NPs at similar concentrations. Moreover, 
the significant differences in results which were consistent across all experimental 
methods analyzed, suggest that the NPs were retained and that the factors released from 
176 
 
NPs were bio-available and bioactive. Culturing an additional set of constructs with NPs 
loaded with vital dyes, in parallel and under similar culture conditions detailed in this 
study would help in providing a visual distribution of NPs in the constructs. This would 
also help in better understanding of NP behavior such as its retention and degradation 
profiles within such a collagenous microenvironment.   
Another limitation of this study at present is the lack of knowledge of accurate 
release profiles of the factors from NPs within the collagen constructs. While PLGA is 
known to undergo only hydrolytic degradation, and therefore their release profiles can be 
expected to be similar within different aqueous environments at similar pH, studies have 
indicated that degradation of PLGA can be accelerated by the presence of enzymes in 
serum and that released by cells in culture
276-277
. However, there is lack of consistency 
and clarity with respect to enzymatic degradation of PLGA. Degradation of PLGA, and 
generation of acidic pH is also known further increase polymeric degradation
278
. 
However, the frequent media change performed every 2 days can aid in minimizing the 
effects of increase in pH. Therefore a certain level of inequality in concentrations of 
factors delivered exogenously and via NPs in this study is bound to exist. A more 
systematic analysis of properties of NP-treated constructs, the concentration of un-
released agents retained within NPs at the end of culture period, and examining its 
degradation profiles over a time-dependent manner would aid in normalizing these 
uncertainties and help in developing more efficient strategies for elastogenic response by 





Treatment of HASMCs within tubular collagen constructs with DOX- and TGF-
β1- loaded PLGA NPs positively influenced overall elastogenic outcomes. Addition of 
NPs, both with and without factors did not adversely affect cell proliferation or 
expression of contractile SMA phenotype, compared to exogenously agent-treated 
constructs. The agents released from the NPs were found to be bioactive, as warranted by 
the positive differences in results obtained between agent-loaded and no-agent NPs, 
primarily in terms of elastic matrix outcomes. While the mRNA expression of elastic 
matrix proteins such as elastin and fibrillin-1 were less with NP-delivery compared to 
exogenous delivery, the quantity of alkali-soluble matrix elastin synthesized by cells 
under both conditions was comparable. Levels of insoluble elastin were uniformly low 
under all treatment conditions. LOX mRNA expression as well as active protein 
quantities were significantly elevated in NP-treated constructs, both with and without 
agents. Similarly, mRNA expression, protein synthesis as well as enzyme activity of 
MMP-9 was significantly suppressed within both NP-treated constructs, with and without 
agents. Expression and activity of MMP-2 on the other seemed to be elevated with the 
addition of NPs. The level of expression and enzyme activity was however lowed in 
constructs with agent-loaded NPs compared to those with blank NPs, indicating 
bioactivity of encapsulated agents. 
Overall, this model demonstrates that the effects of agents delivered from PLGA 
NPs appeared to be comparable to their exogenously delivery, warranting that further 
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studies with similar strategies can greatly benefit in situ elastic matrix repair within 
























CONCLUSIONS AND FUTURE OUTLOOK 
 
7.1. OVERALL CONCLUSIONS 
The concurrent delivery of TGF-β1 and HA-o to adult SMC cultures evaluated in 
previous studies in our lab has successfully demonstrated the elastogenic potential of 
these factors. However, cells, especially SMCs behave very differently in a 2D cell 
culture environment, where their response to external stimuli is often different from that 
seen in vivo. The overall goal of this thesis was to therefore develop an in vitro model 
system, where cellular response to induced elastogenesis will be similar to what can be 
replicated in vivo. The presence of a collagenous matrix is centric to replicating vascular 
tissue architecture and mechanics, and vascular cells, regardless of the choice of scaffolds, 
robustly synthesize collagen. Moreover, collagenous microenvironments are known to 
promote a quiescent phenotype, similar to that seen in vivo, which is often not conducive 
to elastogenesis. Examining the impact of a pre-existing collagenous microenvironment 
on the ability of the cells to synthesize fibrous elastic matrix on their own, and also their 
response to provided elastogenic factors, would be pertinent for a relevant in vitro system. 
We therefore chose a 3D collagen gel model, widely been evaluated for vascular tissue 
engineering applications.   
In the first set of studies, we demonstrated that the elastogenic potential of TGF-
β1 - HA-o combination could be replicated within RASMCs seeded in 3D collagen gels, 
maintained under static tension. We tested six dose combinations - 0.1 ng/ml, 1 ng/ml 
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and 10 ng/ml TGF-β, each with 0.2 µg/ml and 2 µg/ml HA-o, which were exogenously 
supplemented to RASMCs within 3D collagen constructs. Relative to untreated control, 
all constructs receiving the doses were found to induce elastogenesis. While mRNA 
expression of elastin remained unchanged relative to control, all 6 dose combinations up-
regulated mRNA expression of LOX, with highest of up to 2-fold being in constructs 
with 10 ng/ml TGF-β, with both doses of HA-o. Similarly, while tropoelastin protein 
quantities in all cases were comparable to untreated controls, significant increase was 
seen in the presence of alkali-soluble matrix elastin. Highest quantities of the alkali-
soluble matrix elastin content were seen in constructs receiving 0.1 ng/ml TGF-β with 0.2 
µg/ml HA-o. However, quantities of the more crosslinked, alkali-insoluble matrix elastin 
were elevated only in constructs with 10 ng/ml TGF-β and 0.2 µg/ml HA-o treatment 
conditions, where LOX protein content was also moderately elevated relative to other 
treatment conditions (~ 1.5-fold from constructs with 0.1 ng/ml TGF-β 0.2 µg/ml HA-o). 
MMP-2 enzyme activity on the other hand, was elevated in all treatment conditions, 
which likely contributed to the low alkali-soluble matrix elastin content. MMP-9 protein 
content, both active and zymogen forms, was suppressed in all conditions receiving 
treatment, with lowest levels seen in constructs with 0.1 ng/ml and 10 ng/ml TGF-β, with 
respective doses of HA-o. These results were confirmed with histology and IF analysis, 
where a high no. of aligned elastic fibers were found in all treatment conditions, with the 
highest of more than 2 fold being in those with 0.1 ng/ml TGF-β and 0.2 µg/ml HA-o. 
However, induced elastogenesis did not have a significant impact on the mechanical 
properties of the constructs. Tensile modulus was comparable in the select 4 treatment 
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conditions that were tested (~ 60 kPa). This is likely due to the fact that the elastic fibers 
synthesized, though aligned, were mostly discontinuous, and were not present in their 
highly crosslinked, mature forms. Their contribution to the mechanical properties would 
therefore be very minimal. Constructs that received 0.1 ng/ml TGF-β1 and 0.2 µg/ml 
HA-o (termed EFs) were concluded to be most elastogenic; since they induced the 
synthesis of highest quantities of alkali-soluble matrix elastin as well has the highest no. 
of aligned fibers.  
In the next set of studies, our goal was to achieve circumferential orientation of 
EF-treated cells and the synthesized matrix, similar to that needed in vivo within elastic 
arteries. Different from that used in the previous study, we adopted a tubular collagen gel 
model seeded with human SMCs. Since cyclic strains are known have profound impact 
towards this orientation, we developed a bioreactor capable of delivering circumferential 
cyclic strains to cells with the tubular collagen gels. An important consideration for the 
choice of cyclic strain parameters was its impact on MMP synthesis and enzyme activity, 
since it can negatively impact accumulation and assembly of newly synthesized elastic 
matrix. We therefore chose to use low strains of 2.5% which induces relatively lower 
levels of undesirable protease activity. These were tested under 3 frequencies of 0.5 Hz, 
1.5 Hz and 3 Hz, another important parameter equally contributing to cell and matrix 
alignment. EFs were added to all three sets of stretched constructs over 21 days of culture, 
and results were compared with static tubular constructs with and without EFs. Cell 
densities were found to be similar under all test conditions, indicating that none of the 
treatment conditions adversely impacted cell growth. A bimodal trend with increasing 
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frequencies was observed in outcomes of contractile SMC phenotypic markers and elastic 
matrix components, with highest levels observed in constructs stretched under 1.5 Hz. 
For gene expression and protein synthesis of contractile SMC markers, change in 
frequency appeared to have a greater impact than addition of EFs. For example, while no 
changes were found in the static constructs with addition of EFs, SMA mRNA expression 
increased progressively up to 1.5 Hz, where it peaked at 4-fold relative to static 
constructs, and was lowered to 2-fold within constructs stretched at 0.5 and 3 Hz. 
Compared to static constructs, contractile phenotypic markers were elevated in all 
stretched constructs. Application of stretch at 3Hz frequency alone appeared to induce an 
osteogenic switch in SMCs, which showed ~ 2-fold increase in osteopontin mRNA 
expression relative to all other conditions. 
 Elastic matrix outcomes were most pronounced in constructs receiving EFs with 
stretch at 1.5 Hz, in terms of both mRNA expressions and matrix content. In these 
constructs, up to a 7-fold increase was seen in elastin mRNA expression, and up to a 5-
fold increase in alkali-soluble matrix elastin content, relative to static controls. Constructs 
stretched at 0.5 Hz  showed similar levels of gene expression and matrix outputs as that 
of EF-treated static constructs, which were both higher than untreated static controls. 
Application of strains at 3 Hz frequency did not show improvement in elastic matrix 
output, and its levels were comparable to that of untreated static control.  Addition of EFs 
or strains did not significantly influence gene expressions or protein content of other 
elastic matrix proteins (fibrillin, fibulins and LOX), relative to control. Perhaps as a 
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consequence, levels of alkali-insoluble matrix content were uniformly low in all 
constructs.  
MMP-9 gene expressions remained extremely low, but its protein content was 
moderately elevated at higher strain frequencies. Application of strains at all 3 
frequencies did not adversely affect gene expressions or protein content of MMP-2. 
These levels were comparable in all constructs, both static and dynamic.  While its 
enzyme activity was also similar in all conditions, their band intensities were extremely 
high even at low protein concentrations, indicating high levels of enzyme activity. This 
could also be a contributive factor for the low alkali-insoluble matrix elastin outcomes.   
In our next set of studies, we therefore tested the supplementation of Doxycycline 
(DOX), along with EFs, in order to improve elastic matrix outcomes by suppressing 
MMP-2 enzyme activity. We tested two doses of DOX – 0.1 µM and 1 µM, along with 
EFs, in HASMC-seeded tubular collagen gel constructs. These doses were tested on static 
constructs, and those stretched at 2.5% strain at 1.5 Hz (which was shown to promote 
elastogenesis the most in the previous study). Addition of DOX at both doses with EFs 
was effective in significantly suppressing mRNA expression of MMP-2, under both static 
(up to 4-fold) and dynamic (up to 3-fold) conditions, relative to control. While its protein 
content remained unchanged relative to other conditions, MMP-2 enzyme activity was 
lowered to similar levels at both DOX concentrations (up to 2-fold under static and up to 
1.5 fold under dynamic conditions). All DOX + EFs-treated constructs significantly 
increased alkali-soluble matrix content to similar levels, at both DOX concentrations, 
under static and dynamic conditions. Up to 3-fold increase was seen relative to static 
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control, and up to 2.5-fold relative to static constructs treated with EFs alone. Addition of 
0.1 µM DOX with EFs significantly increased synthesis of the mature, highly crosslinked 
alkali-insoluble matrix elastin (up to 2-fold) relative to other treatment conditions. Its 
quantities were similar in all other conditions. mRNA expression and quantities of other 
elastic matrix components remained unchanged. 
Overall, in the 3 studies discussed above we demonstrated induction of significant 
levels of elastogenesis in adult cells from both rat and humans. EFs, together with DOX 
and 2.5% cyclic strains at 1.5 Hz, significantly improved elastic matrix outcomes, both at 
the mRNA and protein levels. However, its translation to an in vivo scenario is limited by 
its highly dose-depended induction of outcomes. In the next set of studies we therefore 
examined if a targeted, nanoparticle-based delivery of these factors would induce 
elastogenesis to similar levels as that seen with exogenous delivery. TGF-β1 and DOX 
were encapsulated separately within PLGA nanoparticles (NPs), and incorporated within 
HASMC-seeded tubular collagen gel constructs, subjected to 2.5% strain at 1.5 Hz 
(ANP). These were compared to constructs with blank NPs (BNP), and those treated with 
exogenous supplementation of TGF-β1and DOX to culture medium, both stretched 
similarly (EDC). Interestingly, while gene expressions of elastin and fibulin were 
comparable to EDC, that of LOX was up-regulated to 1.5-fold relative to EDC. This is 
likely due to the presence of anionic NPs, since a moderate increase in LOX expression 
was seen even in BNP constructs. This was reflected at the protein levels as well, where 
both NP-treated constructs showed significantly larger quantities of LOX. Matrix elastin 
content, both alkali-soluble and –insoluble, in EDC and ANP were comparable, both 4-
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fold higher than BNP constructs. Gene expression, protein content as well as enzyme 
activity of MMP-2 were significantly elevated in NP-treated constructs, relative to EDC. 
These levels however appeared to be lowered within ADC (vs. BNP), indicating that the 
bioactivity of encapsulated agents was maintained. In contrast however, relative to EDC, 
the gene expression, protein content and enzyme activity were significantly lowered in 
both NP-treated constructs, indicating an influence of NPs themselves. Addition of NPs 
did not affect cell densities or SMC phenotype, and these were comparable in all three 
conditions. It is important to note that these results were obtained at TGF-β1 
concentrations 10-fold lower than what was optimized in the previous studies. Overall, 
we were able to successfully demonstrate that localized delivery of TGF-β1 and DOX is 
able to mirror the elastogenic benefits of their exogenous delivery, without causing any 
adverse effects. 
One of the limitations of the studies conducted at 2.5% strain was its effects on 
cell and matrix orientation. They appeared to be oriented more in the longitudinal 
direction, than circumferentially, as was expected. At higher frequencies of 1.5 Hz and 3 
Hz, higher degree of circumferential orientation was observed in regions closer to the 
inner silicone tubing (lumen). Perhaps as a result, compared to other conditions, these 
constructs also showed lesser degree of longitudinal orientation. Any contribution of the 
different treatment conditions to the mechanical properties of the constructs therefore is 
likely to be reflected more in the longitudinal direction than circumferentially. We 
therefore did not record any significant differences in the tensile properties (tested on 
constructs in second set of studies alone) tested on ring segments of the constructs treated 
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under different frequencies, or between static and dynamic. Regardless, we have been 
able to adequately demonstrate the positive influence of various factors on elastogenic 
induction of adult HASMCs.  
Results from these studies demonstrate how even within a quiescent, collagenous 
environment, TGF-β1, HA-o and DOX can be utilized to induce de novo synthesis of 
elastic matrix. These will prove most beneficial in developing efficient strategies for in 
vivo translation of the above factors to repair and rebuild compromised elastic matrices.  
 
7.2. FUTURE OUTLOOK 
Overall results evaluated in this thesis sufficiently demonstrate positive outcomes 
of elastogenic induction of adult vascular cells using several parameters within a relevant 
in vitro model. However, there are several factors that can be addressed in the future 
studies to develop more efficient strategies for induced elastogenesis.  
1) One of the primary limitations of in vitro induction of elastogenesis, is the 
insufficient synthesis of matrix elastin, especially the highly crosslinked form, in 
absolute quantities. While various parameters discussed in the study significantly 
improve these quantities relative to untreated controls, these levels are insufficient 
when compared to what is present in vivo within elastic aortae. This is perhaps 
also contributed to by the low levels of other elastic matrix components such 
fibrillin, fibulins and LOX, all of which play an equally important role in 
regenerating and repairing compromised elastic matrix. Strategies that target at 
improving outcomes of these components, in addition to that needed for elastin 
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synthesis, will significantly improve elastic matrix outcomes for in vivo 
applications. 
2) The cyclic strains of 2.5% utilized in this study were below the 10% 
strains popularly used to demonstrate call and matrix orientation. We 
hypothesized that since strain frequencies play an equally important role in matrix 
alignment, lowering strains levels to suppress negative impact of strain-induced 
MMP activity, and at the same time testing various frequencies, would improve 
orientation. While we were able to effectively suppress increase in strain-induced 
MMP-2 enzyme activity and achieve some degree of circumferential orientation 
at higher frequencies, the degree of orientation is insufficient. Future studies 
conducted at higher strain levels, at the optimized frequency of 1.5 Hz, along with 
the utilization of DOX for MMP suppression, can contribute to improving elastic 
matrix quantities and orientation.   
3) Viability of cells across the thickness of the constructs were not evaluated 
extensively. It is likely that the cells closer to the lumen, where the stress 
concentrations are higher, will be more apoptotic than those further away from it. 
Though results obtained from live-dead assays performed on test constructs 
cultured for 2 days, DNA assay after 21-day treatment, and construct compaction 
ratios indicate overall cell viability, they did not elucidate effect of varying stress 
concentrations across the construct thickness on cell viability, which is also likely 
to affect matrix output. Examining this parameter will be pertinent, especially 
when higher strain amplitudes are utilized.   
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4) When TE vascular grafts are implanted in vivo, the cells within such grafts 
will be subjected to both cyclic stretch (circumferential and longitudinal), as well 
as shear stress due to flow of blood. The bioreactor constructed in our studies was 
capable of delivering cyclic stretch, but did not incorporate the component of flow 
due to the presence of the central silicone tube. The cellular response and final 
matrix outcomes are therefore reflective only of effects of cyclic stretch, and not 
flow. In future studies, it would be pertinent to study the effects of flow along 
with cyclic stretch. However, directly subjecting the collagen gels to pulsatile 
flow without the presence of a central supporting mandrel can have 2 adverse 
consequences,1) irreversible creep of viscous, and insufficiently contracted gels, 
and 2) apoptotic response of SMCs to shear stress which would in turn 
compromise sufficient synthesis of elastic matrix. Incorporating the parameter of 
flow after the gels have substantially contracted and have synthesized elastic 
matrix over 3 weeks, will overcome the above consequences, while at the same 
time also reflect on the effects of shear on TE vascular grafts. 
5) If the future direction of this work is towards developing purely tissue-
engineered strategies for vascular matrix repair, or even to better understand cell-
regulatory factors in induced elastogenesis, pre-aligned scaffolds such as 
electrospun tubular collagen can be utilized. Similar parameters of strain, 
frequency, and EF and Dox delivery optimized in this thesis can be then be 
applied. This would be an alternative to improve cell and matrix orientation at low 
strains, and at the same time suppress MMP-induced elastic matrix degradation. 
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6) In the studies utilizing NP-delivery of factors, we were able to 
demonstrate how localized delivery mirrors effects of exogenous delivery. 
However, the release kinetics of factors from NPs in a serum-rich, cellular, and 
hydrogel/collagenous environment is poorly understood. Studies conducted in a 
time-dependent manner to better understand release kinetics in such an 
environment would profoundly help in efficiently strategizing better delivery 
vehicles that can induce optimum cellular response. NP-based delivery and in-situ 
repair is a great strategy for inducing elastogenesis in vivo. Better understanding 
of parameters that contribute to their outcomes can therefore prove advantageous 
















1. Rodgers UR, Weiss AS. Cellular interactions with elastin. Pathologie Biologie2005 
Sep;53(7):390-8. 
2. Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, Eichwald E, Keating 
MT. Elastin is an essential determinant of arterial morphogenesis. Nature1998 May 
21;393(6682):276-80. 
3. Rosenbloom J, Abrams WR, Mecham R. Extracellular matrix 4: the elastic fiber. FASEB 
J1993 Oct;7(13):1208-18. 
4. Kelleher CM, McLean SE, Mecham RP. Vascular extracellular matrix and aortic 
development. Curr Top Dev Biol2004;62:153-88. 
5. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol 
Rev2009 Jul;89(3):957-89. 
6. Kozel BA, Rongish BJ, Czirok A, Zach J, Little CD, Davis EC, Knutsen RH, Wagenseil 
JE, Levy MA, Mecham RP. Elastic fiber formation: a dynamic view of extracellular 
matrix assembly using timer reporters. J Cell Physiol2006 Apr;207(1):87-96. 
7. Pasquali-Ronchetti I, Baccarani-Contri M. Elastic fiber during development and aging. 
Microsc Res Tech1997 Aug 15;38(4):428-35. 
8. Wagenseil JE, Mecham RP. New insights into elastic fiber assembly. Birth Defects Res C 
Embryo Today2007 Dec;81(4):229-40. 
9. Faury G, Pezet M, Knutsen RH, Boyle WA, Heximer SP, McLean SE, Minkes RK, 
Blumer KJ, Kovacs A, Kelly DP, Li DY, Starcher B, Mecham RP. Developmental 
adaptation of the mouse cardiovascular system to elastin haploinsufficiency. J Clin 
Invest2003 Nov;112(9):1419-28. 
10. Patel A, Fine B, Sandig M, Mequanint K. Elastin biosynthesis: The missing link in tissue-
engineered blood vessels. Cardiovasc Res2006 Jul 1;71(1):40-9. 
11. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and 
epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol2011 Feb;8(2):92-102. 
12. Keeling WB, Armstrong PA, Stone PA, Bandyk DF, Shames ML. An overview of matrix 
metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms. 
Vasc Endovascular Surg2005 Nov-Dec;39(6):457-64. 
13. The Molecular Biology and Pathology of Elastic Tissues. Symposium proceedings. 
Nairobi, Kenya, 1-3 November 1994. Ciba Found Symp1995;192:1-361. 
14. Kielty CM. Elastic fibres in health and disease. Expert Rev Mol Med2006;8(19):1-23. 
191 
 
15. Milewicz DM, Urban Z, Boyd C. Genetic disorders of the elastic fiber system. Matrix 
Biol2000 Nov;19(6):471-80. 
16. Daugherty A, Cassis LA. Mechanisms of abdominal aortic aneurysm formation. Curr 
Atheroscler Rep2002 May;4(3):222-7. 
17. Aggarwal S, Qamar A, Sharma V, Sharma A. Abdominal aortic aneurysm: A 
comprehensive review. Exp Clin Cardiol2011 Spring;16(1):11-5. 
18. Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, Eichwald E, Keating 
MT. Elastin is an essential determinant of arterial morphogenesis. Nature1998 May 
21;393(6682):276-80. 
19. Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, Keating 
MT, Li DY. A critical role for elastin signaling in vascular morphogenesis and disease. 
Development2003 Jan;130(2):411-23. 
20. Rentschler M, Baxter BT. Pharmacological approaches to prevent abdominal aortic 
aneurysm enlargement and rupture. Ann N Y Acad Sci2006 Nov;1085:39-46. 
21. McPhee JT, Hill JS, Eslami MH. The impact of gender on presentation, therapy, and 
mortality of abdominal aortic aneurysm in the United States, 2001-2004. J Vasc 
Surg2007 May;45(5):891-9. 
22. Rabkin DJ. Techniques in Vascular and Interventional Radiology. Introduction. Tech 
Vasc Interv Radiol2008 Sep;11(3):155. 
23. Wilt TJ, Lederle FA, Macdonald R, Jonk YC, Rector TS, Kane RL. Comparison of 
endovascular and open surgical repairs for abdominal aortic aneurysm. Evid Rep Technol 
Assess (Full Rep)2006 Aug(144):1-113. 
24. Salacinski HJ, Goldner S, Giudiceandrea A, Hamilton G, Seifalian AM, Edwards A, 
Carson RJ. The mechanical behavior of vascular grafts: a review. J Biomater Appl2001 
Jan;15(3):241-78. 
25. Droc I, Raithel D, Calinescu FB. Endovascular treatment of abdominal aortic aneurysms: 
indications and results. Minim Invasive Ther Allied Technol2011 Apr;20(2):117-24. 
26. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT, Jr., Matsumura JS, Kohler TR, 
Lin PH, Jean-Claude JM, Cikrit DF, Swanson KM, Peduzzi PN. Outcomes following 
endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. 
JAMA2009 Oct 14;302(14):1535-42. 
27. Mitchell SL, Niklason LE. Requirements for growing tissue-engineered vascular grafts. 
Cardiovasc Pathol2003 Mar-Apr;12(2):59-64. 
28. Long JL, Tranquillo RT. Elastic fiber production in cardiovascular tissue-equivalents. 
Matrix Biol2003 Jun;22(4):339-50. 
192 
 
29. L'Heureux N, Paquet S, Labbe R, Germain L, Auger FA. A completely biological tissue-
engineered human blood vessel. FASEB J1998 Jan;12(1):47-56. 
30. Kim BS, Mooney DJ. Engineering smooth muscle tissue with a predefined structure. J 
Biomed Mater Res1998 Aug;41(2):322-32. 
31. Shaikh FM, Callanan A, Kavanagh EG, Burke PE, Grace PA, McGloughlin TM. Fibrin: a 
natural biodegradable scaffold in vascular tissue engineering. Cells Tissues 
Organs2008;188(4):333-46. 
32. Swartz DD, Russell JA, Andreadis ST. Engineering of fibrin-based functional and 
implantable small-diameter blood vessels. Am J Physiol Heart Circ Physiol2005 
Mar;288(3):H1451-60. 
33. Zhang X, Baughman CB, Kaplan DL. In vitro evaluation of electrospun silk fibroin 
scaffolds for vascular cell growth. Biomaterials2008 May;29(14):2217-27. 
34. Ramamurthi A, Vesely I. Evaluation of the matrix-synthesis potential of crosslinked 
hyaluronan gels for tissue engineering of aortic heart valves. Biomaterials2005 
Mar;26(9):999-1010. 
35. Gao J, Crapo P, Nerem R, Wang Y. Co-expression of elastin and collagen leads to highly 
compliant engineered blood vessels. J Biomed Mater Res A2008 Jun 15;85(4):1120-8. 
36. Liu JY, Swartz DD, Peng HF, Gugino SF, Russell JA, Andreadis ST. Functional tissue-
engineered blood vessels from bone marrow progenitor cells. Cardiovasc Res2007 Aug 
1;75(3):618-28. 
37. Kothapalli CR, Taylor PM, Smolenski RT, Yacoub MH, Ramamurthi A. Transforming 
growth factor beta 1 and hyaluronan oligomers synergistically enhance elastin matrix 
regeneration by vascular smooth muscle cells. Tissue Eng Part A2009 Mar;15(3):501-11. 
38. Shanley CJ, Gharaee-Kermani M, Sarkar R, Welling TH, Kriegel A, Ford JW, Stanley JC, 
Phan SH. Transforming growth factor-beta 1 increases lysyl oxidase enzyme activity and 
mRNA in rat aortic smooth muscle cells. J Vasc Surg1997 Mar;25(3):446-52. 
39. Gacheru SN, Thomas KM, Murray SA, Csiszar K, Smith-Mungo LI, Kagan HM. 
Transcriptional and post-transcriptional control of lysyl oxidase expression in vascular 
smooth muscle cells: effects of TGF-beta 1 and serum deprivation. J Cell Biochem1997 
Jun 1;65(3):395-407. 
40. Dai J, Losy F, Guinault AM, Pages C, Anegon I, Desgranges P, Becquemin JP, Allaire E. 
Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic 
aneurysms: a first approach to induction of functional healing by endovascular gene 




41. Losy F, Dai J, Pages C, Ginat M, Muscatelli-Groux B, Guinault AM, Rousselle E, 
Smedile G, Loisance D, Becquemin JP, Allaire E. Paracrine secretion of transforming 
growth factor-beta1 in aneurysm healing and stabilization with endovascular smooth 
muscle cell therapy. J Vasc Surg2003 Jun;37(6):1301-9. 
42. Wu WJ, Vrhovski B, Weiss AS. Glycosaminoglycans mediate the coacervation of human 
tropoelastin through dominant charge interactions involving lysine side chains. J Biol 
Chem1999 Jul 30;274(31):21719-24. 
43. Fornieri C, Baccarani-Contri M, Quaglino D, Jr., Pasquali-Ronchetti I. Lysyl oxidase 
activity and elastin/glycosaminoglycan interactions in growing chick and rat aortas. J Cell 
Biol1987 Sep;105(3):1463-9. 
44. Joddar B, Ramamurthi A. Fragment size- and dose-specific effects of hyaluronan on 
matrix synthesis by vascular smooth muscle cells. Biomaterials2006 May;27(15):2994-
3004. 
45. Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH, Geelkerken RH, 
Lindeman JH. Doxycycline therapy for abdominal aneurysm: Improved proteolytic 
balance through reduced neutrophil content. J Vasc Surg2009 Mar;49(3):741-9. 
46. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical 
trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an 
abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and 
cytotoxic T cells. Circulation2009 Apr 28;119(16):2209-16. 
47. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale 
for a prospective randomized clinical trial. Ann N Y Acad Sci1999 Jun 30;878:159-78. 
48. Huffman MD, Curci JA, Moore G, Kerns DB, Starcher BC, Thompson RW. Functional 
importance of connective tissue repair during the development of experimental 
abdominal aortic aneurysms. Surgery2000 Sep;128(3):429-38. 
49. Weinberg CB, Bell E. A blood vessel model constructed from collagen and cultured 
vascular cells. Science1986 Jan 24;231(4736):397-400. 
50. Kanda K, Matsuda T. In vitro reconstruction of hybrid arterial media with molecular and 
cellular orientations. Cell Transplant1994 Nov-Dec;3(6):537-45. 
51. Seliktar D, Black RA, Vito RP, Nerem RM. Dynamic mechanical conditioning of 
collagen-gel blood vessel constructs induces remodeling in vitro. Ann Biomed Eng2000 
Apr;28(4):351-62. 
52. Kim BS, Nikolovski J, Bonadio J, Smiley E, Mooney DJ. Engineered smooth muscle 




53. Song J, Rolfe BE, Hayward IP, Campbell GR, Campbell JH. Effects of collagen gel 
configuration on behavior of vascular smooth muscle cells in vitro: association with 
vascular morphogenesis. In Vitro Cell Dev Biol Anim2000 Oct;36(9):600-10. 
54. Higgins SP, Solan AK, Niklason LE. Effects of polyglycolic acid on porcine smooth 
muscle cell growth and differentiation. J Biomed Mater Res A2003 Oct 1;67(1):295-302. 
55. Annambhotla S, Bourgeois S, Wang X, Lin PH, Yao Q, Chen C. Recent advances in 
molecular mechanisms of abdominal aortic aneurysm formation. World J Surg2008 
Jun;32(6):976-86. 
56. Thie M, Schlumberger W, Semich R, Rauterberg J, Robenek H. Aortic smooth muscle 
cells in collagen lattice culture: effects on ultrastructure, proliferation and collagen 
synthesis. Eur J Cell Biol1991 Aug;55(2):295-304. 
57. Kim BS, Nikolovski J, Bonadio J, Mooney DJ. Cyclic mechanical strain regulates the 
development of engineered smooth muscle tissue. Nat Biotechnol1999 Oct;17(10):979-
83. 
58. Kim BS, Mooney DJ. Scaffolds for engineering smooth muscle under cyclic mechanical 
strain conditions. J Biomech Eng2000 Jun;122(3):210-5. 
59. Isenberg BC, Tranquillo RT. Long-term cyclic distention enhances the mechanical 
properties of collagen-based media-equivalents. Ann Biomed Eng2003 Sep;31(8):937-49. 
60. Jones JA, Spinale FG, Ikonomidis JS. Transforming growth factor-beta signaling in 
thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc 
Res2009;46(2):119-37. 
61. Guo DC, Papke CL, He R, Milewicz DM. Pathogenesis of thoracic and abdominal aortic 
aneurysms. Ann N Y Acad Sci2006 Nov;1085:339-52. 
62. Kielty CM, Sherratt MJ, Shuttleworth CA. Elastic fibres. J Cell Sci2002 Jul 15;115(Pt 
14):2817-28. 
63. Balazs EA. Chemistry and molecular biology of the intercellular matrix. London, New 
York,: Academic Press; 1970. 
64. Baccaranicontri M, Vincenzi D, Cicchetti F, Mori G, Pasqualironchetti I. 
Immunocytochemical Localization of Proteoglycans within Normal Elastin Fibers. Eur J 
Cell Biol1990 Dec;53(2):305-12. 
65. Hoeve CA, Flory PJ. The elastic properties of elastin. Biopolymers1974 Apr;13(4):677-
86. 
66. Trask TM, Trask BC, Ritty TM, Abrams WR, Rosenbloom J, Mecham RP. Interaction of 
tropoelastin with the amino-terminal domains of fibrillin-1 and fibrillin-2 suggests a role 
for the fibrillins in elastic fiber assembly. J Biol Chem2000 Aug 11;275(32):24400-6. 
195 
 
67. Berman I. Color atlas of basic histology. 3rd ed. New York: Lange Medical 
Books/McGraw-Hill; 2003. 
68. Robert L, Hornebeck W. Elastin and elastases. Boca Raton, Fla.: CRC Press; 1989. 
69. Foster JA, Bruenger E, Gray WR, Sandberg LB. Isolation and amino acid sequences of 
tropoelastin peptides. J Biol Chem1973 Apr 25;248(8):2876-9. 
70. Sage H, Gray WR. Studies on the evolution of elastin--I. Phylogenetic distribution. Comp 
Biochem Physiol B1979;64(4):313-27. 
71. Fazio MJ, Mattei MG, Passage E, Chu ML, Black D, Solomon E, Davidson JM, Uitto J. 
Human elastin gene: new evidence for localization to the long arm of chromosome 7. Am 
J Hum Genet1991 Apr;48(4):696-703. 
72. Indik Z, Yeh H, Ornstein-Goldstein N, Sheppard P, Anderson N, Rosenbloom JC, 
Peltonen L, Rosenbloom J. Alternative splicing of human elastin mRNA indicated by 
sequence analysis of cloned genomic and complementary DNA. Proc Natl Acad Sci U S 
A1987 Aug;84(16):5680-4. 
73. Mecham RP, Whitehouse L, Hay M, Hinek A, Sheetz MP. Ligand affinity of the 67-kD 
elastin/laminin binding protein is modulated by the protein's lectin domain: visualization 
of elastin/laminin-receptor complexes with gold-tagged ligands. J Cell Biol1991 
Apr;113(1):187-94. 
74. Hinek A, Mecham RP, Keeley F, Rabinovitch M. Impaired elastin fiber assembly related 
to reduced 67-kD elastin-binding protein in fetal lamb ductus arteriosus and in cultured 
aortic smooth muscle cells treated with chondroitin sulfate. J Clin Invest1991 
Dec;88(6):2083-94. 
75. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic 
Acid Res Mol Biol2001;70:1-32. 
76. Rucker RB, Murray J. Cross-linking amino acids in collagen and elastin. Am J Clin 
Nutr1978 Jul;31(7):1221-36. 
77. Narayanan AS, Page RC, Kuzan F, Cooper CG. Elastin cross-linking in vitro. Studies on 
factors influencing the formation of desmosines by lysyl oxidase action on tropoelastin. 
Biochem J1978 Sep 1;173(3):857-62. 
78. Gacheru SN, Trackman PC, Shah MA, Ogara CY, Spacciapoli P, Greenaway FT, Kagan 
HM. Structural and Catalytic Properties of Copper in Lysyl Oxidase. Journal of 
Biological Chemistry1990 Nov 5;265(31):19022-7. 
79. Chadwick D, Goode J, Ciba Foundation. The molecular biology and pathology of elastic 
tissues. Chichester ; New York: J. Wiley; 1995. 




81. Ye S, Humphries S, Henney A. Matrix metalloproteinases: implication in vascular matrix 
remodelling during atherogenesis. Clin Sci1998 Feb;94(2):103-10. 
82. Pasnik J, Moll JA, Szalowska DA, Baj Z, Moll J, Moll M, Sysa A, Zeman K. Matrix 
metallo protein ases and tissue inhibitors of metaloproteinases may be may act as 
proinflammatory markers after cardiopulmonary bypass in children. Inflamm Res2005 
Aug;54:S204-S. 
83. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: 
the good, the bad, and the ugly. Circ Res2002 Feb 22;90(3):251-62. 
84. Robert L. The molecular biology and pathology of elastic tissues. Ciba F 
Symp1995;192:1-3. 
85. Larsen M, Artym VV, Green JA, Yamada KM. The matrix reorganized: extracellular 
matrix remodeling and integrin signaling. Curr Opin Cell Biol2006 Oct;18(5):463-71. 
86. Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb 
Haemost2006 Jan;95(1):36-42. 
87. Kielty CM, Stephan S, Sherratt MJ, Williamson M, Shuttleworth CA. Applying elastic 
fibre biology in vascular tissue engineering. Philos Trans R Soc Lond B Biol Sci2007 
Aug 29;362(1484):1293-312. 
88. Hungerford JE, Owens GK, Argraves WS, Little CD. Development of the aortic vessel 
wall as defined by vascular smooth muscle and extracellular matrix markers. Dev 
Biol1996 Sep 15;178(2):375-92. 
89. Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in 
culture. Int Rev Cytol1996;169:183-265. 
90. Thyberg J, Hedin U, Sjolund M, Palmberg L, Bottger BA. Regulation of differentiated 
properties and proliferation of arterial smooth muscle cells. Arteriosclerosis1990 Nov-
Dec;10(6):966-90. 
91. Hoofnagle MH, Wamhoff BR, Owens GK. Lost in transdifferentiation. J Clin Invest2004 
May;113(9):1249-51. 
92. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for 
therapy. Annu Rev Biochem1995;64:403-34. 
93. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and 
outside of the cell. J Cell Biochem2003 Mar 1;88(4):660-72. 
94. Steve Berg. Synthesis of Collagen. Available from: 
http://course1.winona.edu/sberg/308s02/Lec-note/11-new.htm 
95. Varki A. Essentials of glycobiology. 2nd ed. Cold Spring Harbor, N.Y.: Cold Spring 
Harbor Laboratory Press; 2009. 
197 
 
96. Imberty A, Lortat-Jacob H, Perez S. Structural view of glycosaminoglycan-protein 
interactions. Carbohydr Res2007 Feb 26;342(3-4):430-9. 
97. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell 
Biol2005 Aug;6(8):646-56. 
98. Mochizuki S, Brassart B, Hinek A. Signaling pathways transduced through the elastin 
receptor facilitate proliferation of arterial smooth muscle cells. J Biol Chem2002 Nov 
22;277(47):44854-63. 
99. Rodgers UR, Weiss AS. Cellular interactions with elastin. Pathol Biol (Paris)2005 
Sep;53(7):390-8. 
100. Ito S, Ishimaru S, Wilson SE. Inhibitory effect of type 1 collagen gel containing alpha-
elastin on proliferation and migration of vascular smooth muscle and endothelial cells. 
Cardiovasc Surg1997 Apr;5(2):176-83. 
101. Fulop T, Khalil A, Larbi A. The role of elastin peptides in modulating the immune 
response in aging and age-related diseases. Pathol Biol (Paris)2012 Feb;60(1):28-33. 
102. Brooke BS, Bayes-Genis A, Li DY. New insights into elastin and vascular disease. 
Trends Cardiovas Med2003 Jul;13(5):176-81. 
103. Basalyga DM, Simionescu DT, Xiong WF, Baxter T, Starcher BC, Vyavahare NR. 
Elastin degradation and calcification in an abdominal aorta injury model - Role of matrix 
metalloproteinases. Circulation2004 Nov 30;110(22):3480-7. 
104. Fulop T, Jacob MP, Wallach J, Hauck M, Seres I, Varga Z, Robert L. [The elastin-
laminin receptor]. J Soc Biol2001;195(2):157-64. 
105. Spofford CM, Chilian WM. The elastin-laminin receptor functions as a 
mechanotransducer in vascular smooth muscle. Am J Physiol Heart Circ Physiol2001 
Mar;280(3):H1354-60. 
106. Fulop T, Jr., Douziech N, Jacob MP, Hauck M, Wallach J, Robert L. Age-related 
alterations in the signal transduction pathways of the elastin-laminin receptor. Pathol Biol 
(Paris)2001 May;49(4):339-48. 
107. Kunecki M, Nawrocka A. Elastin-laminin receptor and abdominal aortic aneurysms. New 
subject to study? A review. Pathol Biol (Paris)2001 May;49(4):333-8. 
108. O'Connell MK, Murthy S, Phan S, Xu C, Buchanan J, Spilker R, Dalman RL, Zarins CK, 
Denk W, Taylor CA. The three-dimensional micro- and nanostructure of the aortic 
medial lamellar unit measured using 3D confocal and electron microscopy imaging. 
Matrix Biol2008 Apr;27(3):171-81. 
109. Apter JT. Correlation of visco-elastic properties with microscopic structure of large 
arteries. IV. Thermal responses of collagen, elastin, smooth muscle, and intact arteries. 
Circ Res1967 Dec;21(6):901-18. 
198 
 
110. Dobrin PB, Conway M, Canfield T. Elastin, Collagen and the Biaxial Elastic Properties 
of Dog Carotid-Artery. Fed Proc1980;39(3):384-. 
111. Segura AM, Luna RE, Horiba K, Stetler-Stevenson WG, McAllister HA, Willerson JT, 
Ferrans VJ. Immunohistochemistry of matrix metalloproteinases and their inhibitors in 
thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. 
Circulation1998 Nov 10;98(19):Ii331-Ii7. 
112. Hanada K, Vermeij M, Garinis GA, de Waard MC, Kunen MG, Myers L, Maas A, 
Duncker DJ, Meijers C, Dietz HC, Kanaar R, Essers J. Perturbations of vascular 
homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ Res2007 Mar 
16;100(5):738-46. 
113. Francke U. Williams-Beuren syndrome: genes and mechanisms. Hum Mol 
Genet1999;8(10):1947-54. 
114. Curran ME, Atkinson DL, Ewart AK, Morris CA, Leppert MF, Keating MT. The Elastin 
Gene Is Disrupted by a Translocation Associated with Supravalvular Aortic-Stenosis. 
Cell1993 Apr 9;73(1):159-68. 
115. Tantcheva-Poor I, Schuster A, Kornak U, Chelius K, Mauch C. [Congenital Autosomal 
Recessive Cutis laxa Type II A Wrinkly-Skin-Syndrome.]. Klin Padiatr2012 Jul 20. 
116. Brooke BS, Bayes-Genis A, Li DY. New insights into elastin and vascular disease. 
Trends Cardiovasc Med2003 Jul;13(5):176-81. 
117. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, 
predisposition, and prevention. Circulation1998 Mar 10;97(9):916-31. 
118. Saito A, Motomura N, Kakimi K, Ono M, Takai D, Sumida S, Takamoto S. 
Cryopreservation does not alter the allogenicity and development of vasculopathy in 
post-transplant rat aortas. Cryobiology2006 Apr;52(2):251-60. 
119. Wilson GJ, Courtman DW, Klement P, Lee JM, Yeger H. Acellular matrix: a 
biomaterials approach for coronary artery bypass and heart valve replacement. Ann 
Thorac Surg1995 Aug;60(2 Suppl):S353-8. 
120. Allaire E, Bruneval P, Mandet C, Becquemin JP, Michel JB. The immunogenicity of the 
extracellular matrix in arterial xenografts. Surgery1997 Jul;122(1):73-81. 
121. Allaire E, Mandet C, Bruneval P, Bensenane S, Becquemin JP, Michel JB. Cell and 
extracellular matrix rejection in arterial concordant and discordant xenografts in the rat. 
Transplantation1996 Sep 27;62(6):794-803. 
122. Lai L, Prather RS. Progress in producing knockout models for xenotransplantation by 
nuclear transfer. Ann Med2002;34(7-8):501-6. 
123. Lederle FA, Kane RL, MacDonald R, Wilt TJ. Systematic review: repair of unruptured 
abdominal aortic aneurysm. Ann Intern Med2007 May 15;146(10):735-41. 
199 
 
124. Chambers D, Epstein D, Walker S, Fayter D, Paton F, Wright K, Michaels J, Thomas S, 
Sculpher M, Woolacott N. Endovascular stents for abdominal aortic aneurysms: a 
systematic review and economic model. Health Technol Assess2009 Oct;13(48):1-189, 
215-318, iii. 
125. Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, 
diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res 
Opin2004 Apr;20(4):419-32. 
126. Dodd BR, Spence RA. Doxycycline inhibition of abdominal aortic aneurysm growth: a 
systematic review of the literature. Curr Vasc Pharmacol2011 Jul 1;9(4):471-8. 
127. Hanemaaijer R, Visser H, Koolwijk P, Sorsa T, Salo T, Golub LM, van Hinsbergh VW. 
Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines 
(CMTs) in human endothelial cells. Adv Dent Res1998 Nov;12(2):114-8. 
128. Uitto VJ, Firth JD, Nip L, Golub LM. Doxycycline and chemically modified tetracyclines 
inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann N Y 
Acad Sci1994 Sep 6;732:140-51. 
129. Franklin IJ, Harley SL, Greenhalgh RM, Powell JT. Uptake of tetracycline by aortic 
aneurysm wall and its effect on inflammation and proteolysis. Br J Surg1999 
Jun;86(6):771-5. 
130. Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG, Reilly JM, Sicard GA, Thompson 
RW. Preoperative treatment with doxycycline reduces aortic wall expression and 
activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J 
Vasc Surg2000 Feb;31(2):325-42. 
131. Smith GN, Jr., Brandt KD, Hasty KA. Activation of recombinant human neutrophil 
procollagenase in the presence of doxycycline results in fragmentation of the enzyme and 
loss of enzyme activity. Arthritis Rheum1996 Feb;39(2):235-44. 
132. Smith GN, Jr., Brandt KD, Hasty KA. Procollagenase is reduced to inactive fragments 
upon activation in the presence of doxycycline. Ann N Y Acad Sci1994 Sep 6;732:436-8. 
133. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline 
inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal 
aortic aneurysm: preservation of aortic elastin associated with suppressed production of 
92 kD gelatinase. J Vasc Surg1996 Feb;23(2):336-46. 
134. Xiong W, Knispel RA, Dietz HC, Ramirez F, Baxter BT. Doxycycline delays aneurysm 
rupture in a mouse model of Marfan syndrome. J Vasc Surg2008 Jan;47(1):166-72; 
discussion 72. 
135. Boyle JR, McDermott E, Crowther M, Wills AD, Bell PR, Thompson MM. Doxycycline 
inhibits elastin degradation and reduces metalloproteinase activity in a model of 
aneurysmal disease. J Vasc Surg1998 Feb;27(2):354-61. 
200 
 
136. Wills A, Thompson MM, Crowther M, Brindle NP, Nasim A, Sayers RD, Bell PR. 
Elastase-induced matrix degradation in arterial organ cultures: an in vitro model of 
aneurysmal disease. J Vasc Surg1996 Oct;24(4):667-79. 
137. Nakashima H, Aoki M, Miyake T, Kawasaki T, Iwai M, Jo N, Oishi M, Kataoka K, Ohgi 
S, Ogihara T, Kaneda Y, Morishita R. Inhibition of experimental abdominal aortic 
aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of 
nuclear factor kappaB and ets transcription factors. Circulation2004 Jan 6;109(1):132-8. 
138. Teckman JH, Lindblad D. Alpha-1-antitrypsin deficiency: diagnosis, pathophysiology, 
and management. Curr Gastroenterol Rep2006 Feb;8(1):14-20. 
139. Simionescu A, Philips K, Vyavahare N. Elastin-derived peptides and TGF-beta1 induce 
osteogenic responses in smooth muscle cells. Biochem Biophys Res Commun2005 Aug 
26;334(2):524-32. 
140. Thie M, Schlumberger W, Semich R, Rauterberg J, Robenek H. Aortic smooth muscle 
cells in collagen lattice culture: effects on ultrastructure, proliferation and collagen 
synthesis. Eur J Cell Biol1991 Aug;55(2):295-304. 
141. Li S, Lao J, Chen BP, Li YS, Zhao Y, Chu J, Chen KD, Tsou TC, Peck K, Chien S. 
Genomic analysis of smooth muscle cells in 3-dimensional collagen matrix. FASEB 
J2003 Jan;17(1):97-9. 
142. Foster JA, Rich CB, Miller M, Benedict MR, Richman RA, Florini JR. Effect of age and 
IGF-I administration on elastin gene expression in rat aorta. J Gerontol1990 
Jul;45(4):B113-8. 
143. Noguchi A, Nelson T. IGF-I stimulates tropoelastin synthesis in neonatal rat pulmonary 
fibroblasts. Pediatr Res1991 Sep;30(3):248-51. 
144. Rich CB, Goud HD, Bashir M, Rosenbloom J, Foster JA. Developmental regulation of 
aortic elastin gene expression involves disruption of an IGF-I sensitive repressor complex. 
Biochem Biophys Res Commun1993 Nov 15;196(3):1316-22. 
145. McGowan SE, McNamer R. Transforming growth factor-beta increases elastin 
production by neonatal rat lung fibroblasts. Am J Respir Cell Mol Biol1990 
Oct;3(4):369-76. 
146. Mauviel A, Chen YQ, Kahari VM, Ledo I, Wu M, Rudnicka L, Uitto J. Human 
recombinant interleukin-1 beta up-regulates elastin gene expression in dermal fibroblasts. 
Evidence for transcriptional regulation in vitro and in vivo. J Biol Chem1993 Mar 
25;268(9):6520-4. 
147. Zhang G, Suggs LJ. Matrices and scaffolds for drug delivery in vascular tissue 
engineering. Adv Drug Deliv Rev2007 May 30;59(4-5):360-73. 
201 
 
148. Kothapalli CR, Ramamurthi A. Lysyl oxidase enhances elastin synthesis and matrix 
formation by vascular smooth muscle cells. J Tissue Eng Regen Med2009 Dec;3(8):655-
61. 
149. Kothapalli CR, Ramamurthi A. Copper nanoparticle cues for biomimetic cellular 
assembly of crosslinked elastin fibers. Acta Biomater2009 Feb;5(2):541-53. 
150. Hayashi A, Suzuki T, Tajima S. Modulations of elastin expression and cell proliferation 
by retinoids in cultured vascular smooth muscle cells. J Biochem1995 Jan;117(1):132-6. 
151. Tukaj C, Trzonkowski P, Pikula M, Hallmann A, Tukaj S. Increased migratory properties 
of aortal smooth muscle cells exposed to calcitriol in culture. J Steroid Biochem Mol 
Biol2010 Jul;121(1-2):208-11. 
152. Tukaj C, Kubasik-Juraniec J, Kraszpulski M. Morphological changes of aortal smooth 
muscle cells exposed to calcitriol in culture. Med Sci Monit2000 Jul-Aug;6(4):668-74. 
153. Toole BP, Wight TN, Tammi MI. Hyaluronan-cell interactions in cancer and vascular 
disease. J Biol Chem2002 Feb 15;277(7):4593-6. 
154. Toole BP. Hyaluronan and its binding proteins, the hyaladherins. Curr Opin Cell 
Biol1990 Oct;2(5):839-44. 
155. Laurent TC, Fraser JR. Hyaluronan. FASEB J1992 Apr;6(7):2397-404. 
156. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell 
surface receptor for hyaluronate. Cell1990 Jun 29;61(7):1303-13. 
157. Underhill CB. The interaction of hyaluronate with the cell surface: the hyaluronate 
receptor and the core protein. Ciba Found Symp1989;143:87-99; discussion 100-6, 281-5. 
158. Orlidge A, D'Amore PA. Cell specific effects of glycosaminoglycans on the attachment 
and proliferation of vascular wall components. Microvasc Res1986 Jan;31(1):41-53. 
159. Culty M, Miyake K, Kincade PW, Sikorski E, Butcher EC, Underhill C. The hyaluronate 
receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell 
Biol1990 Dec;111(6 Pt 1):2765-74. 
160. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr 
Opin Cell Biol2002 Oct;14(5):617-23. 
161.Rossler A, Hinghofer-Szalkay H. Hyaluronan fragments: an information-carrying system? 
Horm Metab Res2003 Feb;35(2):67-8. 
162. Joddar B, Ibrahim S, Ramamurthi A. Impact of delivery mode of hyaluronan oligomers 




163. Joddar B, Ramamurthi A. Elastogenic effects of exogenous hyaluronan oligosaccharides 
on vascular smooth muscle cells. Biomaterials2006 Nov;27(33):5698-707. 
164. Haga JH, Li YS, Chien S. Molecular basis of the effects of mechanical stretch on 
vascular smooth muscle cells. J Biomech2007;40(5):947-60. 
165. Kanda K, Matsuda T. Behavior of arterial wall cells cultured on periodically stretched 
substrates. Cell Transplant1993 Nov-Dec;2(6):475-84. 
166. Kona S, Chellamuthu P, Xu H, Hills SR, Nguyen KT. Effects of cyclic strain and growth 
factors on vascular smooth muscle cell responses. Open Biomed Eng J2009;3:28-38. 
167. Liu B, Qu MJ, Qin KR, Li H, Li ZK, Shen BR, Jiang ZL. Role of cyclic strain frequency 
in regulating the alignment of vascular smooth muscle cells in vitro. Biophys J2008 Feb 
15;94(4):1497-507. 
168. Qu MJ, Liu B, Wang HQ, Yan ZQ, Shen BR, Jiang ZL. Frequency-dependent phenotype 
modulation of vascular smooth muscle cells under cyclic mechanical strain. J Vasc 
Res2007;44(5):345-53. 
169. Lee KW, Stolz DB, Wang Y. Substantial expression of mature elastin in arterial 
constructs. Proc Natl Acad Sci U S A2011 Feb 15;108(7):2705-10. 
170. O'Callaghan CJ, Williams B. Mechanical strain-induced extracellular matrix production 
by human vascular smooth muscle cells: role of TGF-beta(1). Hypertension2000 
Sep;36(3):319-24. 
171. Wernig F, Mayr M, Xu Q. Mechanical stretch-induced apoptosis in smooth muscle cells 
is mediated by beta1-integrin signaling pathways. Hypertension2003 Apr;41(4):903-11. 
172. Seliktar D, Nerem RM, Galis ZS. Mechanical strain-stimulated remodeling of tissue-
engineered blood vessel constructs. Tissue Eng2003 Aug;9(4):657-66. 
173. Venkataraman L, Ramamurthi A. Induced elastic matrix deposition within three-
dimensional collagen scaffolds. Tissue Eng Part A2011 Nov;17(21-22):2879-89. 
174. Xie SZ, Fang NT, Liu S, Zhou P, Zhang Y, Wang SM, Gao HY, Pan LF. Differentiation 
of smooth muscle progenitor cells in peripheral blood and its application in tissue 
engineered blood vessels. J Zhejiang Univ Sci B2008 Dec;9(12):923-30. 
175. Ramamurthi A, Vesely I. Smooth muscle cell adhesion on crosslinked hyaluronan gels. J 
Biomed Mater Res2002 Apr;60(1):195-205. 
176. Xu ZC, Li H, Zhou GD, Li G, Liu Y, Zhang WJ, Cui L, Liu W, Cao YL. [Constructing of 
smooth muscle layers of tissue engineered blood vessel in a bioreactor]. Zhonghua Zheng 
Xing Wai Ke Za Zhi2008 May;24(3):220-4. 
203 
 
177. Iwasaki K, Kojima K, Kodama S, Paz AC, Chambers M, Umezu M, Vacanti CA. 
Bioengineered three-layered robust and elastic artery using hemodynamically-equivalent 
pulsatile bioreactor. Circulation2008 Sep 30;118(14):S52-S7. 
178. Lin S, Sandig M, Mequanint K. Three-dimensional topography of synthetic scaffolds 
induces elastin synthesis by human coronary artery smooth muscle cells. Tissue Eng Part 
A2011 Jun;17(11-12):1561-71. 
179. Cheng ST, Chen ZF, Chen GQ. The expression of cross-linked elastin by rabbit blood 
vessel smooth muscle cells cultured in polyhydroxyalkanoate scaffolds. 
Biomaterials2008 Nov;29(31):4187-94. 
180. Bashur CA, Ramamurthi A. Aligned electrospun scaffolds and elastogenic factors for 
vascular cell-mediated elastic matrix assembly. J Tissue Eng Regen Med2011 Sep 23. 
181. Crapo PM, Wang Y. Physiologic compliance in engineered small-diameter arterial 
constructs based on an elastomeric substrate. Biomaterials2010 Mar;31(7):1626-35. 
182. Keire PA, L'Heureux N, Vernon RB, Merrilees MJ, Starcher B, Okon E, Dusserre N, 
McAllister TN, Wight TN. Expression of versican isoform V3 in the absence of ascorbate 
improves elastogenesis in engineered vascular constructs. Tissue Eng Part A2010 
Feb;16(2):501-12. 
183. Bashur CA, Venkataraman L, Ramamurthi A. Tissue engineering and regenerative 
strategies to replicate biocomplexity of vascular elastic matrix assembly. Tissue Eng Part 
B Rev2012 Jun;18(3):203-17. 
184. Kothapalli CR, Gacchina CE, Ramamurthi A. Utility of hyaluronan oligomers and 
transforming growth factor-beta1 factors for elastic matrix regeneration by aneurysmal 
rat aortic smooth muscle cells. Tissue Eng Part A2009 Nov;15(11):3247-60. 
185. Ghosh J, Murphy MO, Turner N, Khwaja N, Halka A, Kielty CM, Walker MG. The role 
of transforming growth factor beta1 in the vascular system. Cardiovasc Pathol2005 Jan-
Feb;14(1):28-36. 
186. Davis ME, Hsieh PCH, Grodzinsky AJ, Lee RT. Custom design of the cardiac 
microenvironment with biomaterials. Circ Res2005 Jul 8;97(1):8-15. 
187. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general 
approaches and a review of recent developments. J R Soc Interface. [Review]. 2011 
Feb;8(55):153-70. 
188. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular 
microenvironments for morphogenesis in tissue engineering. Nat Biotech2005 
Jan;23(1):47-55. 




190. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to 
cells and tissue. Adv Drug Deliv Rev2003;55(3):329-47. 
191. Pitsillides CM, Joe EK, Wei XB, Anderson RR, Lin CP. Selective cell targeting with 
light-absorbing microparticles and nanoparticles. Biophys J2003 Jun;84(6):4023-32. 
192. Sarikaya M, Tamerler C, Jen AKY, Schulten K, Baneyx F. Molecular biomimetics: 
nanotechnology through biology. Nat Mater2003 Sep;2(9):577-85. 
193. Altman GH, Diaz F, Jakuba C, Calabro T, Horan RL, Chen JS, Lu H, Richmond J, 
Kaplan DL. Silk-based biomaterials. Biomaterials2003 Feb;24(3):401-16. 
194. Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variables and 
applications. Biomaterials2003 Nov;24(24):4337-51. 
195. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials2000 
Dec;21(24):2529-43. 
196. Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev2001 Jul;101(7):1869-
79. 
197. Li WJ, Laurencin CT, Caterson EJ, Tuan RS, Ko FK. Electrospun nanofibrous structure: 
A novel scaffold for tissue engineering. J Biomed Mater Res2002 Jun 15;60(4):613-21. 
198. Matthews JA, Wnek GE, Simpson DG, Bowlin GL. Electrospinning of collagen 
nanofibers. Biomacromolecules2002 Mar-Apr;3(2):232-8. 
199. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery 
and tissue engineering. J Biomater Sci Polym Ed2007 Mar;18(3):241-68. 
200. Kim SS, Park MS, Jeon O, Choi CY, Kim BS. Poly(lactide-co-glycolide)/hydroxyapatite 
composite scaffolds for bone tissue engineering. Biomaterials2006 Mar;27(8):1399-409. 
201. Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, Lin AS, Guldberg RE, Mooney 
DJ. Integrated approach to designing growth factor delivery systems. FASEB J2007 
Dec;21(14):3896-903. 
202. Chen RR, Silva EA, Yuen WW, Mooney DJ. Spatio-temporal VEGF and PDGF delivery 
patterns blood vessel formation and maturation. Pharm Res2007 Feb;24(2):258-64. 
203. Nguyen KT, West JL. Photopolymerizable hydrogels for tissue engineering applications. 
Biomaterials2002 Nov;23(22):4307-14. 
204. Ratner BD, Bryant SJ. Biomaterials: Where we have been and where we are going. Annu 
Rev Biomed Eng2004 2004;6:41-75. 
205. Silva EA, Mooney DJ. Spatiotemporal control of vascular endothelial growth factor 




206. Silva EA, Mooney DJ. Synthetic extracellular matrices for tissue engineering and 
regeneration. Curr Top Dev Biol2004 2004;64:181-205. 
207. Ahmann KA, Weinbaum JS, Johnson SL, Tranquillo RT. Fibrin degradation enhances 
vascular smooth muscle cell proliferation and matrix deposition in fibrin-based tissue 
constructs fabricated in vitro. Tissue Eng Part A2010 Oct;16(10):3261-70. 
208. Chau Y, Tan FE, Langer R. Synthesis and characterization of dextran-peptide-
methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II 
and matrix metalloproteinase IX. Bioconjug Chem2004 Jul-Aug;15(4):931-41. 
209. Lutolf MR, Weber FE, Schmoekel HG, Schense JC, Kohler T, Muller R, Hubbell JA. 
Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. 
Nat Biotechnol2003 May;21(5):513-8. 
210. Safran SA, Gov N, Nicolas A, Schwarz US, Tlusty T. Physics of cell elasticity, shape and 
adhesion. Physica a-Statistical Mechanics and Its Applications2005 Jul 1;352(1):171-201. 
211. Flemming RG, Murphy CJ, Abrams GA, Goodman SL, Nealey PF. Effects of synthetic 
micro- and nano-structured surfaces on cell behavior. Biomaterials1999 Mar;20(6):573-
88. 
212. Ji W, Sun Y, Yang F, van den Beucken JJ, Fan M, Chen Z, Jansen JA. Bioactive 
electrospun scaffolds delivering growth factors and genes for tissue engineering 
applications. Pharm Res2011 Jun;28(6):1259-72. 
213. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of 
biodegradable nanoparticles: effect of surface modifications. J Pharm Sci1998 
Oct;87(10):1229-34. 
214. Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ, Levy RJ. 
Formulation and characterization of biodegradable nanoparticles for intravascular local 
drug delivery. Journal of Controlled Release1997 Jan 18;43(2-3):197-212. 
215. Gertler A. The non-specific electrostatic nature of the adsorption of elastase and other 
basic proteins on elastin. Eur J Biochem1971 Jun 29;20(4):541-6. 
216. Kagan HM, Simpson DE, Tseng L. Substrate-directed modulation of elastin oxidation by 
lysyl oxidase. Connect Tissue Res1981;8(3-4):213-7. 
217. Gacchina CE, Ramamurthi A. Impact of pre-existing elastic matrix on TGFbeta1 and HA 
oligomer-induced regenerative elastin repair by rat aortic smooth muscle cells. J Tissue 
Eng Regen Med2010 Jul 23. 
218. Shi Y, Vesely I. Fabrication of mitral valve chordae by directed collagen gel shrinkage. 
Tissue Eng2003 Dec;9(6):1233-42. 
206 
 
219. Juncosa-Melvin N, Boivin GP, Galloway MT, Gooch C, West JR, Sklenka AM, Butler 
DL. Effects of cell-to-collagen ratio in mesenchymal stem cell-seeded implants on tendon 
repair biomechanics and histology. Tissue Eng2005 Mar-Apr;11(3-4):448-57. 
220. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-beta induces 
bimodal proliferation of connective tissue cells via complex control of an autocrine 
PDGF loop. Cell1990 Nov 2;63(3):515-24. 
221. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal 
Biochem1980 Mar 1;102(2):344-52. 
222. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods2001 Dec;25(4):402-8. 
223. Lee JS, Basalyga DM, Simionescu A, Isenburg JC, Simionescu DT, Vyavahare NR. 
Elastin calcification in the rat subdermal model is accompanied by up-regulation of 
degradative and osteogenic cellular responses. Am J Pathol2006 Feb;168(2):490-8. 
224. Loria RM, Kos WL, Campbell AE, Madge GE. Suppression of aortic elastic tissue 
autofluorescence for the detection of viral antigen. Histochemistry1979 Jun 18;61(2):151-
5. 
225. Bashur CA, Dahlgren LA, Goldstein AS. Effect of fiber diameter and orientation on 
fibroblast morphology and proliferation on electrospun poly(D,L-lactic-co-glycolic acid) 
meshes. Biomaterials2006 Nov;27(33):5681-8. 
226. 95. Dawson-Saunders`, B. and Trapp`, R.G.`, 1994. Estimating and comparing 
proportions. In: Dawson-Saunders`, B.`, Editor`, 1994. Basic and Clinical Biostatistics`, 
Appleton & Lange`, East Norwalk`, pp. 143–161. 
227. Long JL, Tranquillo RT. Elastic fiber production in cardiovascular tissue-equivalents. 
Matrix Biol2003 Jun;22(4):339-50. 
228. Johnson DJ, Robson P, Hew Y, Keeley FW. Decreased elastin synthesis in normal 
development and in long-term aortic organ and cell cultures is related to rapid and 
selective destabilization of mRNA for elastin. Circ Res1995 Dec;77(6):1107-13. 
229. L'Heureux N, Germain L, Labbe R, Auger FA. In vitro construction of a human blood 
vessel from cultured vascular cells: a morphologic study. J Vasc Surg1993 
Mar;17(3):499-509. 
230. Kothapalli CR, Ramamurthi A. Induced elastin regeneration by chronically activated 
smooth muscle cells for targeted aneurysm repair. Acta Biomater2010 Jan;6(1):170-8. 
231. Grainger DJ, Kemp PR, Witchell CM, Weissberg PL, Metcalfe JC. Transforming growth 
factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by 
extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry 
into M phase. Biochem J1994 Apr 1;299 ( Pt 1):227-35. 
207 
 
232. Gacchina CE, Deb PP, Barth J, Ramamurthi A. Elastogenic Inductability of Smooth 
Muscle Cells from a Rat Model of Late-Stage Abdominal Aortic Aneurysms. Tissue Eng 
Part A2011 Feb 22. 
233. Ibrahim S, Joddar B, Craps M, Ramamurthi A. A surface-tethered model to assess size-
specific effects of hyaluronan (HA) on endothelial cells. Biomaterials2007 
Feb;28(5):825-35. 
234. Shi Y, Vesely I. Characterization of statically loaded tissue-engineered mitral valve 
chordae tendineae. J Biomed Mater Res A2004 Apr 1;69(1):26-39. 
235. Gupta V, Grande-Allen KJ. Effects of static and cyclic loading in regulating extracellular 
matrix synthesis by cardiovascular cells. Cardiovasc Res2006 Dec 1;72(3):375-83. 
236. Schutte SC, Chen Z, Brockbank KG, Nerem RM. Cyclic strain improves strength and 
function of a collagen-based tissue-engineered vascular media. Tissue Eng Part A2010 
Oct;16(10):3149-57. 
237. Seliktar D, Nerem RM, Galis ZS. The role of matrix metalloproteinase-2 in the 
remodeling of cell-seeded vascular constructs subjected to cyclic strain. Ann Biomed 
Eng2001 Nov;29(11):923-34. 
238. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, Schieffer B. 
Mechanical stretch enhances mRNA expression and proenzyme release of matrix 
metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. 
Circ Res2003 Jun 13;92(11):e80-6. 
239. Gacchina C, Brothers T, Ramamurthi A. Evaluating smooth muscle cells from CaCl2-
induced rat aortal expansions as a surrogate culture model for study of elastogenic 
induction of human aneurysmal cells. Tissue Eng Part A2011 Aug;17(15-16):1945-58. 
240. Nikolovski J, Kim BS, Mooney DJ. Cyclic strain inhibits switching of smooth muscle 
cells to an osteoblast-like phenotype. FASEB J2003 Mar;17(3):455-7. 
241. Blanchard JF. Epidemiology of abdominal aortic aneurysms. Epidemiol 
Rev1999;21(2):207-21. 
242. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW, Jr., Kent KC, Upchurch GR, 
Jr., Chaikof EL, Mills JL, Fleckten B, Longo GM, Lee JK, Thompson RW. Prolonged 
administration of doxycycline in patients with small asymptomatic abdominal aortic 
aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg2002 
Jul;36(1):1-12. 
243. Bartoli MA, Parodi FE, Chu J, Pagano MB, Mao D, Baxter BT, Buckley C, Ennis TL, 
Thompson RW. Localized administration of doxycycline suppresses aortic dilatation in 




244. Sho E, Chu J, Sho M, Fernandes B, Judd D, Ganesan P, Kimura H, Dalman RL. 
Continuous periaortic infusion improves doxycycline efficacy in experimental aortic 
aneurysms. J Vasc Surg2004 Jun;39(6):1312-21. 
245. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline 
modulates smooth muscle cell growth, migration, and matrix remodeling after arterial 
injury. Am J Pathol2002 Mar;160(3):1089-95. 
246. Franco C, Ho B, Mulholland D, Hou G, Islam M, Donaldson K, Bendeck MP. 
Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization 
of fibrillar collagen matrices. Am J Pathol2006 May;168(5):1697-709. 
247. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines 
inhibit connective tissue breakdown: new therapeutic implications for an old family of 
drugs. Crit Rev Oral Biol Med1991;2(3):297-321. 
248. Liu J, Xiong W, Baca-Regen L, Nagase H, Baxter BT. Mechanism of inhibition of matrix 
metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J 
Vasc Surg2003 Dec;38(6):1376-83. 
249. Kim HS, Luo L, Pflugfelder SC, Li DQ. Doxycycline inhibits TGF-beta1-induced MMP-
9 via Smad and MAPK pathways in human corneal epithelial cells. Invest Ophthalmol 
Vis Sci2005 Mar;46(3):840-8. 
250. Ventura JJ, Kennedy NJ, Flavell RA, Davis RJ. JNK regulates autocrine expression of 
TGF-beta1. Mol Cell2004 Jul 23;15(2):269-78. 
251. Schlumberger W, Thie M, Rauterberg J, Robenek H. Collagen synthesis in cultured aortic 
smooth muscle cells. Modulation by collagen lattice culture, transforming growth factor-
beta 1, and epidermal growth factor. Arterioscler Thromb1991 Nov-Dec;11(6):1660-6. 
252. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, 
Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M. Regression of abdominal aortic 
aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med2005 Dec;11(12):1330-8. 
253. Yamawaki-Ogata A, Hashizume R, Satake M, Kaneko H, Mizutani S, Moritan T, Ueda Y, 
Narita Y. A doxycycline loaded, controlled-release, biodegradable fiber for the treatment 
of aortic aneurysms. Biomaterials2010 Dec;31(36):9554-64. 
254. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric 
nanoparticles as drug delivery devices. Journal of Controlled Release2001 Jan 29;70(1-
2):1-20. 
255. Lee KY, Peters MC, Anderson KW, Mooney DJ. Controlled growth factor release from 
synthetic extracellular matrices. Nature2000 Dec 21-28;408(6815):998-1000. 




257. Flemming RG, Murphy CJ, Abrams GA, Goodman SL, Nealey PF. Effects of synthetic 
micro- and nano-structured surfaces on cell behavior. Biomaterials1999 Mar;20(6):573-
88. 
258. Wu XS. Synthesis, characterization, biodegradation, and drug delivery application of 
biodegradable lactic/glycolic acid polymers: Part III. Drug delivery application. Artif 
Cells Blood Substit Immobil Biotechnol2004;32(4):575-91. 
259. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA 
microspheres. Adv Drug Deliv Rev1997 Oct 13;28(1):5-24. 
260. Mitic SS, Miletic GZ, Kostic DA, Naskovic-Dokic DC, Arsic BB, Rasic ID. A rapid and 
reliable determination of doxycycline hyclate by HPLC with UV detection in 
pharmaceutical samples. J Serb Chem Soc2008;73(6):665-71. 
261. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(T)(-Delta Delta C) method. Methods2001 Dec;25(4):402-8. 
262. Stegemann JP, Nerem RM. Altered response of vascular smooth muscle cells to 
exogenous biochemical stimulation in two- and three-dimensional culture. Exp Cell 
Res2003 Feb 15;283(2):146-55. 
263. Matt P, Habashi J, Carrel T, Cameron DE, Van Eyk JE, Dietz HC. Recent advances in 
understanding Marfan syndrome: should we now treat surgical patients with losartan? J 
Thorac Cardiovasc Surg2008 Feb;135(2):389-94. 
264. Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M. Losartan 
therapy in adults with Marfan syndrome: study protocol of the multi-center randomized 
controlled COMPARE trial. Trials2010;11:3. 
265. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable 
Controlled Drug Delivery Carrier. Polymers (Basel)2011 Sep 1;3(3):1377-97. 
266. Lu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C. Current advances in 
research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol 
Diagn2009 May;9(4):325-41. 
267. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based 
nanoparticles: An overview of biomedical applications. J Control Release2012 Jul 
20;161(2):505-22. 
268. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J 
Biomater Sci Polym Ed2006;17(3):247-89. 
269. Wang XY, Xu H, Zhao YQ, Wang SN, Abe H, Naito M, Liu YL, Wang GQ. 
Poly(lactide-co-glycolide) encapsulated hydroxyapatite microspheres for sustained 
release of doxycycline. Mater Sci Eng B-Adv2012 Mar 15;177(4):367-72. 
210 
 
270. Patel RS, Cho DY, Tian C, Chang A, Estrellas KM, Lavin D, Furtado S, Mathiowitz E. 
Doxycycline delivery from PLGA microspheres prepared by a modified solvent removal 
method. J Microencapsul2012;29(4):344-52. 
271. Lu L, Stamatas GN, Mikos AG. Controlled release of transforming growth factor beta1 
from biodegradable polymer microparticles. J Biomed Mater Res2000 Jun 5;50(3):440-
51. 
272. Jaklenec A, Hinckfuss A, Bilgen B, Ciombor DM, Aaron R, Mathiowitz E. Sequential 
release of bioactive IGF-I and TGF-beta 1 from PLGA microsphere-based scaffolds. 
Biomaterials2008 Apr;29(10):1518-25. 
273. Kagan HM, Tseng L, Simpson DE. Control of elastin metabolism by elastin ligands. 
Reciprocal effects on lysyl oxidase activity. J Biol Chem1981 Jun 10;256(11):5417-21. 
274. Wu WJ, Vrhovski B, Weiss AS. Glycosaminoglycans mediate the coacervation of human 
tropoelastin through dominant charge interactions involving lysine side chains. Journal of 
Biological Chemistry1999 Jul 30;274(31):21719-24. 
275. Bartholomew JS, Anderson JC. Investigation of Relationships between Collagens, Elastin 
and Proteoglycans in Bovine Thoracic Aorta by Immunofluorescence Techniques. 
Histochem J1983;15(12):1177-90. 
276. Alexis F. Factors affecting the degradation and drug-release mechanism of poly (lactic 
acid) and poly [(lactic acid)-co-(glycolic acid)] Polym Int. 2005`;54:36–46. 
277. Lu L, Peter SJ, Lyman MD, Lai HL, Leite SM, Tamada JA, Uyama S, Vacanti JP, Langer 
R, Mikos AG. In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) 
foams. Biomaterials2000 Sep;21(18):1837-45. 
278. Zolnik BS, Burgess DJ. Effect of acidic pH on PLGA microsphere degradation and 
release. J Control Release2007 Oct 8;122(3):338-44. 
 
 
 
 
 
 
 
 
